


**CUMULATIVE
SUPPLEMENT 10
JAN'96-OCT'96**

APPROVED DRUG PRODUCTS

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

16TH EDITION

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT
DIVISION OF DATABASE MANAGEMENT**



RM
301.45
.A66
1996
Oct
Suppl

ST. LOUIS COLLEGE OF PHARMACY LIBRARY

JAN 16 1997

Prepared By
Division of Database Management
Office of Management
Center for Drug Evaluation and Research, FDA

RM301.45 .A66 1996 Oct Suppl

Approved drug products with
therapeutic equivalence

C:355661 M:174736 O:12937927

SUBSCRIBE NOW!

Available in March 1997

New 17th Edition

Library Use Only



**APPROVED
DRUG PRODUCTS**

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

**17TH EDITION
1997**

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List
- Discontinued Drug Product List
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Biopharmaceutic Guidance Availability
- ANDA Suitability Petitions
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

16TH EDITION

Cumulative Supplement 10

OCTOBER 1996

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Products Requiring Revised Labeling for Full Approval	iv
1.3 Change of a Therapeutic Equivalent Code for a Drug Entity	v
1.4 Reference Listed Drug	vi
1.5 Court Order Regarding Abbott U.S. Patent No. 4112097 (terazosin HCl)	vii
1.6 Court Order Affecting Uruguay Round Agreements Act-Extended Patents	vii
1.7 Applicant Name Changes	vii
1.8 Availability of the Publication and Updating Procedures	ix
1.9 Report of Counts for the Prescription Drug Product List	x
2.0 DRUG PRODUCT LISTS	
2.1 Prescription Drug Product List	1
2.2 OTC Drug Product List	60
2.3 Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	64
2.4 Orphan Drug Product Designations	65
2.5 Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	72
2.6 Biopharmaceutic Guidance Availability	73
2.7 ANDA Suitability Petitions	74
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Exclusivity Terms	78
B. Patent and Exclusivity Lists	80

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

16TH EDITION

**CUMULATIVE SUPPLEMENT 10
OCTOBER 1996**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 16th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >DLT> (DELETE) to the left of the line containing shaded print. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the shaded print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 16th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 17th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval

on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

<u>Products</u>	<u>Federal Register Reference</u>
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release;transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 CHANGE OF A THERAPEUTIC EQUIVALENT CODE FOR A DRUG ENTITY

Propantheline Bromide

In Cumulative Supplement 1 of the *Approved Drug Products with Therapeutic Equivalence Evaluations*, 16th Edition, (Orange Book), the Agency proposed to change the therapeutic equivalence code for propantheline bromide oral tablets from a drug product not presenting a bioequivalence problem (**AA**) to a drug product with a potential bioequivalence problem (**BP**).

The Agency solicited comments from interested persons to be received no later than 60 days from the first day of the month following the publication of Cumulative Supplement 1. The proposal did not elicit any comments from the readers. In addition, the two firms who hold an active ANDA and are marketing the drug product were contacted to inform them that the codes for their propantheline drug products were going to be changed. Since there were no comments submitted by the readers or by the two firms who hold an active ANDA, the therapeutic equivalence code for propantheline bromide tablets will be changed to one reflecting a potential bioequivalence problem. Therefore, all oral propantheline bromide tablets will be changed in this month's Cumulative Supplement from **(AA)** to **(BP)** to reflect it has a potential for a bioequivalence problem.

An acceptable *in vivo* bioequivalence study, among other information, will be required to change the code from **(BP)** to **(AB)** for an already approved ANDA listed in the Orange Book. Any ANDA submission must contain an acceptable *in vivo* bioequivalence study for filing purposes.

1.4 REFERENCE LISTED DRUG

A reference listed drug (21 CFR 314.94(a)(3)) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.

FDA has identified in the Prescription Drug Product and OTC Drug Product Lists those reference listed drugs to which the *in vivo* bioequivalence and, in some instances, the *in vitro* bioequivalence of the applicant's product is compared. By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. Such variations could result if generic drugs were compared to different reference listed drugs. However, in some instances when multiple NDAs are approved for a single drug product, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. A firm wishing to market a generic version of an NDA listed drug that is not designated as the reference listed may petition the Agency through the Citizen Petition procedure (see 21 CFR 10.25(a) and CFR 10.30). When the Citizen Petition is approved, the second NDA will be designated as an additional reference listed drug and the petitioner may submit an Abbreviated New Drug Application citing the designated reference listed drug. Section 1.7, *Therapeutic Equivalence Evaluations Codes* of the *Introduction* to the *Approved Drug Products with Therapeutic Equivalence Evaluations* publication explains the coding system for multisource drug products listed under the same heading with two reference listed drugs.

The concept of having only one reference listed drug was intended to apply to drug products in which bioequivalence is demonstrated through *in vivo* methodology. It was not intended to apply to two NDA drug products in which the *in vivo* determination of bioequivalence is self evident and a waiver of *in vivo* bioequivalence is granted by the agency. These types of drug products are assigned therapeutic equivalence codes, e.g., of **AN**, **AT**, **AA**. Therefore, drug products that do not represent a bioequivalence problem with two or more NDAs will have the reference listed drug designation assigned to each NDA.

The reference listed drug is identified by the symbol "+" in the Prescription Drug Product List. These identified reference listed drugs represent the best judgement of the Division of Bioequivalence at this time. The prescription Drug Product List identifies reference drugs for oral dosage forms, injectables, ophthalmics, otics, and topical products. It is recommended that a firm planning to conduct an *in vivo* bioequivalence study, or planning to manufacture a batch of a drug product for which an *in vivo* waiver of bioequivalence will be requested, contact the Division of Bioequivalence, OFFICE OF GENERIC DRUGS, to confirm the appropriate reference listed drug.

1.5 COURT ORDER REGARDING ABBOTT U.S. PATENT NO. 4112097, (TERAZOSIN HCL)

On April 9, 1996, the United States District Court for the Northern District of Illinois (Eastern Division) issued an order in the case of Abbott Labs v. Geneva Pharmaceuticals, Inc., directing Abbott to remove U.S. Patent No. 4112097 from the Orange Book. To comply with that order, Abbott has requested that FDA remove patent 4112097 from the Orange Book. The FDA complied with this request in the March 1996 cumulative supplement. On April 9, 1996, Abbott appealed the district court's decision to the U.S. Court of Appeals for the Federal Circuit.

1.6 COURT ORDER AFFECTING URUGUAY ROUND AGREEMENTS ACT-EXTENDED PATENTS

As a result of the April 4, 1996, decision of the United States Court of Appeals for the Federal Circuit in Merck, et al. v. Kessler, patent expiration dates for certain patents subject to patent term extensions under the Uruguay Round Agreements Act and to the patent term extension provisions at 35 U.S.C. § 156 may be changed. FDA is publishing a notice in the *Federal Register* advising NDA and NADA applicants that patent expiration dates changed by the Merck decision must be submitted within 60 days. Because there may be changes in listed patents as a result of the Merck decision, users of this publication should consult the most recent supplement, and are encouraged to confirm that patent information upon which they intend to rely is current. (See the *Patent and Exclusivity Addendum* to the *Approved Drug Products with Therapeutic Equivalence Evaluations*, 16th Edition that explains the background information on this court decision).

1.7 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs

[New Abbreviated Names]]. When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)

1ST TEXAS PHARMACEUTICALS INC
SUB SCHERER LABORATORIES
(1ST TX)

BARRE NATIONAL INC
(BARRE)

BOEHRINGER MANNHEIM PHARMACEUTICALS CORP
(BOEHRINGER MANNHEIM)

DAVID BULL LABORATORIES PARTY LTD
(BULL D)

HOECHST ROUSSEL PHARMACEUTICALS INC
(HOECHST ROUSSEL)

KM LEE LABORATORIES INC
(KM LEE)

PHARMACIA INC
(PHARMACIA)

SCHWARZ PHARMA KREMERS
URBAN CO SUB SCHWARZ PHARMA AG
(SPKU)

NEW APPLICANT NAME (NEW ABBREVIATED NAME)

SCHERER LABORATORIES, INC
(SCHERER)

ALPHARMA USPD INC
(ALPHARMA)

BOEHRINGER MANNHEIM CORPORATION
THERAPEUTICS DIVISION
(BOEHRINGER MANNHEIM)

FH FAULDING AND CO LTD
(FAULDING)
THEN CHANGED TO
FAULDING PHARMACEUTICAL CO
(FAULDING)

HOECHST MARION ROUSSEL INC
(HOECHST MARION RSSL)

KM LEE LABORATORIES INC
(LEE KM)

PHARMACIA AND UPJOHN CO
(PHARMACIA AND UPJOHN)

SCHWARZ PHARMA INC
(SCHWARZ PHARMA)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

UPJOHN CO
(UPJOHN)

PHARMACIA AND UPJOHN CO
(PHARMACIA AND UPJOHN)

UPJOHN MANUFACTURING CO
(UPJOHN)

PHARMACIA AND UPJOHN CARIBE INC
(PHARMACIA AND UPJOHN)

1.8 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is now available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

The following *Approved Drug Products with Therapeutic Equivalence Evaluations* files are now available on Internet and are updated each October and April: Prescription Drug Product List; OTC Drug Products; Discontinued Drug Products; and Appendices. The update in October will include drug products that have been approved through August and the update in April will include drug products that have been approved through December.

These files may be accessed on the Internet's World Wide Web. FDA's Internet site replaces the Agency's electronic bulletin board and offers more information, in a more user-friendly form. To access the CDER Home Page, use this Uniform Resource Locator (URL): <http://www.fda.gov/cder/>. You do not need an Internet connection to reach the CDER Home Page; you can use the free dial-up connection (800) 222-0185. For further assistance, please call (301) 443-4908.

The Prescription Drug Products and OTC Drug Product files will be available on a monthly basis in the near future.

1.9 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1995) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 1995</u>	<u>MAR 1996</u>	<u>JUN 1996</u>	<u>SEP 1996</u>
DRUG PRODUCTS LISTED	9286	9303	9384	9403
SINGLE SOURCE	2217 (23.9%)	2248 (24.2%)	2323 (24.8%)	2331 (24.8%)
MULTISOURCE	7069 (76.1%)	7055 (75.8%)	7061 (75.2%)	7072 (75.2%)
THERAPEUTICALLY EQUIVALENT	6437 (69.3%)	6425 (69.0%)	6490 (69.2%)	6519 (69.3%)
NOT THERAPEUTICALLY EQUIVALENT	440 (4.7%)	443 (4.8%)	468 (5.0%)	449 (4.8%)
EXCEPTIONS ¹	192 (2.1%)	187 (2.0%)	103 (1.0%)	104 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	--	6	15	14
NUMBER OF APPLICANTS	586	592	621	636

¹Amino acid-containing products of varying composition (see Introduction, page xvi of the List).

EXP DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 10 / JAN'96 - OCT'96

	<u>ACETAMINOPHEN; BUTALBITAL</u>					
TABLET; ORAL						
BUTALBITAL AND ACETAMINOPHEN HALSEY	N89568 001 OCT 05, 1988	325MG; 50MG				N89568 001 OCT 05, 1988
@	325MG; 50MG					
<u>ACETAMINOPHEN; BUTALBITAL; CAFFEINE</u>						
CAPSULE; ORAL ESGIC-PLUS + MIKART	N40085 001 MAR 28, 1996	500MG; 50MG; 40MG				N40085 001 MAR 28, 1996
TABLET; ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE MIKART	N89451 001 MAY 23, 1988	500MG; 50MG; 40MG				N89451 001 MAY 23, 1988
+ 	N89451 001 MAY 23, 1988	500MG; 50MG; 40MG				N89451 001 MAY 23, 1988
<u>ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE</u>						
CAPSULE; ORAL DHC PLUS	N88584 001 MAR 04, 1986	356.4MG; 30MG; 16MG				N88584 001 MAR 04, 1986
FURDUE FREDERICK	N88584 001 MAR 04, 1986	356.4MG; 30MG; 16MG				N88584 001 MAR 04, 1986
+ 	N89166 001 MAY 14, 1986	356.4MG; 30MG; 16MG				N89166 001 MAY 14, 1986
SYNALGOS-DC-A WYETH AYERTS	N89166 001 MAY 14, 1986	356.4MG; 30MG; 16MG				N89166 001 MAY 14, 1986
@	356.4MG; 30MG; 16MG					
<u>ACETAMINOPHEN; CODEINE PHOSPHATE</u>						
SOLUTION; ORAL						
ACETAMINOPHEN AND CODEINE PHOSPHATE	N40119 001 APR 26, 1996	120MG/5ML; 12MG/5ML				N40119 001 APR 26, 1996
H I TECH PHARMA	N40098 001 SEP 20, 1996	120MG/5ML; 12MG/5ML				N40098 001 SEP 20, 1996
MOVA	N85057 001	120MG/5ML; 12MG/5ML				N85057 001
JOHNSON RW	N85057 001	120MG/5ML; 12MG/5ML				N85057 001
<u>ACETAMINOPHEN; CODEINE PHOSPHATE #1</u>						
TABLET; ORAL						
ANEXSIA KING PHARMS	N89160 001 APR 23, 1987	500MG; 5MG				N89160 001 APR 23, 1987
MALLINCRODT	N89160 001 APR 23, 1987	500MG; 5MG				N89160 001 APR 23, 1987
ANEXSIA 10/660 + MALLINCRODT	N40084 003 JUL 29, 1996	660MG; 10MG				N40084 003 JUL 29, 1996

ACETAMINOPHEN, HYDROCODONE BITARTRATE

TABLET; ORAL

ANEXSIA 10/660
MALLINCKRODT

660MG;10MG

N40084 003
JUL 29, 1996

ANEXSIA 7.5/650
KING PHARMS

650MG;7.5MG

N89725 001
SEP 30, 1987

MALLINCKRODT

650MG;7.5MG

N89725 001
SEP 30, 1987

HYDROCODONE BITARTRATE AND ACETAMINOPHEN
KING PHARMS

500MG;5MG

N40084 002
JUN 01, 1995

750MG;7.5MG

N40084 001
JUN 01, 1995

MALLINCKRODT

500MG;5MG

N40084 002
JUN 01, 1995

750MG;7.5MG

N40084 001
JUN 01, 1995

ROYCE LABS

500MG;2.5MG

N40123 003
MAR 04, 1996

500MG;5MG

N40122 001
MAR 04, 1996

500MG;7.5MG

N40123 004
MAR 04, 1996

650MG;7.5MG

N40123 001
MAR 04, 1996

650MG;10MG

N40123 002
MAR 04, 1996

750MG;7.5MG

N40122 002
MAR 04, 1996

VINTAGE PHARMS

500MG;7.5MG

N40144 001
FEB 22, 1996

650MG;10MG

N40143 001
FEB 22, 1996

750MG;7.5MG

N40157 001
APR 12, 1996

LORTAB

+ GRAHAM

500MG;10MG

N40100 001
JAN 26, 1996

* UCE

500MG;10MG

N40100 001
JAN 26, 1996

VICODIN HP

KNOLL PHARM

660MG;10MG

N40117 001
SEP 23, 1996

ACETAMINOPHEN, OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

AA VINTAGE PHARMS 500MG;5MG

N40106 001
JUL 30, 1996

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA VINTAGE PHARMS 325MG;5MG

N40105 001
JUL 30, 1996

ACETAMINOPHEN, PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB SUPERPHARM 650MG;100MG

N71319 001
JAN 06, 1987

N71319 001
JAN 06, 1987

@ 650MG;100MG

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETIC ACID

AT MORTON GROVE 2%

N40166 001
JUL 26, 1996

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

HYDROCORTISONE AND ACETIC ACID

AT MORTON GROVE 2%;1%

N40168 001
AUG 30, 1996

ACITRETIN

> ADD >

CAPSULE; ORAL

SORIATANE

ROCHE 10MG

N19821 001
OCT 28, 1996

N19821 002
OCT 28, 1996

+ 25MG

> ADD >

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDECAPSULE; ORALSEMPREX-D
+ GLAXO WELLCOME

8MG; 60MG

N19806 001
MAR 25, 1994
N19806 001
MAR 25, 1994

+ MEDEVA

8MG; 60MG

ADAPALENEGEL; TOPICAL
DIFFERIN
+ GALDERMA

0.1%

N20380 001
MAY 31, 1996SOLUTION; TOPICAL
DIFFERIN
+ GALDERMA

0.1%

N20338 001
MAY 31, 1996ALBENDAZOLETABLET; ORAL
ALBENZA
+ SMITHKLINE BEECHAM

200MG

N20666 001
JUN 11, 1996ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL
AB ARMSTRONG PHARMS

0.09MG/INH

AB MEDISOL

0.09MG/INH

N72273 001
AUG 14, 1996
N74072 001
AUG 01, 1996ALBUTEROL SULFATEAEROSOL, METERED; INHALATION
PROVENTIL-HFA
+ 3M

EQ 0.09MG BASE/INH

N20503 001
AUG 15, 1996ALBUTEROL SULFATE

SOLUTION; INHALATION

VENTOLIN
AN GLAXO WELLCOME

EQ 0.083% BASE

N19773 001
APR 23, 1992

AN +

EQ 0.083% BASE

N19773 001
APR 23, 1992

AN

EQ 0.5% BASE

N19269 002
JAN 16, 1987

AN +

EQ 0.5% BASE

N19269 002
JAN 16, 1987

SYRUP; ORAL

PROVENTIL
AA SCHERING

EQ 2MG BASE/5ML

N18062 001
JAN 19, 1983

AA +

EQ 2MG BASE/5ML

N18062 001
JAN 19, 1983> ADD > ALBUTEROL SULFATE; IPATROPIUM BROMIDE> ADD > AEROSOL, METERED; INHALATION
> ADD > COMBIVENT> ADD > + BOEHRINGER INGELHEIM EQ 0.09MG BASE/INH;
> ADD > 0.018MG/INHN20291 001
OCT 24, 1996ALLOPURINOL SODIUMINJECTABLE; INJECTION
ZYLOPRIM

+ GLAXO WELLCOME

EQ 500MG BASE/VIAL

N20298 001
MAY 17, 1996ALPRAZOLAMTABLET; ORAL
AB ALPRAZOLAM

NOVOPHARM

2MG

N74085 004
FEB 26, 1996

ALPROSTADIL

INJECTABLE; INJECTION
CAVERJECT

PHARMACIA AND UPJOHN 0.005MG/VIAL

N20379 003
JUN 27, 1996

> ADD >
> ADD >

EQ 12% BASE

N20508 001
AUG 29, 1996

AMMONIUM LACTATE

CREAM; TOPICAL
LAC-HYDRIN
WESTWOOD SQUIBB

AMINO ACIDS

INJECTABLE; INJECTION
AMINOSYN-HF 8%
ABBOTT

8%

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER

15%

CLINTEC NUTR

N20345 001
APR 04, 1996

> ADD >
> ADD >

500MG
250MG

N62216 004
N62216 003

HEPATASOL 8%

BAXTER

N20360 001
APR 04, 1996

> DLT >
> DLT >

TABLET, CHEWABLE; ORAL
AMOXICILLIN
APOTHECON

125MG

N64131 001
MAY 06, 1996

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

@ PHOENIX LABS NY

100MG

200MG

100MG

200MG

N85409 001
N85410 001
N85409 001
N85410 001

AB
AB
AB
AB

CLONMEL HLTH CARE

125MG

N64139 001

JAN 29, 1996

N64139 002

JAN 29, 1996

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HCL

@ HALSEY

25MG

25MG

N85922 001
N85922 001

AB

AB

AUGMENTIN '200'

200MG/5ML;

EQ 28.5MG BASE/5ML

N50725 001

MAY 31, 1996

ENDEP

@ ROCHE

150MG

150MG

N85303 001
N85303 001

AB

AUGMENTIN '400'

400MG/5ML;

EQ 57MG BASE/5ML

N50725 002

MAY 31, 1996

AMMONIUM LACTATE

CREAM; TOPICAL

LAC-HYDRIN

BRISTOL MYERS

EQ 12% BASE

N20508 001
AUG 29, 1996

> DLT >
> DLT >

TABLET, CHEWABLE; ORAL
AUGMENTIN '200'

200MG;EQ 28.5MG BASE

N50726 001

MAY 31, 1996

875MG;EQ 125MG BASE

N50720 001

FEB 13, 1996

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET, CHEWABLE; ORAL
AUGMENTIN '400'
+ SMITHKLINE BEECHAM

400MG; EQ 57MG BASE
N50726 002
MAY 31, 1996

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE
SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET, ORAL
ADDERALL 10
RICHWOOD PHARM

2.5MG; 2.5MG; 2.5MG; 2.5MG
N11522 007
FEB 13, 1996

ADDERALL 20
+ RICHWOOD PHARM

5MG; 5MG; 5MG; 5MG
N11522 008
FEB 13, 1996

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

BIPHETAMINE 12.5
@ FISOXS

EQ 6.25MG BASE;
EQ 6.25MG BASE;
EQ 6.25MG BASE;
EQ 6.25MG BASE
N10093 007
N10093 007

BIPHETAMINE 20

@ FISOXS
@ MEDEVA PHARMS

EQ 10MG BASE; EQ 10MG BASE
EQ 10MG BASE; EQ 10MG BASE
N10093 003
N10093 003

BIPHETAMINE 7.5
@ FISOXS

EQ 3.75MG BASE;
EQ 3.75MG BASE;
EQ 3.75MG BASE;
EQ 3.75MG BASE
N10093 009
N10093 009

AMPHOTERICIN B

SUSPENSION; ORAL
FUNGIZONE

+ BRISTOL MYERS SQUIBB 100MG/ML

N50341 003

AMPICILLIN SODIUM

INJECTABLE; INJECTION

OMNIPEN-N

+ WYETH AYERST

N60626 005

AMPICILLIN SODIUM

INJECTABLE; INJECTION

OMNIPEN-N

+ WYETH AYERST

PENBRITIN-S

+ WYETH AYERST

AP AP AP AP AP AP AP

EQ 2GM BASE/VIAL

EQ 125MG BASE/VIAL

EQ 250MG BASE/VIAL

EQ 500MG BASE/VIAL

EQ 1GM BASE/VIAL

EQ 2GM BASE/VIAL

EQ 125MG BASE/VIAL

EQ 250MG BASE/VIAL

EQ 500MG BASE/VIAL

EQ 1GM BASE/VIAL

EQ 2GM BASE/VIAL

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE, ORAL

PFIZERPEN-A

PFIZER

@ @

EQ 250MG BASE

EQ 500MG BASE

EQ 250MG BASE

EQ 500MG BASE

POWDER FOR RECONSTITUTION; ORAL

PFIZERPEN-A

PFIZER

@ @

EQ 125MG BASE/5ML

EQ 250MG BASE/5ML

EQ 125MG BASE/5ML

EQ 250MG BASE/5ML

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

POWDER FOR RECONSTITUTION; ORAL

POLYICILLIN-PFB

@ APOTHECON

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

EQ 3.5GM BASE/BOT; 1GM/BOT

BENTIROMIDE

SOLUTION; ORAL
CHYNEX
SAVAGE LABS

> DLT >
> DLT >
> DLT >
> DLT >
> ADD >
> ADD >

500MG/7.5ML

500MG/7.5ML

N18366 001
DEC 29, 1983
N18366 001
DEC 29, 1983

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

AP

PHARMACIA AND UPJOHN EQ 15 UNITS BASE/VIAL

+

EQ 30 UNITS BASE/VIAL

N64084 001
JUN 01, 1996
N64084 002
JUN 01, 1996

BETA-CAROTENE

CAPSULE; ORAL

SOLATENE

* ROCHE

@

30MG
30MG

N17589 001
N17589 001

BETAINE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

CYSTADANE

+ ORPHAN MEDCL

1GM/SCOOPFUL

N20576 001
OCT 25, 1996

BROMPHENIRAMINE MALEATE

TABLET; ORAL

DIMETANE

* ROBINS AH

AA

@ WHITEHALL ROBINS

4MG
4MG

N10799 003
N10799 003

BETAMETHASONE BENZOATE

CREAM; TOPICAL

UTICORT

* PARKE DAVIS

@

0.025%
0.025%

N16998 002
N16998 002

BUCLIZINE HYDROCHLORIDE

TABLET; ORAL

BUCLADIN-S

STUART

@

50MG
50MG

N10911 006
N10911 006

BISMUTH SUBSALICYLATE, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

+ PROCTER AND GAMBLE 262.4MG:250MG:500MG

N50719 001
AUG 15, 1996

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN

AP

+ BRISTOL MYERS SQUIBB EQ 15 UNITS BASE/VIAL

EQ 15 UNITS BASE/VIAL

> ADD >
> ADD >
> ADD >
> ADD >

N50443 001
N50443 001

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

WELLBUTRIN

+ GLAXO WELLCOME

50MG

N20358 001
OCT 04, 1996

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENEX

+ RECKITT AND COLMAN

EQ 0.3MG BASE/ML

BUPRENORPHINE HCL

EQ 0.3MG BASE/ML

N18401 001
N74137 001
JUN 03, 1996

BUPROPION HYDROCHLORIDE

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
TABLET, EXTENDED RELEASE; ORAL
WELLBUTRIN
+ GLAXO WELLCOME 100MG
N20358 002
OCT 04, 1996
+ 150MG
N20358 003
OCT 04, 1996

CREAM; TOPICAL
DOVONEX
+ BRISTOL MYERS SQUIBB 0.005%

N20554 001
JUL 22, 1996

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL
BUSPAR
* BRISTOL MYERS SQUIBB 10MG
N18731 002
SEP 29, 1986
N18731 002
SEP 29, 1986
N18731 003
APR 22, 1996
N18731 004
APR 22, 1996

> DLT >
> DLT >
> DLT >
> DLT >
> ADD >
> ADD >
INJECTABLE; INJECTION
CIBACALCIN
* CIBA 0.5MG/VIAL
N18470 001
OCT 31, 1986
N18470 001
OCT 31, 1986

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE;
SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

AT
DELPLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
FRESENIUS
25.7MG/100ML; 1.5GM/100ML;
15.2MG/100ML; 567MG/100ML;
392MG/100ML
N18379 002
AT
DELPLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
FRESENIUS
25.7MG/100ML; 2.5GM/100ML;
15.2MG/100ML; 567MG/100ML;
392MG/100ML
N18379 003
AT
DELPLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
FRESENIUS
25.7MG/100ML; 3.5GM/100ML;
15.2MG/100ML; 567MG/100ML;
392MG/100ML
N18379 007
JUN 24, 1988
AT
DELPLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
FRESENIUS
25.7MG/100ML; 4.25GM/100ML;
15.2MG/100ML; 567MG/100ML;
392MG/100ML
N18379 001
AT
DELPLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
FRESENIUS
25.7MG/100ML; 1.5GM/100ML;
5.08MG/100ML; 538MG/100ML;
448MG/100ML
N18379 004
JUL 07, 1982
AT
DELPLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
FRESENIUS
25.7MG/100ML; 2.5GM/100ML;
5.08MG/100ML; 538MG/100ML;
448MG/100ML
N18379 005
JUL 07, 1982

BUTABARBITAL SODIUM

ELIXIR; ORAL
SARISOL
HAUSEY
30MG/5ML
30MG/5ML
N84723 001
N84723 001
TABLET; ORAL
SARISOL NO. 1
HAUSEY
15MG
15MG
N84719 001
N84719 001
SARISOL NO. 2
HAUSEY
30MG
30MG
N84719 002
N84719 002

BUTENAFINE HYDROCHLORIDE

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
CREAM; TOPICAL
MENTAX
+ PENEDERM
1%
N20524 001
OCT 18, 1996

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE;
SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

AT DELFLX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
FRESENIUS 25.7MG/100ML; 3.5GM/100ML;
5.08MG/100ML; 538MG/100ML;
448MG/100ML N18379 008
JUN 24, 1988

AT DELFLX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
FRESENIUS 25.7MG/100ML; 4.25GM/100ML;
5.08MG/100ML; 538MG/100ML;
448MG/100ML N18379 006
JUL 07, 1982

AT INPERSOL W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
FRESENIUS 25.7MG/100ML; 1.5GM/100ML;
15.2MG/100ML; 567MG/100ML;
392MG/100ML N18379 002

AT INPERSOL W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
FRESENIUS 25.7MG/100ML; 2.5GM/100ML;
15.2MG/100ML; 567MG/100ML;
392MG/100ML N18379 003

AT INPERSOL W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
FRESENIUS 25.7MG/100ML; 3.5GM/100ML;
15.2MG/100ML; 567MG/100ML;
392MG/100ML N18379 007
JUN 24, 1988

AT INPERSOL W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
FRESENIUS 25.7MG/100ML; 4.25GM/100ML;
15.2MG/100ML; 567MG/100ML;
392MG/100ML N18379 001

AT INPERSOL-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
FRESENIUS 25.7MG/100ML; 1.5GM/100ML;
5.08MG/100ML; 538MG/100ML;
448MG/100ML N18379 004
JUL 07, 1982

AT INPERSOL-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
FRESENIUS 25.7MG/100ML; 2.5GM/100ML;
5.08MG/100ML; 538MG/100ML;
448MG/100ML N18379 005
JUL 07, 1982

AT INPERSOL-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
FRESENIUS 25.7MG/100ML; 3.5GM/100ML;
5.08MG/100ML; 538MG/100ML;
448MG/100ML N18379 008
JUN 24, 1988

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE;
SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

AT INPERSOL-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
FRESENIUS 25.7MG/100ML; 4.25GM/100ML;
5.08MG/100ML; 538MG/100ML;
448MG/100ML N18379 006
JUL 07, 1982

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM
CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM
PHOSPHATE, DIBASIC

INJECTABLE; INTRATHECAL
ELLIOTT'S B SOLUTION
+ ORPHAN MEDCL

0.2MG/ML; 0.8MG/ML; 0.3MG/ML; 0.3MG/ML;
1.9MG/ML; 7.3MG/ML;
0.2MG/ML N20577 001
SEP 27, 1996

CAPTOPRIL

TABLET; ORAL

CAPOTEN

AB BRISTOL MYERS SQUIBB 100MG
AB 100MG
75MG

* 150MG

@ 75MG

@ 150MG

AB CAPTOPRIL 12.5MG
BAKER NORTON

AB 25MG

AB 50MG

AB 100MG

AB 12.5MG

N18343 003
N18343 003
N18343 007

JUN 13, 1995

N18343 004

JUN 13, 1995

N18343 007

JUN 13, 1995

N18343 004

JUN 13, 1995

N74590 004

AUG 30, 1996

N74590 002

AUG 30, 1996

N74590 001

AUG 30, 1996

N74590 003

AUG 30, 1996

N74433 001

FEB 13, 1996

CAPTOPRIL

TABLET: ORAL
CAPTOPRIL
BIOCRAFT

<u>AB</u>	<u>25MG</u>	N74433 002	<u>AB</u>	<u>100MG</u>	N74519 004
<u>AB</u>	<u>50MG</u>	FEB 13, 1996	<u>AB</u>	<u>12.5MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>	N74433 003	<u>AB</u>	<u>25MG</u>	N74477 001
<u>AB</u>	<u>12.5MG</u>	FEB 13, 1996	<u>AB</u>	<u>50MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>	N74433 004	<u>AB</u>	<u>100MG</u>	N74477 002
<u>AB</u>	<u>50MG</u>	FEB 13, 1996	<u>AB</u>	<u>12.5MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>	N74576 001	<u>AB</u>	<u>25MG</u>	N74477 003
<u>AB</u>	<u>12.5MG</u>	FEB 13, 1996	<u>AB</u>	<u>50MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>	N74576 002	<u>AB</u>	<u>100MG</u>	N74477 004
<u>AB</u>	<u>50MG</u>	APR 23, 1996	<u>AB</u>	<u>12.5MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>	N74576 003	<u>AB</u>	<u>25MG</u>	N74481 001
<u>AB</u>	<u>12.5MG</u>	APR 23, 1996	<u>AB</u>	<u>50MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>	N74576 004	<u>AB</u>	<u>100MG</u>	N74481 002
<u>AB</u>	<u>50MG</u>	APR 23, 1996	<u>AB</u>	<u>12.5MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>	N74462 001	<u>AB</u>	<u>25MG</u>	N74481 003
<u>AB</u>	<u>12.5MG</u>	FEB 13, 1996	<u>AB</u>	<u>50MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>	N74462 002	<u>AB</u>	<u>100MG</u>	N74481 004
<u>AB</u>	<u>50MG</u>	FEB 13, 1996	<u>AB</u>	<u>12.5MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>	N74462 003	<u>AB</u>	<u>25MG</u>	N74483 001
<u>AB</u>	<u>12.5MG</u>	FEB 13, 1996	<u>AB</u>	<u>50MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>	N74462 004	<u>AB</u>	<u>100MG</u>	N74483 002
<u>AB</u>	<u>50MG</u>	FEB 13, 1996	<u>AB</u>	<u>12.5MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>	N74386 001	<u>AB</u>	<u>25MG</u>	N74483 003
<u>AB</u>	<u>12.5MG</u>	MAY 23, 1996	<u>AB</u>	<u>50MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>	N74386 002	<u>AB</u>	<u>100MG</u>	N74483 004
<u>AB</u>	<u>50MG</u>	MAY 23, 1996	<u>AB</u>	<u>12.5MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>	N74386 003	<u>AB</u>	<u>25MG</u>	N74423 001
<u>AB</u>	<u>12.5MG</u>	MAY 23, 1996	<u>AB</u>	<u>50MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>	N74386 004	<u>AB</u>	<u>100MG</u>	N74423 002
<u>AB</u>	<u>50MG</u>	MAY 23, 1996	<u>AB</u>	<u>12.5MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>	N74418 001	<u>AB</u>	<u>25MG</u>	N74423 003
<u>AB</u>	<u>12.5MG</u>	FEB 13, 1996	<u>AB</u>	<u>50MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>	N74418 002	<u>AB</u>	<u>100MG</u>	N74423 004
<u>AB</u>	<u>50MG</u>	FEB 13, 1996	<u>AB</u>	<u>12.5MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>	N74418 003	<u>AB</u>	<u>25MG</u>	N74434 001
<u>AB</u>	<u>12.5MG</u>	FEB 13, 1996	<u>AB</u>	<u>50MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>	N74418 004	<u>AB</u>	<u>100MG</u>	N74434 002
<u>AB</u>	<u>50MG</u>	FEB 13, 1996	<u>AB</u>	<u>12.5MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>	N74519 001	<u>AB</u>	<u>25MG</u>	N74434 003
<u>AB</u>	<u>12.5MG</u>	FEB 13, 1996	<u>AB</u>	<u>50MG</u>	N74434 004
<u>AB</u>	<u>25MG</u>	N74519 002	<u>AB</u>	<u>100MG</u>	FEB 13, 1996
<u>AB</u>	<u>50MG</u>	FEB 13, 1996	<u>AB</u>	<u>12.5MG</u>	N74322 001
<u>AB</u>		N74519 003	<u>AB</u>	<u>25MG</u>	FEB 13, 1996
<u>AB</u>		FEB 13, 1996	<u>AB</u>	<u>50MG</u>	

EON LABS

CAPTOPRIL

TABLET: ORAL
CAPTOPRIL
EON LABS

<u>AB</u>	<u>100MG</u>	HALLMARK PHARMS	<u>AB</u>	<u>100MG</u>	N74519 004
<u>AB</u>	<u>12.5MG</u>		<u>AB</u>	<u>25MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>		<u>AB</u>	<u>50MG</u>	N74477 001
<u>AB</u>	<u>50MG</u>		<u>AB</u>	<u>100MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>		<u>AB</u>	<u>12.5MG</u>	N74477 002
<u>AB</u>	<u>12.5MG</u>		<u>AB</u>	<u>25MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>		<u>AB</u>	<u>50MG</u>	N74477 003
<u>AB</u>	<u>50MG</u>		<u>AB</u>	<u>100MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>		<u>AB</u>	<u>12.5MG</u>	N74477 004
<u>AB</u>	<u>12.5MG</u>		<u>AB</u>	<u>25MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>		<u>AB</u>	<u>50MG</u>	N74481 001
<u>AB</u>	<u>50MG</u>		<u>AB</u>	<u>100MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>		<u>AB</u>	<u>12.5MG</u>	N74481 002
<u>AB</u>	<u>12.5MG</u>		<u>AB</u>	<u>25MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>		<u>AB</u>	<u>50MG</u>	N74481 003
<u>AB</u>	<u>50MG</u>		<u>AB</u>	<u>100MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>		<u>AB</u>	<u>12.5MG</u>	N74481 004
<u>AB</u>	<u>12.5MG</u>		<u>AB</u>	<u>25MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>		<u>AB</u>	<u>50MG</u>	N74483 001
<u>AB</u>	<u>50MG</u>		<u>AB</u>	<u>100MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>		<u>AB</u>	<u>12.5MG</u>	N74483 002
<u>AB</u>	<u>12.5MG</u>		<u>AB</u>	<u>25MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>		<u>AB</u>	<u>50MG</u>	N74483 003
<u>AB</u>	<u>50MG</u>		<u>AB</u>	<u>100MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>		<u>AB</u>	<u>12.5MG</u>	N74483 004
<u>AB</u>	<u>12.5MG</u>		<u>AB</u>	<u>25MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>		<u>AB</u>	<u>50MG</u>	N74423 001
<u>AB</u>	<u>50MG</u>		<u>AB</u>	<u>100MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>		<u>AB</u>	<u>12.5MG</u>	N74423 002
<u>AB</u>	<u>12.5MG</u>		<u>AB</u>	<u>25MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>		<u>AB</u>	<u>50MG</u>	N74423 003
<u>AB</u>	<u>50MG</u>		<u>AB</u>	<u>100MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>		<u>AB</u>	<u>12.5MG</u>	N74423 004
<u>AB</u>	<u>12.5MG</u>		<u>AB</u>	<u>25MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>		<u>AB</u>	<u>50MG</u>	N74434 001
<u>AB</u>	<u>50MG</u>		<u>AB</u>	<u>100MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>		<u>AB</u>	<u>12.5MG</u>	N74434 002
<u>AB</u>	<u>12.5MG</u>		<u>AB</u>	<u>25MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>		<u>AB</u>	<u>50MG</u>	N74434 003
<u>AB</u>	<u>50MG</u>		<u>AB</u>	<u>100MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>		<u>AB</u>	<u>12.5MG</u>	N74434 004
<u>AB</u>	<u>12.5MG</u>		<u>AB</u>	<u>25MG</u>	FEB 13, 1996
<u>AB</u>	<u>25MG</u>		<u>AB</u>	<u>50MG</u>	N74322 001
<u>AB</u>	<u>50MG</u>		<u>AB</u>	<u>100MG</u>	FEB 13, 1996
<u>AB</u>	<u>100MG</u>		<u>AB</u>	<u>12.5MG</u>	

NOVOPHARM

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL
NOVOPHARM

AB 25MG
FEB 13, 1996
AB 50MG
FEB 13, 1996
AB 100MG
FEB 13, 1996
AB 12.5MG
FEB 13, 1996
AB 25MG
FEB 13, 1996
AB 50MG
FEB 13, 1996
AB 100MG
FEB 13, 1996
AB 12.5MG
FEB 13, 1996
AB 25MG
FEB 13, 1996
AB 50MG
FEB 13, 1996
AB 100MG
FEB 13, 1996
AB 12.5MG
FEB 13, 1996
AB 25MG
FEB 13, 1996
AB 50MG
FEB 13, 1996
AB 100MG
FEB 13, 1996
AB 12.5MG
FEB 13, 1996
AB 25MG
FEB 13, 1996
AB 50MG
FEB 13, 1996
AB 100MG
FEB 13, 1996

ROYCE LABS

WEST WARD

CARBAMAZEPINE

TABLET; ORAL
CARBAMAZEPINE
TARO

> ADD > AB 200MG
> ADD >

TABLET, EXTENDED RELEASE; ORAL
TEGRETOL-XR
+ CIBA GEIGY
+
100MG
200MG

N20234 001
MAR 25, 1996
N20234 002
MAR 25, 1996

CARBAMAZEPINE

TABLET, EXTENDED RELEASE; ORAL
TEGRETOL-XR
+ CIBA GEIGY
400MG

N20234 003
MAR 25, 1996

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL
WEST WARD

AA 350MG

N40124 001
JAN 24, 1996

CARMUSTINE

IMPLANT; INTRACRANIAL
GLIADEL
+ GUILFORD PHARMS
7.7MG

N20637 001
SEP 23, 1996

CEFACLOR

CAPSULE; ORAL
CEFACLOR
BIOCRAFT

AB EQ 250MG BASE
AB EQ 500MG BASE
AB EQ 250MG BASE
AB EQ 500MG BASE
AB EQ 250MG BASE
AB EQ 500MG BASE
AB EQ 250MG BASE
AB EQ 500MG BASE

N64081 001
SEP 16, 1996
N64081 002
SEP 16, 1996
N64148 001
MAY 23, 1996
N64148 002
MAY 23, 1996
N64145 001
JUN 24, 1996
N64145 002
JUN 24, 1996

TABLET, EXTENDED RELEASE; ORAL
CECLOR CD
+ LILLY
+
EQ 375MG BASE
EQ 500MG BASE

N50673 001
JUN 28, 1996
N50673 002
JUN 28, 1996

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER
* BAXTER
EQ 10MG BASE/ML
N50566 003
JUN 08, 1983
EQ 20MG BASE/ML
N50566 004
JUN 08, 1983
EQ 10MG BASE/ML
N50566 003
JUN 08, 1983
EQ 20MG BASE/ML
N50566 004
JUN 08, 1983

> DLT >
> DLT >
> DLT >
> DLT >
> DLT >
> DLT >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

INJECTABLE; INJECTION
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER
* FUJISAWA
EQ 20MG BASE/ML
N50589 003
APR 13, 1995
EQ 40MG BASE/ML
N50589 004
APR 13, 1995

CEFIZOX IN PLASTIC CONTAINER
+ FUJISAWA
EQ 20MG BASE/ML
N50589 003
APR 13, 1995
EQ 40MG BASE/ML
N50589 004
APR 13, 1995

CEFEPIME HYDROCHLORIDE (ARGININE FORMULATION)

INJECTABLE; INJECTION
MAXIPIME
+ BRISTOL MYERS SQUIBB EQ 500MG BASE/VIAL
N50679 001
JAN 18, 1996
EQ 1GM BASE/VIAL
N50679 002
JAN 18, 1996
EQ 2GM BASE/VIAL
N50679 003
JAN 18, 1996

INJECTABLE; INJECTION
ROCEPHIN
ROCHE
EQ 500MG BASE/VIAL
N62654 001
APR 30, 1987
EQ 500MG BASE/VIAL
N62654 001
APR 30, 1987

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION
CEPTAZ
+ GLAXO WELLCOME
500MG/VIAL
N50646 001
SEP 27, 1990
500MG/VIAL
N50646 001
SEP 27, 1990

CEPHALEXIN
CAPSULE; ORAL
CEFANEX
APOTHECON
EQ 250MG BASE
N63063 001
SEP 29, 1989
EQ 500MG BASE
N63063 002
SEP 29, 1989
EQ 250MG BASE
N62872 001
JUN 20, 1988
EQ 500MG BASE
N62871 001
JUL 05, 1988
EQ 250MG BASE
N62872 001
JUN 20, 1988
EQ 500MG BASE
N62871 001
JUL 05, 1988

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER
AP BAXTER
EQ 10MG BASE/ML
N63221 001
APR 29, 1993
EQ 10MG BASE/ML
N63221 001
APR 29, 1993

FORTAZ IN PLASTIC CONTAINER
AP GLAXO WELLCOME
EQ 10MG BASE/ML
N50634 001
APR 28, 1989
EQ 10MG BASE/ML
N50634 001
APR 28, 1989

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

* CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER
 * BAXTER

EQ 20MG BASE/ML	N62422 003
	JAN 31, 1984
EQ 20MG BASE/ML	N62422 005
	JUL 16, 1991
EQ 20MG BASE/ML	N62730 001
	MAR 05, 1987
EQ 40MG BASE/ML	N62422 004
	JAN 31, 1984
EQ 40MG BASE/ML	N62422 006
	JUL 16, 1991
EQ 40MG BASE/ML	N62730 002
	MAR 05, 1987
EQ 20MG BASE/ML	N62422 003
	JAN 31, 1984
EQ 20MG BASE/ML	N62422 005
	JUL 16, 1991
EQ 20MG BASE/ML	N62730 001
	MAR 05, 1987
EQ 40MG BASE/ML	N62422 004
	JAN 31, 1984
EQ 40MG BASE/ML	N62422 006
	JUL 16, 1991
EQ 40MG BASE/ML	N62730 002
	MAR 05, 1987

CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER

* BAXTER

EQ 20MG BASE/ML	N62422 001
	JAN 31, 1984
EQ 40MG BASE/ML	N62422 002
	JAN 31, 1984
EQ 20MG BASE/ML	N62422 001
	JAN 31, 1984
EQ 40MG BASE/ML	N62422 002
	JAN 31, 1984

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL
 ZYRTEC
 + PFIZER

5MG/5ML
 N20346 001
 SEP 27, 1996

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HCL

HAILEY

AB	5MG	N85340 001
AB	10MG	N85339 001
AB	25MG	N84685 001
@	5MG	N85340 001
@	10MG	N85339 001
@	25MG	N84685 001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT HI TECH PHARMA 0.12%

N74356 001
 MAY 07, 1996

CHLOROTRIANISENE

CAPSULE; ORAL

TACE

* HOECHST MARION RSSL 25MG
 @ 25MG

> DLT >
 > ADD >

N13444 001
 N11444 001

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION

CHLOR-TRIMETON

AP * SCHERING PLOUGH 10MG/ML
 @ 10MG/ML

N08826 001
 N08826 001

AP * CHLORPHENIRAMINE MALEATE 10MG/ML
 @ 10MG/ML

N86096 001
 N86096 001

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

TUSSIONEX

* FISON

N20346 001
 SEP 27, 1996

5MG/5ML

EQ 8MG MALEATE/5ML;
 EQ 10MG BITARTRATE/5ML

N19111 001
 DEC 31, 1987

+ MEDEVA PHARMS

EQ 8MG MALEATE/5ML;
 EQ 10MG BITARTRATE/5ML

N19111 001
 DEC 31, 1987

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HCL

© WARNER CHILCOTT

0.3MG

N72140 001
JUN 13, 1988> ADD >
> ADD >
> ADD >CLOTRIMAZOLE

SOLUTION; TOPICAL

CLOTRIMAZOLE

TARO

1%

N74580 001
JUL 29, 1996> DLT >
> DLT >
> ADD >
> ADD >CLOZAPINE

TABLET; ORAL

CLOZAPINE

CREIGHTON

25MG

N74546 001
AUG 30, 1996

100MG

N74546 002
AUG 30, 1996> DLT >
> DLT >
> DLT >
> ADD >
> ADD >CLOZARIL

AB + SANDOZ

25MG

N19758 001
SEP 26, 1989

100MG

N19758 002
SEP 26, 1989> DLT >
> DLT >
> DLT >
> ADD >
> ADD >CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHERAZINE VC W/ CODEINE

HAUSEY

10MG/5ML; 5MG/5ML;

6.25MG/5ML

N88870 001
MAR 02, 1987

10MG/5ML; 5MG/5ML;

6.25MG/5ML

N88870 001
MAR 02, 1987PROMETHAZINE VC W/ CODEINE

CENCI

10MG/5ML; 5MG/5ML;

6.25MG/5ML

N88816 001
NOV 22, 1985> DLT >
> DLT >
> DLT >CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE VC W/ CODEINE

© CENCI

10MG/5ML; 5MG/5ML;
6.25MG/5MLN88816 001
NOV 22, 1985CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE W/ CODEINE

© CENCI

10MG/5ML; 6.25MG/5ML

N88814 001
NOV 22, 1985

©

10MG/5ML; 6.25MG/5ML

N88814 001
NOV 22, 1985CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE

© CENCI

10MG/5ML; 30MG/5ML;

1.25MG/5ML

N89018 001
JUL 23, 1986

©

10MG/5ML; 30MG/5ML;

1.25MG/5ML

N89018 001
JUL 23, 1986CORTICORELIN OVINE TRIFLUATE

INJECTABLE; INJECTION

ACTHREL

+ FERRING LABS

EQ 0.1MG BASE/VIAL

N20162 001
MAY 23, 1996CROMOLYN SODIUM

CAPSULE; ORAL

GASTROCROM

* FISOXS

100MG

N19188 001
DEC 22, 1989

+ MEDEVA PHARMS

100MG

N19188 001
DEC 22, 1989

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 10 / JAN'96 - OCT'96

CROMOLYN SODIUM

CONCENTRATE; ORAL

GASTROCROM

* FISON'S

100MG/5ML

+ MEDEVA PHARMS

100MG/5ML

N20479 001

FEB 29, 1986

N20479 001

FEB 29, 1996

SOLUTION/DROPS; OPHTHALMIC

CROLOM

BAUSCH AND LOMB

4%

> DLT >

> DLT >

> ADD >

> ADD >

> DLT >

> DLT >

> ADD >

> ADD >

> ADD >

OPTICROM

* FISON'S

4%

4%

4%

4%

4%

4%

CYANOCOBALAMIN

INJECTABLE; INJECTION

BETALIN 12

LILLY

AP

AP

AP

0.1MG/ML

1MG/ML

0.1MG/ML

1MG/ML

CYANOCOBALAMIN

DELL LABS

AP

AP

AP

0.1MG/ML

1MG/ML

0.03MG/ML

0.03MG/ML

0.1MG/ML

1MG/ML

CYCLOTHIAZIDE

TABLET; ORAL

ANHYDRON

* LILLY

@

2MG

2MG

N13157 002

N13157 002

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HCL

HALESY

2MG/5ML

2MG/5ML

@

N89199 001

JUL 03, 1986

N89199 001

JUL 03, 1986

DALTEPARIN SODIUM

INJECTABLE; INJECTION

FRAGMIN

+ PHARMACIA AND UPJOHN 5,000 IU/0.2ML

N20287 003

MAR 18, 1996

DANAZOL

CAPSULE; ORAL

DANAZOL

BARR

200MG

N74582 001

AUG 09, 1996

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

N74582 001

AUG 09, 1996

N17557 002

N50704 002

APR 08, 1996

N74430 001

FEB 09, 1996

N74430 002

FEB 09, 1996

DESMOPRESSIN ACETATESPRAY, METERED; NASAL
STIMATE

* ARMOUR PHARM

0.15MG/INH

N20355 001

MAR 07, 1994

+ CENTEON

0.15MG/INH

N20355 001

MAR 07, 1994

DESOGESTREL; ETHINYL ESTRADIOLTABLET; ORAL-21
ORTHO-CEPT

JOHNSON RW

0.15MG;0.03MG

N20301 001

DEC 14, 1992

+

0.15MG;0.03MG

N20301 001

DEC 14, 1992

DESOXIMETASONE

OINTMENT; TOPICAL

DESOXIMETASONE

TARO

0.25%

N74286 001

JUN 07, 1996

TOPICORT

AB + HOECHST MARION RSSL

0.25%

N18763 001

SEP 30, 1983

DEXAMETHASONE

CONCENTRATE; ORAL

DEXAMETHASONE INTENSOL

+ ROXANE

1MG/ML

N88252 001

SEP 01, 1983

SOLUTION; ORAL

DEXAMETHASONE INTENSOL

ROXANE

0.5MG/0.5ML

N88252 001

SEP 01, 1983

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

DEXACIDIN

CIBA

0.1%;EQ 3.5MG BASE/GM;

10,000 UNITS/GM

N62566 001

FEB 22, 1985

AT

IOLAB

0.1%;EQ 3.5MG BASE/GM;

10,000 UNITS/GM

N62566 001

FEB 22, 1985

SUSPENSION/DROPS; OPHTHALMIC

DEXACIDIN

CIBA

0.1%;EQ 3.5MG BASE/ML;

10,000 UNITS/ML

N62544 001

OCT 29, 1984

AT

IOLAB

0.1%;EQ 3.5MG BASE/ML;

10,000 UNITS/ML

N62544 001

OCT 29, 1984

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

BAUSCH AND LOMB

EQ 0.1% PHOSPHATE

N40069 001

JUL 26, 1996

AT

DEXFENFLURAMINE HYDROCHLORIDE

CAPSULE; ORAL

REDUX

+ INTERNEURON

15MG

N20344 001

APR 29, 1996

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

HALSEY

10MG

N83930 001

N83930 001

@

10MG

N86521 001

N86521 001

@

5MG

N86521 001

N84051 002

@

5MG

N84051 002

N84051 002

+ *

10MG

N84051 002

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 10 / JAN '96 - OCT '96

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

<u>AA</u>	SYRUP; ORAL			
	<u>PHEAZINE DM</u>			
	<u>HALSEY</u>	<u>15MG/5ML; 5.25MG/5ML</u>	<u>N88913 001</u>	
			<u>MAR 02, 1987</u>	
		<u>15MG/5ML; 6.25MG/5ML</u>	<u>N88913 001</u>	
			<u>MAR 02, 1987</u>	
	<u>PROMETHAZINE HCL AND DEXTROMETHORPHAN HYDROBROMIDE</u>			
	<u>HI TECH PHARMA</u>	<u>15MG/5ML; 6.25MG/5ML</u>	<u>N40027 001</u>	
			<u>JUL 31, 1996</u>	

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
 DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
 MCGAW N18386 001
 10GM/100ML; 200MG/100ML N18386 001
 10GM/100ML; 200MG/100ML N18386 001
 DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 MCGAW N18229 001
 10GM/100ML; 450MG/100ML N18229 001
 10GM/100ML; 450MG/100ML N18229 001
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 MCGAW N18376 001
 2.5GM/100ML; 900MG/100ML N18376 001
 2.5GM/100ML; 900MG/100ML N18376 001

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

<u>AP</u>	INJECTABLE; INJECTION			
	<u>MD-76</u>			
	<u>MALLINCKRODT</u>	<u>56%; 10%</u>	<u>N19292 001</u>	
			<u>SEP 29, 1989</u>	
	<u>MD-76R</u>			
	<u>+ MALLINCKRODT</u>	<u>56%; 10%</u>	<u>N19292 001</u>	
			<u>SEP 29, 1989</u>	

DIATRIZOATE SODIUM

<u>AT</u>	SOLUTION; URETERAL			
	<u>HYPAAQUE SODIUM 20%</u>			
	<u>NYCOMED</u>	<u>20%</u>	<u>N09561 002</u>	
		<u>20%</u>	<u>N09561 002</u>	

DICLOFENAC SODIUM

<u>AB</u>	TABLET, DELAYED RELEASE; ORAL			
	<u>DICLOFENAC SODIUM</u>			
	<u>NOVOPHARM</u>	<u>75MG</u>	<u>N74390 001</u>	
			<u>AUG 15, 1996</u>	
	<u>PUREPAC PHARM</u>	<u>50MG</u>	<u>N74514 001</u>	
			<u>MAR 26, 1996</u>	
		<u>75MG</u>	<u>N74514 002</u>	
			<u>MAR 26, 1996</u>	
	TABLET, EXTENDED RELEASE; ORAL			
	<u>VOLTAREN-XR</u>			
	<u>+ GEIGY</u>	<u>100MG</u>	<u>N20254 001</u>	
			<u>MAR 08, 1996</u>	

DICLOXACILLIN SODIUM

<u>AB</u>	CAPSULE; ORAL			
	<u>DICLOXACILLIN SODIUM</u>			
	<u>APOTHECON</u>	<u>EQ 250MG BASE</u>	<u>N61454 001</u>	
		<u>EQ 250MG BASE</u>	<u>N61454 001</u>	
		<u>EQ 500MG BASE</u>	<u>N61454 003</u>	
		<u>EQ 500MG BASE</u>	<u>N61454 003</u>	
	<u>PATHOCIL</u>			
	<u>+ WYETH AYERST</u>	<u>EQ 250MG BASE</u>	<u>N50011 002</u>	
		<u>EQ 250MG BASE</u>	<u>N50011 002</u>	
		<u>EQ 500MG BASE</u>	<u>N50011 003</u>	
			<u>MAR 28, 1983</u>	
		<u>EQ 500MG BASE</u>	<u>N50011 003</u>	
			<u>MAR 28, 1983</u>	

POWDER FOR RECONSTITUTION; ORAL

<u>AB</u>	<u>DICLOXACILLIN SODIUM</u>			
	<u>APOTHECON</u>	<u>EQ 62.5MG BASE/5ML</u>	<u>N61455 001</u>	
		<u>EQ 62.5MG BASE/5ML</u>	<u>N61455 001</u>	
	<u>PATHOCIL</u>			
	<u>+ WYETH AYERST</u>	<u>EQ 62.5MG BASE/5ML</u>	<u>N50092 001</u>	
		<u>EQ 62.5MG BASE/5ML</u>	<u>N50092 001</u>	

DICYCLOMINE HYDROCHLORIDE

<u>AB</u>	CAPSULE; ORAL			
	<u>DICYCLOMINE HCL</u>			
	<u>LANNETT</u>	<u>10MG</u>	<u>N84285 001</u>	

DICYCLOMINE HYDROCHLORIDEINJECTABLE; INJECTION
BENTYL PRESERVATIVE FREEAP HOECHST MARION RSSL 10MG/MLN20506 001
OCT 04, 1996
N20506 002
OCT 04, 1996
N20506 003
OCT 04, 1996TABLET; ORAL
DICYCLOMINE HCLAB WEST WARD 20MGN40161 001
OCT 01, 1996> ADD > DILTIAZEM MALATE

> ADD > TABLET, EXTENDED RELEASE; ORAL

> ADD > TIAMATE

> ADD > + MERCK EQ 120MG HCL

> ADD > + EQ 180MG HCL

> ADD > + EQ 240MG HCL

DIFLUNISALTABLET; ORAL
DIFLUNISALAB GENEVA PHARMS 500MGN74604 001
JUN 10, 1996AB PUREPAC PHARM 250MGN74285 001
MAY 07, 1996AB 500MGN74285 002
MAY 07, 1996> ADD > DILTIAZEM MALATE; ENALAPRIL MALEATE

> ADD > TABLET, EXTENDED RELEASE; ORAL

> ADD > TECZEM

> ADD > + MERCK EQ 180MG HCL; 5MG

N20507 001
OCT 04, 1996DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

AA DIPHENHYDRAMINE HCLAA 50MGN87914 001
JUN 04, 1984
N87914 001
JUN 04, 1984DIGOXININJECTABLE; INJECTION
DIGOXINAP SANOFI WINTHROP 0.25MG/MLN40093 001
MAY 16, 1996AP DIGOXIN PEDIATRICAP SANOFI WINTHROP 0.1MG/MLN40092 001
APR 25, 1996* LANOXIN* GLAXO WELLCOME 0.1MG/ML

N09330 004

AP LANOXIN PEDIATRICAP GLAXO WELLCOME 0.1MG/ML

N09330 004

DILTIAZEM HYDROCHLORIDEINJECTABLE; INJECTION
CARDIZEMAP HOECHST MARION RSSL 5MG/MLN20027 001
OCT 24, 1991AP DILTIAZEM HCLAP BEDFORD 5MG/MLN74617 001
FEB 28, 1996

ELIXIR; ORAL

AA BELIXAA HALSEYAA 12.5MG/5ML

AA 12.5MG/5ML

N86586 001
OCT 03, 1983
N86586 001
OCT 03, 1983AA DIBENILAA CENCIAA 12.5MG/5ML

AA 12.5MG/5ML

N88304 001
DEC 16, 1983
N88304 001
DEC 16, 1983AA DIPHENHYDRAMINE HCLAA CENCIAA 12.5MG/5ML

AA 12.5MG/5ML

N87941 001
DEC 17, 1982
N87941 001
DEC 17, 1982

INJECTABLE: INJECTION

5MG/ML

N74521 001
OCT 18, 1996

IV PERSANTINE + BOEHRINGER INGELHEIM 5MG/ML

N19817 001
DEC 13, 1990

DOXYCYCLINE HYCLATE
SUPERPHARM

EQ 100MG BASE

N62494 001
FEB 20, 1985
N62494 001
FEB 20, 1985

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL
DISOPYRAMIDE PHOSPHATE
KV PHARM EQ 100N

N71929 001
AUG 19, 1988
N71929 001
AUG 19, 1988

2.5MG/ML;
EQ 0.05MG BASE/ML

N71982 001
MAY 04, 1988

EO 100MG BASE

$$\begin{array}{r} > \text{DLI} > \\ > \hline > \text{ADD} > \\ > \hline > \text{ADD} > \end{array}$$

2.5MG/ML;
EQ 0.05MG BASE/ML

AB NORPACE CR
SEARLE

EQ 100MG BASE
EO 100MG BASE

N18655 001
JUL 20, 1982
N18655 001
JUL 20, 1982

2.5MG/ML;
EQ 0.05MG BASE/ML
2.5MG/ML;
EQ 0.05MG BASE/ML

N16049 001

DOBUTAMINE HYDROCHLORIDE

INJECTABLE: INJECTION

DOBUTAMINE HCL
ABOTT
EQ 1.25GM BASE/100ML

N74634 001
SEP 27, 1996

10MG/ML

N40044 001
MAR 20, 1996

EQ 12.5MG BASE/ML

N74381 001
SEP 26, 1996

ESERVATIVE FREE
10MG/ML

N40043 001
MAR 20, 1996

DOCETAXEL

INJECTABLE; INJECTION
TAXOTERE
+ RHONE POULENC

N20449 001
MAY 14, 1996

ap + ROCHE TENSILON PRESERVATIVE FREE 10MG/ML

N07959 002

DOPAMTNE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL
SANOFI WINTHROP

N74403 001
MAY 23, 1996

40MG/ML

ENCATINIDE HYDROCHLORIDE

CAPSULE; ORAL
ENKAID
© BRISTOL
©

N18981 002
DEC 24, 1986
N18981 003
DEC 24, 1986

ENCAINIDE HYDROCHLORIDE

CAPSULE; ORAL
ENKAID

BRISTOL MYERS SQUIBB 25MG
35MG

N18981 002
DEC 24, 1986
N18981 003
DEC 24, 1986

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL

ILOSONE

@ DISTA

@ LILLY

AB +

EQ 125MG BASE/5ML
EQ 250MG BASE/5ML
EQ 125MG BASE/5ML
EQ 250MG BASE/5ML

N61894 001
N61894 002
N50010 001
N50010 002

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL W/ EPINEPHRINE

0.01MG/ML; 1%
0.01MG/ML; 1%

N83154 001
N83154 001

EQ 500MG BASE/VIAL

N62586 001
JAN 04, 1988
N62586 002
JAN 04, 1988
N62586 001
JAN 04, 1988
N62586 002
JAN 04, 1988

ERYTHROMYCIN

ointment; OPHTHALMIC
ERYTHROMYCIN

AT ADV REMEDIES

0.5%

N64030 001
JUL 18, 1996

EQ 500MG BASE/VIAL
EQ 1GM BASE/VIAL

ESTRADIOL

SOLUTION; TOPICAL
ERYTHRO-STATIN

AT HI TECH PHARMA

2%

N64101 001
OCT 22, 1996

0.0375MG/24HR

SWAB; TOPICAL
ERYCETTE

AT + J AND J

2%

N50594 001
FEB 15, 1985

0.05MG/24HR

AT * JOHNSON RW

2%

N50594 001
FEB 15, 1985

0.075MG/24HR

AT ERYTHROMYCIN

2%

N64126 001
JUL 03, 1996

0.1MG/24HR

AT STIEFEL

2%

N64128 001
JUL 03, 1996

0.0375MG/24HR

AT + CIBA GEIGY

2%

N64126 001
JUL 03, 1996

0.05MG/24HR

AT +

2%

N64128 001
JUL 03, 1996

0.075MG/24HR

AT +

2%

N64126 001
JUL 03, 1996

0.1MG/24HR

AT +

2%

N64128 001
JUL 03, 1996

0.0375MG/24HR

AT +

2%

N64126 001
JUL 03, 1996

0.05MG/24HR

AT +

2%

N64128 001
JUL 03, 1996

0.075MG/24HR

AT +

2%

N64126 001
JUL 03, 1996

0.1MG/24HR

AT +

2%

N64128 001
JUL 03, 1996

0.0375MG/24HR

AT +

2%

N64126 001
JUL 03, 1996

0.05MG/24HR

AT +

2%

N64128 001
JUL 03, 1996

0.075MG/24HR

AT +

2%

N64126 001
JUL 03, 1996

0.1MG/24HR

AT +

2%

N64128 001
JUL 03, 1996

0.0375MG/24HR

AT +

2%

N64126 001
JUL 03, 1996

0.05MG/24HR

AT +

2%

N64128 001
JUL 03, 1996

0.075MG/24HR

AT +

2%

N64126 001
JUL 03, 1996

0.1MG/24HR

AT +

2%

N64128 001
JUL 03, 1996

0.0375MG/24HR

AT +

2%

N64126 001
JUL 03, 1996

0.05MG/24HR

AT +

2%

N64128 001
JUL 03, 1996

0.075MG/24HR

AT +

2%

N64126 001
JUL 03, 1996

0.1MG/24HR

AT +

2%

N64128 001
JUL 03, 1996

0.0375MG/24HR

AT +

2%

N64126 001
JUL 03, 1996

0.05MG/24HR

AT +

2%

N64128 001
JUL 03, 1996

0.075MG/24HR

AT +

2%

N64126 001
JUL 03, 1996

0.1MG/24HR

AT +

2%

N64128 001
JUL 03, 1996

0.0375MG/24HR

AT +

2%

N64126 001
JUL 03, 1996

0.05MG/24HR

AT +

2%

N64128 001
JUL 03, 1996

0.075MG/24HR

INSERT, EXTENDED RELEASE; VAGINAL
ESTRING

+ PHARMACIA AND UPJOHN 0.0075MG/24HR

N61894 001

EQ 125MG BASE/5ML
EQ 250MG BASE/5ML

AB DISTA

AB +

N20472 001
APR 26, 1996

ESTRADIOLTABLET; ORALESTRACE

BRISTOL MYERS SQUIBB 0.5MG

AB N81295 001 JUN 30, 1993
 AB N84499 001
 AB N84500 001

ESTRADIOL

WATSON LABS

0.5MG

AB N40114 003 MAR 14, 1996
 AB N40114 001
 AB N40114 002 MAR 14, 1996

2MG

ESTRONEINJECTABLE; INJECTIONESTROGENIC SUBSTANCE

* WYETH AYERST

2MG/ML

2MG/ML

NATURAL ESTROGENIC SUBSTANCE-ESTRONESTERIS

2MG/ML

BP N83488 001
 BP N83488 001
 BP N85237 001
 BP N85237 001
 BP N85237 001 NOV 23, 1982

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATETABLET; ORAL-21

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL 1/35-21

AB N27270 001 DEC 30, 1991
 AB N27270 001

AB N27272 001 DEC 30, 1991
 AB N27272 001

ZOVIA 1/35E-21

WATSON LABS

0.035MG;1MG

AB N72720 001 DEC 30, 1991
 AB N72722 001 DEC 30, 1991

ZOVIA 1/50E-21

WATSON LABS

0.05MG;1MG

0.05MG;1MG

TABLET; ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL 1/35-28

AB N27271 001 DEC 30, 1991
 AB N27271 001

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATETABLET; ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL 1/50-28

AB N27273 001 DEC 30, 1991
 AB N27273 001

ZOVIA 1/35E-28

WATSON LABS

0.035MG;1MG

AB N27271 001 DEC 30, 1991
 AB N27271 001

ZOVIA 1/50E-28

WATSON LABS

0.05MG;1MG

AB N27273 001 DEC 30, 1991
 AB N27273 001

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATETABLET; ORAL-28

LOESTRIN PE 1.5/30

* PARKE DAVIS

0.03MG;75MG;1.5MG

LOESTRIN PE 1/20

* PARKE DAVIS

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

0.02MG;75MG;1MG

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

> ADD >
 > ADD >
 > ADD >
 > ADD >

TABLET; ORAL-28
 LOESTRIN FE 1.5/30
 + PARKE DAVIS
 LOESTRIN FE 1/20
 + PARKE DAVIS

0.03MG;1.5MG
 0.02MG;1MG

N17355 001
 N17354 001

EVANS BLUE

INJECTABLE; INJECTION
 EVANS BLUE
 @ PARKE DAVIS

0.5%

N08041 001

FAMCICLOVIR

TABLET; ORAL
 FAMVIR

SMITHKLINE BEECHAM 250MG

N20363 001
 APR 26, 1996

ETODOLAC

TABLET; ORAL

LODINE
 * WYETH AVERST

400MG

N18922 004
 JUL 29, 1993

400MG

N18922 004
 JUL 29, 1993

500MG

N18922 005
 JUN 28, 1996

FAMOTIDINE

INJECTABLE; INJECTION
 PERCID IV PRESERVATIVE FREE
 * MERCK

10MG/ML

N19510 004
 NOV 04, 1986

PERCID PRESERVATIVE FREE
 + MERCK

10MG/ML

N19510 004
 NOV 04, 1986

> ADD >
 > ADD >
 > ADD >
 > ADD >
 > ADD >

TABLET, EXTENDED RELEASE; ORAL
 LODINE XL
 + WYETH AVERST

400MG

N20584 001
 OCT 25, 1996

600MG

N20584 002
 OCT 25, 1996

FERUMOXIDESETOPOSIDE

INJECTABLE; INJECTION
 ETOPOSIDE
 GENSLA

20MG/ML

N74529 001
 JUL 24, 1996

20MG/ML

N74513 001
 MAR 14, 1996

20MG/ML

N74513 001
 MAR 14, 1996

20MG/ML

N74227 001
 FEB 22, 1996

20MG/ML

N74228 001
 OCT 15, 1996

20MG/ML

N74228 001
 OCT 15, 1996

STERIS

PHARMACHEMIE (NL)

20MG/ML

N74228 001
 OCT 15, 1996

ALLEGRA
 + HOECHST MARION RSSL 60MG

N20625 001

JUL 25, 1996

ALLEGRA
 + HOECHST MARION RSSL 60MG

N20625 001

JUL 25, 1996

> DLT >
 > DLT >
 > DLT >
 > DLT >

FLECAINIDE ACETATEETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION
 ETOPOPHOS
 + BRISTOL MYERS SQUIBB EQ 100MG BASE/VIAL

20MG/ML

N20457 001
 MAY 17, 1996

TABLET; ORAL
 TAMBOCOR
 3M

50MG

N18830 004
 AUG 23, 1988

FLECAINIDE ACETATE

> DLT >
> DLT >
> DLT >
> DLT >
> DLT >
> DLT >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

TABLET; ORAL
TAMBOCOR
3M

100MG

150MG

50MG

100MG

150MG

200MG

N18830 001

OCT 31, 1985

N18830 003

JUN 03, 1988

N18830 004

AUG 23, 1988

N18830 001

OCT 31, 1985

N18830 003

JUN 03, 1988

N18830 002

OCT 31, 1985

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE
HAMILTON PHARMA CA

0.01%

0.025%

0.025%

0.2%

N12787 004

N12787 002

N12787 005

N16161 002

N12787 004

N12787 002

N12787 005

N16161 002

AT

AT

AT

AT

AT

AT

AT

AT

SYNALAR

+ SYNTEX

+ SYNTEX

+ SYNTEX

SYNALAR-HP

+ SYNTEX

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE
HAMILTON PHARMA CA

0.025%

0.025%

N13960 001

N13960 001

AT

AT

SYNALAR

+ SYNTEX

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE
HAMILTON PHARMA CA

0.01%

0.01%

N15296 001

N15296 001

AT

AT

SYNALAR

+ SYNTEX

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

HAMILTON PHARMA CA

0.05%

FLUOCINONIDE EMOLLIENT BASE

HAMILTON PHARMA CA

0.05%

LIDEX

+ SYNTEX

LIDEX-E

+ SYNTEX

0.05%

0.05%

GEL; TOPICAL

FLUOCINONIDE

HAMILTON PHARMA CA

0.05%

LIDEX

+ SYNTEX

OINTMENT; TOPICAL

FLUOCINONIDE

HAMILTON PHARMA CA

0.05%

LIDEX

+ SYNTEX

0.05%

SOLUTION; TOPICAL

FLUOCINONIDE

HAMILTON PHARMA CA

0.05%

LIDEX

+ SYNTEX

0.05%

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

+ PHARMACIA

50MG/ML

AP

PHARMACIA AND UPJOHN

50MG/ML

AP

FLUOROURACIL

+ ROCHE

50MG/ML

AP

AP

50MG/ML

50MG/ML

N16908 002

N16908 003

N16908 002

N16908 003

N16908 002

N16908 003

N17373 001

N17373 001

N16909 002

N16909 002

N18849 001

APR 06, 1984

N18849 001

APR 06, 1984

N40023 001

OCT 18, 1991

N40023 001

OCT 18, 1991

N12209 001

N12209 001

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

BEDFORD

AO 25MG/ML

N74531 001

AUG 30, 1996

AO 25MG/ML

N74795 001

SEP 10, 1996

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HCL

PHARM ASSOC

5MG/ML

N74725 001

SEP 16, 1996

ELIXIR; ORAL

FLUPHENAZINE HCL

PHARM ASSOC

2.5MG/5ML

N40146 001

AUG 21, 1996

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HCL

SUPERPHARM

15MG

N71659 001

AUG 04, 1988

30MG

N71660 001

AUG 04, 1988

15MG

N71659 001

AUG 04, 1988

30MG

N71660 001

AUG 04, 1988

15MG

N71767 001

DEC 04, 1987

30MG

N71768 001

DEC 04, 1987

15MG

N71767 001

DEC 04, 1987

30MG

N71768 001

DEC 04, 1987

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT

GLAXO WELLCOME

0.044MG/INH

N20548 001

MAR 27, 1996

0.11MG/INH

N20548 002

MAR 27, 1996

0.22MG/INH

N20548 003

MAR 27, 1996

+

FOLIC ACID

TABLET; ORAL

FOLIC ACID

HAILEY

@

1MG

N83598 001

N83598 001

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

+ PARKE DAVIS

EQ 50MG PHENYTOIN NA/ML

N20450 001

AUG 05, 1996

FUROSEMIDE

TABLET; ORAL

FUROSEMIDE

SUPERPHARM

20MG

N18370 002

JUN 26, 1984

N18370 001

FEB 10, 1983

N18370 002

JUN 26, 1984

N18370 001

FEB 10, 1983

N18413 001

NOV 30, 1983

N18413 002

NOV 30, 1983

N18413 001

NOV 30, 1983

N18413 002

NOV 30, 1983

GANCICLOVIRIMPLANT; IMPLANTATION

VITRASERT
* CHIRON VISION

+

4.5-6.4MG

4.5MG

N20569 001
MAR 04, 1996
N20569 001
MAR 04, 1996

GANCICLOVIR SODIUMINJECTABLE; INJECTION

CYTOVENE IV
+ ROCHE

* SYNTEX

EQ 500MG BASE/VIAL

EQ 500MG BASE/VIAL

N19661 001
JUN 23, 1989
N19661 001
JUN 23, 1989

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION

GEMZAR
+ LILLY

+

EQ 200MG BASE/VIAL

EQ 1GM BASE/VIAL

N20509 001
MAY 15, 1996
N20509 002
MAY 15, 1996

GENTAMICIN SULFATEINJECTABLE; INJECTION

GENTAMICIN SULFATE
ABBOTT

AP

AP

AP

AP

AP

AP

AP

EQ 60MG BASE/100ML

EQ 70MG BASE/100ML

EQ 80MG BASE/100ML

EQ 90MG BASE/100ML

EQ 100MG BASE/100ML

EQ 1.2MG BASE/ML

EQ 1.4MG BASE/ML

N62413 006
AUG 11, 1983
N62413 007
AUG 11, 1983
N62413 008
AUG 11, 1983
N62413 009
AUG 11, 1983
N62413 010
AUG 11, 1983
N62413 001
AUG 11, 1983
N62413 002
AUG 11, 1983

GENTAMICIN SULFATEINJECTABLE; INJECTION

GENTAMICIN SULFATE
ABBOTT

AP

AP

AP

EQ 1.6MG BASE/ML

EQ 1.8MG BASE/ML

EQ 2MG BASE/ML

EQ 60MG BASE/100ML

EQ 70MG BASE/100ML

EQ 80MG BASE/100ML

EQ 90MG BASE/100ML

EQ 100MG BASE/100ML

EQ 1.2MG BASE/ML

EQ 1.4MG BASE/ML

EQ 1.6MG BASE/ML

EQ 1.8MG BASE/ML

EQ 2MG BASE/ML

N62413 003
AUG 11, 1983
N62413 004
AUG 11, 1983
N62413 005
AUG 11, 1983
N62413 006
AUG 11, 1983
N62413 007
AUG 11, 1983
N62413 008
AUG 11, 1983
N62413 009
AUG 11, 1983
N62413 010
AUG 11, 1983
N62413 001
AUG 11, 1983
N62413 002
AUG 11, 1983
N62413 003
AUG 11, 1983
N62413 004
AUG 11, 1983
N62413 005
AUG 11, 1983

OINTMENT; OPHTHALMIC

GENTACIDIN

CIBA

AT

AT

EQ 0.3% BASE

EQ 0.3% BASE

N62501 001
JUL 26, 1984
N62501 001
JUL 26, 1984

SOLUTION/DROPS; OPHTHALMIC

GENTACIDIN

CIBA

AT

AT

EQ 0.3% BASE

EQ 0.3% BASE

N62480 001
MAR 30, 1984
N62480 001
MAR 30, 1984

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE
 NOVOPHARM

AB 5MG
 N74387 001
 MAR 04, 1996
 AB 10MG
 N74387 002
 MAR 04, 1996

GLUTETHIMIDE

TABLET; ORAL
GLUTETHIMIDE
 HALSEY

250MG
 N89458 001
 OCT 10, 1986
 250MG
 N89458 001
 OCT 10, 1986

GLYBURIDE

TABLET; ORAL
GLYNASE
 PHARMACIA AND UPJOHN

AB 3MG
 N20051 002
 MAR 04, 1992
 6MG
 N20051 004
 SEP 24, 1993
 AB 3MG
 N20051 002
 MAR 04, 1992
 6MG
 N20051 004
 SEP 24, 1993

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE
 ABBOTT

AP 0.2MG/ML
 N89393 001
 JUN 15, 1988
 0.2MG/ML
 N89393 001
 JUN 15, 1988

GOSERELIN ACETATE

IMPLANT; IMPLANTATION
 ZOLADEX
 + ZENECA

EQ 10.8MG BASE
 N20578 001
 JAN 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN
 BAUSCH AND LOMB

AT 0.025MG/ML; EQ 1.75MG BASE/ML;
 10,000 UNITS/ML
 N64047 001
 JAN 31, 1996

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
 HALDOL DECANOATE 100
 + JOHNSON RW

EQ 100MG BASE/ML
 N18701 002
 OCT 31, 1989

HALOPROGIN

CREAM; TOPICAL

HALOTEX
 + WESTWOOD SQUIBB

1%
 1%
 N16942 001
 N16942 001

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN LOCK FLUSH
 SOLOPAK

AP 100 UNITS/ML
 N87905 001
 APR 20, 1983
 100 UNITS/ML
 N87905 001
 APR 20, 1983

HEPARIN SODIUM

Lilly

AP 1,000 UNITS/ML
 N03521 001
 APR 20, 1983
 AP 20,000 UNITS/ML
 N03521 004
 APR 20, 1983
 AP 1,000 UNITS/ML
 N03521 001
 APR 20, 1983
 AP 20,000 UNITS/ML
 N03521 004
 APR 20, 1983

AP MARSAM

N89393 001
 JUN 15, 1988
 N89393 001
 JUN 15, 1988

ORGANON

AP 1,000 UNITS/ML
 N00552 008
 JUN 07, 1996
 AP 5,000 UNITS/ML
 N00552 009
 JUN 07, 1996
 AP 10,000 UNITS/ML
 N00552 010
 JUN 07, 1996
 AP 1,000 UNITS/ML
 N00552 008
 JUN 07, 1996
 AP 5,000 UNITS/ML
 N00552 009
 JUN 07, 1996
 AP 10,000 UNITS/ML
 N00552 010
 JUN 07, 1996

PHARM SPEC ASSOC

AP 20,000 UNITS/ML
 N17780 004
 JUN 07, 1996
 AP 1,000 UNITS/ML
 N17780 001
 JUN 07, 1996
 AP 5,000 UNITS/ML
 N17780 002
 JUN 07, 1996

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

@ PHARM SPEC ASSOC

PHARM SPEC'LTS ASSOC

AP
AP
AP
AP
AP

10,000 UNITS/ML
20,000 UNITS/ML
1,000 UNITS/ML
5,000 UNITS/ML
10,000 UNITS/ML
10,000 UNITS/ML

N17780 003
N17780 004
N17780 001
N17780 002
N17780 003
N40095 001

SANOFI WINTHROP

SOLOPAK

1,000 UNITS/ML
5,000 UNITS/ML
10,000 UNITS/ML
5,000 UNITS/0.5ML
1,000 UNITS/ML
5,000 UNITS/ML
10,000 UNITS/ML
5,000 UNITS/0.5ML

JUL 26, 1996
N87043 001
N87077 001
N87107 001
N87395 001
N87043 001
N87077 001
N87107 001
N87395 001

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

MCGAW

5,000 UNITS/100ML
5,000 UNITS/100ML

N19134 001
MAR 29, 1985
N19134 001
MAR 29, 1985

AP

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HCL

HALSEY

10MG
10MG

N89218 001
JAN 22, 1986
N89218 001
JAN 22, 1986

AA

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDRO-D

HALSEY

25MG
50MG
25MG
50MG

N86504 001
N83891 002
N86504 001
N83891 002

AB

AB

@

@

HYDROCHLOROTHIAZIDE

BARR

50MG
50MG

N84771 001
N84771 001

AB

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

SUPERPHARM

25MG

AB

N17780 003

AB

N17780 004

50MG

AB

N17780 001

100MG

AB

N17780 002

25MG

AB

N17780 003

50MG

AB

N40095 001

100MG

AB

JUL 26, 1996

25MG

AB

N87043 001

50MG

AB

N87077 001

100MG

AB

N87107 001

25MG

AB

N87395 001

50MG

AB

N87043 001

100MG

AB

N87077 001

25MG

AB

N87107 001

50MG

AB

N87395 001

100MG

AB

JUL 26, 1996

25MG

AB

N87043 001

50MG

AB

N87077 001

100MG

AB

N87107 001

25MG

AB

N87395 001

50MG

AB

N87043 001

100MG

AB

N87077 001

25MG

AB

N87107 001

50MG

AB

N87395 001

100MG

AB

JUL 26, 1996

25MG

AB

N87043 001

50MG

AB

N87077 001

100MG

AB

N87107 001

25MG

AB

N87395 001

50MG

AB

N87043 001

100MG

AB

N87077 001

25MG

AB

N87107 001

50MG

AB

N87395 001

100MG

AB

JUL 26, 1996

25MG

AB

N87043 001

50MG

AB

N87077 001

100MG

AB

N87107 001

25MG

AB

N87395 001

50MG

AB

N87043 001

100MG

AB

N87077 001

25MG

AB

N87107 001

50MG

AB

N87395 001

100MG

AB

JUL 26, 1996

25MG

AB

N87043 001

50MG

AB

N87077 001

100MG

AB

N87107 001

25MG

AB

N87395 001

50MG

AB

N87043 001

100MG

AB

N87077 001

25MG

AB

N87107 001

50MG

AB

N87395 001

100MG

AB

JUL 26, 1996

25MG

AB

N87043 001

50MG

AB

N87077 001

100MG

AB

N87107 001

25MG

AB

N87395 001

50MG

AB

N87043 001

100MG

AB

N87077 001

25MG

AB

N87107 001

50MG

AB

N87395 001

100MG

AB

JUL 26, 1996

25MG

AB

N87043 001

50MG

AB

N87077 001

100MG

AB

N87107 001

25MG

AB

N87395 001

50MG

AB

N87043 001

100MG

AB

N87077 001

25MG

AB

N87107 001

50MG

AB

N87395 001

100MG

AB

JUL 26, 1996

25MG

AB

N87043 001

50MG

AB

N87077 001

100MG

AB

N87107 001

25MG

AB

N87395 001

50MG

AB

N87043 001

100MG

AB

N87077 001

25MG

AB

N87107 001

50MG

AB

N87395 001

100MG

AB

JUL 26, 1996

25MG

AB

N87

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

ALPHAREDISOL

AP * MERCK SHARP DOHME

1MG/ML
1MG/ML

N80778 001
N80778 001

HYDROXOCOBALAMIN

AP STERIS

1MG/ML
1MG/ML

N85528 001
N85998 001

1MG/ML
1MG/ML

N85528 001
N85998 001

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

AP HYDROXYCHLOROQUINE SULFATE
INVAMED 200MG

AB

N40150 001
JAN 27, 1996

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCL

AP SOLOPAK

25MG/ML
50MG/ML
25MG/ML
50MG/ML

N86822 001
N87310 001
N86822 001
N87310 001

TABLET; ORAL

HYDROXYZINE HCL

AB HALSEY

10MG

N89366 001

MAY 02, 1988

N89366 001

MAY 02, 1988

N88794 001

DEC 05, 1984

N88795 001

DEC 05, 1984

N88796 001

DEC 05, 1984

N88794 001

DEC 05, 1984

N88795 001

DEC 05, 1984

N88796 001

DEC 05, 1984

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB CHELSEA LABS

EQ 25MG HCL

N40156 001

JUL 15, 1996

N40156 002

JUL 15, 1996

EQ 50MG HCL

IBUPROFEN

SUSPENSION; ORAL
CHILDREN'S MOTRIN
EX * MCNEIL CONS PRODS

100MG/5ML

N19842 001

SEP 19, 1989

IBU

EX KNOLL PHARM

100MG/5ML

N19784 001

DEC 18, 1989

MOTRIN

EX + MCNEIL CONS PRODS

100MG/5ML

N19842 001

SEP 19, 1989

RUFEN

EX KNOLL PHARM

100MG/5ML

N19784 001

DEC 18, 1989

TABLET; ORAL

IBU

AB KNOLL PHARM

400MG

N18197 001

N70083 001

FEB 22, 1985

N70088 001

FEB 08, 1985

N70099 001

MAR 23, 1985

N70745 001

JUL 23, 1986

IBUPROFEN

AB HALSEY

300MG

N71028 001

MAR 23, 1987

N71029 001

MAR 23, 1987

N71030 001

MAR 23, 1987

N72137 001

FEB 05, 1988

N71028 001

MAR 23, 1987

⊙

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN
@ HALSEY

AB PARKE DAVIS

AB

50MG

25MG

50MG

25MG

50MG

N70635 001
JUN 03, 1987

N18806 001
NOV 23, 1984

N18806 002
NOV 23, 1984

N18806 001
NOV 23, 1984

N18806 002
NOV 23, 1984

INSULIN LISPRO

INJECTABLE; INJECTION
HUMALOG
+ LILLY

100 UNITS/ML

N20563 001
JUN 14, 1996

IODIXANOL

INJECTABLE; INJECTION
VISIPAQUE 270
+ NYCOMED

55%

N20351 001
MAR 22, 1996

VISIPAQUE 320
+ NYCOMED

65.2%

N20351 002
MAR 22, 1996

IOPAMIDOL

INJECTABLE; INJECTION
ISOVUE-200
@ BRACCO

41%

41%

ISOVUE-250
BRACCO

51%

51%

N20327 001
OCT 12, 1994

N20327 001
OCT 12, 1994

N20327 002
OCT 12, 1994

N20327 002
OCT 12, 1994

IOPAMIDOL

INJECTABLE; INJECTION
ISOVUE-300
BRACCO

61%

+

61%

ISOVUE-370
BRACCO

76%

+

76%

N20327 003
OCT 12, 1994
N20327 003
OCT 12, 1994

N20327 004
OCT 12, 1994
N20327 004
OCT 12, 1994

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
CAMPTOSAR
+ PHARMACIA AND UPJOHN 20MG/ML

N20571 001
JUN 14, 1996

IRON DEXTRAN

INJECTABLE; INJECTION
DEXFERRUM
BP LUITPOLD

EQ 50MG IRON/ML

N40024 001
FEB 23, 1996

ISONIAZID

TABLET; ORAL
ISONIAZID
DANBURY PHARMA

50MG

100MG

50MG

100MG

100MG

100MG

100MG

100MG

100MG

100MG

100MG

100MG

N80522 001
N80523 001
N80522 001
N80523 001
N80523 001
N88231 001
MAR 17, 1983
N88231 001
MAR 17, 1983
N80153 001
N80153 001
N80153 001
N83632 001
N83632 001
N80368 001
N80368 002

ISONIAZID

TABLET; ORAL

ISONIAZID

@ PHOENIX LABS NY

50MG

@ ZENITH LABS

100MG

@

100MG

@

100MG

@

300MG

LANIAZID

LANNETT

50MG

50MG

N80368 001

N80368 002

N80270 001

N83610 001

N80270 001

N83610 001

N80140 001

N80140 001

ISOSORBIDE DINITRATE

TABLET; ORAL

SORBITRATE

ZENECA

5MG

EX

10MG

EX

TABLET; SUBLINGUAL

SORBITRATE

ZENECA

2.5MG

EX

EX

5MG

TABLET; CHEWABLE; ORAL

SORBITRATE

ZENECA

5MG

+

10MG

ISOSORBIDE MONONITRATE

TABLET; ORAL

MONOKET

* SCHWARZ

10MG

10MG

N20215 002

JUN 30, 1993

N20215 002

JUN 30, 1993

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

IMDUR

@ SCHERING

30MG

+

30MG

N20225 001

AUG 12, 1993

N20225 001

AUG 12, 1993

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALAR

+ PARKE DAVIS

EQ 50MG BASE/ML

EQ 100MG BASE/ML

N16812 002

N16812 003

+ KETAMINE HCL

BEDFORD

EQ 50MG BASE/ML

EQ 100MG BASE/ML

N74524 001

MAR 22, 1996

N74524 002

MAR 22, 1996

N74549 001

JUN 27, 1996

N74549 002

JUN 27, 1996

LACTULOSE

SOLUTION; ORAL

LACTULOSE

PHARM ASSOC

10GM/15ML

N74623 001

JUL 30, 1996

SOLUTION; ORAL, RECTAL

CEPHULAC

HOECHST MARION RSSL

10GM/15ML

10GM/15ML

N17657 001

N17657 001

+ GENERLAC

MORTON GROVE

10GM/15ML

N74603 001

OCT 31, 1996

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

XALATAN

+ PHARMACIA AND UPJOHN 0.005%

N20597 001

JUN 05, 1996

LEUCOVORIN CALCIUM

POWDER FOR RECONSTITUTION; ORAL
LEUCOVORIN CALCIUM
IMMUNEX

EQ 60MG BASE/VIAL
EQ 60MG BASE/VIAL

N08107 003
JAN 30, 1987
N08107 003
JAN 30, 1987

Ⓢ

LEVONUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
AKBETA
AKORN

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

0.25%
0.5%

LEVONUNOLOL HCL
ALCON

> ADD >
> ADD >
> ADD >
> ADD >

0.25%
0.5%

LEVONORGESTREL

IMPLANT; IMPLANTATION
LEVONORGESTREL
WYETH AYERST

75MG/IMPLANT

N20627 001
AUG 15, 1996

LIDOCAINE

FILM, EXTENDED RELEASE; BUCCAL
LIDOCAINE
+ NOVEN

23MG/PATCH
46.1MG/PATCH

N20575 001
MAY 21, 1996
N20575 002
MAY 21, 1996

+

OINTMENT; TOPICAL

ALPHACAINE
CARLISLE

5%
5%
5%
5%

Ⓢ
Ⓢ
Ⓢ
Ⓢ

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
ALPHACAINE HCL

AP
Ⓢ

2%
2%

LIDOCAINE HCL
ABBOTT

20%
20%

N84721 001
N84721 001

N89362 001
MAY 25, 1988
N89362 001
MAY 25, 1988

AP
Ⓢ

1%
2%

N83387 001
N83388 001

AP
Ⓢ

1%
1%
2%
2%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

AP
Ⓢ

2%
4%
20%

LINDANE

CREAM; TOPICAL

* REED AND CARNRICK

@

+

1%
1%
1%
1%N06309 001
N84218 001
N06309 001
N84218 001

CAPSULE; ORAL

LORABID
LILLY

+

200MG
400MGN50668 001
DEC 31, 1991
N50668 002
APR 05, 1996

LOTION; TOPICAL

* REED AND CARNRICK

@

1%
1%
1%
1%N06309 003
N84218 002
N84218 002
N06309 003> ADD >
> ADD >
> ADD >
> ADD >SYRUP; ORAL
CLARITIN
+ SCHERING

1MG/ML

N20641 001
OCT 10, 1996

SHAMPOO; TOPICAL

* REED AND CARNRICK

@

1%
1%
1%
1%N10718 001
N84219 001
N84219 001
N10718 001

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
CLARITIN-D 24 HOUR
+ SCHERING

10MG; 240MG

N20470 001
AUG 23, 1996LISINOPRIL

TABLET; ORAL

* REED AND CARNRICK

@

2.5MG
2.5MGN19777 005
APR 29, 1993
N19777 005
APR 29, 1993

INJECTABLE; INJECTION

LORAZEPAM

MARSAM

AP

2MG/ML

N74535 001
SEP 12, 1996

AP

2MG/ML

N74551 001
SEP 12, 1996

AP

1MG/0.5ML

N74551 003
SEP 12, 1996

AP

4MG/ML

N74535 002
SEP 12, 1996

AP

4MG/ML

N74551 002
SEP 12, 1996

LITHIUM CITRATE

SYRUP; ORAL

* REED AND CARNRICK

@

EQ 300MG CARBONATE/5ML
EQ 300MG CARBONATE/5MLN17672 001
N17672 001

TABLET; ORAL

LORAZEPAM

HALSEY

AB

0.5MG

N71434 001
SEP 01, 1987

AB

1MG

N71435 001
SEP 01, 1987

AB

2MG

N71436 001
SEP 01, 1987

AB

200MG

N50668 001
DEC 31, 1991LORACARBEEF

CAPSULE; ORAL

* REED AND CARNRICK

@

200MG

N50668 001
DEC 31, 1991

0.5MG

N71434 001
SEP 01, 1987

1MG

N71435 001
SEP 01, 1987

2MG

N71436 001
SEP 01, 1987

LORAZEPAM

TABLET; ORAL

LORAZEPAM

@ HALSEY

0.5MG

N71434 001

> DLT ->

1MG

SEP 01, 1987

N71435 001

2MG

SEP 01, 1987

N71436 001

@ SUPERPHARM

0.5MG

SEP 01, 1987

N71245 001

1MG

FEB 09, 1987

N71246 001

2MG

FEB 09, 1987

N71247 001

0.5MG

FEB 09, 1987

N71245 001

1MG

FEB 09, 1987

N71246 001

2MG

FEB 09, 1987

N71247 001

MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

ABBOTT

EQ 0.1MG MANGANESE/ML

N18962 001

JUN 26, 1986

EQ 0.1MG MANGANESE/ML

N18962 001

JUN 26, 1986

MANGANESE SULFATE

INJECTABLE; INJECTION

MANGANESE SULFATE

FUJISAWA

EQ 0.1MG MANGANESE/ML

N19228 001

MAY 05, 1987

EQ 0.1MG MANGANESE/ML

N19228 001

MAY 05, 1987

MECLOCYCLINE SULFOSALICYLATE

CREAM; TOPICAL

MECLAN

+ J AND J

18

N50518 001

> ADD ->

MECLOCYCLINE SULFOSALICYLATE

CREAM; TOPICAL

MECLAN

+ JOHNSON RW

18

N50518 001

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

BARR

EQ 50MG BASE

N72848 001

MAR 20, 1989

EQ 100MG BASE

N72809 001

MAR 20, 1989

EQ 50MG BASE

N72848 001

MAR 20, 1989

EQ 100MG BASE

N72809 001

MAR 20, 1989

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

MEDROXYPROGESTERONE ACETATE

BARR

2.5MG

N40159 001

AUG 09, 1996

5MG

N40159 002

AUG 09, 1996

10MG

N40159 003

AUG 09, 1996

MEGESTROL ACETATE

TABLET; ORAL

MEGESTROL ACETATE

BARR

20MG

N74621 002

AUG 16, 1996

INJECTABLE; INJECTION

DEMEROL

+ SANOFI WINTHROP

+ +

+ +

+ +

25MG/ML50MG/ML75MG/ML100MG/ML

N05010 007

N05010 002

N05010 009

N05010 003

METHYLTESTOSTERONE

TABLET; ORAL
ORETON METHYL
SCHERING

BP
25MG
25MG

N03158 002
N03158 002

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL
ABBOTT

EQ 10MG BASE/2ML

N70505 001
JUN 23, 1989

EQ 5MG BASE/ML

N70505 001
JUN 23, 1989

EQ 10MG BASE/2ML

N70506 001
JUN 22, 1989

EQ 5MG BASE/ML

N70506 001
JUN 22, 1989

EQ 10MG BASE/2ML

N73117 001
JAN 17, 1991

EQ 5MG BASE/ML

N73117 001
JAN 17, 1991

EQ 10MG BASE/2ML

N73118 001
JAN 17, 1991

EQ 5MG BASE/ML

N73118 001
JAN 17, 1991

EQ 10MG BASE/2ML

N71990 001
JAN 18, 1989

EQ 10MG BASE/2ML

N72155 001
MAR 30, 1992

EQ 5MG BASE/ML

N72155 001
MAR 30, 1992

EQ 10MG BASE/2ML

N7244 001
MAR 30, 1992

EQ 5MG BASE/ML

N7244 001
MAR 30, 1992

EQ 10MG BASE/2ML

N7247 001
MAY 18, 1992

EQ 5MG BASE/ML

N7247 001
MAY 18, 1992

EQ 10MG BASE/2ML

N70847 001
NOV 07, 1988

EQ 5MG BASE/ML

N70847 001
NOV 07, 1988

EQ 10MG BASE/2ML

N71291 001
MAR 03, 1989

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL
FAULding

EQ 5MG BASE/ML

N71291 001
MAR 03, 1989

EQ 5MG BASE/ML

N71990 001
JAN 18, 1989

EQ 10MG BASE/2ML

N73135 001
NOV 27, 1991

EQ 5MG BASE/ML

N73135 001
NOV 27, 1991

EQ 5MG BASE/ML

N74147 001
AUG 02, 1996

EQ 10MG BASE/2ML

N70623 001
MAR 02, 1987

EQ 5MG BASE/ML

N70623 001
MAR 02, 1987

EQ 10MG BASE/2ML

N17862 001
N17862 001

EQ 5MG BASE/ML

N17862 001
N17862 001

EQ 10MG BASE/2ML

N17862 001
N17862 001

EQ 5MG BASE/ML

N17862 001
N17862 001

EQ 10MG BASE/2ML

N17862 001
N17862 001

EQ 5MG BASE/ML

N17862 001
N17862 001

EQ 10MG BASE/2ML

N17862 001
N17862 001

EQ 5MG BASE/ML

N17862 001
N17862 001

EQ 10MG BASE/2ML

N17862 001
N17862 001

EQ 5MG BASE/ML

N17862 001
N17862 001

EQ 10MG BASE/2ML

N17862 001
N17862 001

EQ 5MG BASE/ML

N17862 001
N17862 001

EQ 10MG BASE/2ML

N17862 001
N17862 001

EQ 5MG BASE/ML

N17862 001
N17862 001

EQ 10MG BASE/2ML

N17862 001
N17862 001

EQ 5MG BASE/ML

N17862 001
N17862 001

EQ 10MG BASE/2ML

N17862 001
N17862 001

EQ 5MG BASE/ML

N17862 001
N17862 001

EQ 10MG BASE/2ML

N17862 001
N17862 001

EQ 5MG BASE/ML

N17862 001
N17862 001

EQ 10MG BASE/2ML

N17862 001
N17862 001

EQ 5MG BASE/ML

N17862 001
N17862 001

EQ 10MG BASE/2ML

N17862 001
N17862 001

METOLAZONE

TABLET; ORAL
ZAROXOLYN
* FISOXS
MEDEVA PHARMS

10MG
2.5MG
5MG
10MG

N17386 003
N17386 001
N17386 002
N17386 003

N74450 001
MAY 16, 1996
N74450 002
MAY 16, 1996
N74450 003
MAY 16, 1996

METRONIDAZOLE

GEL; VAGINAL
METROGEL
* CURATEK
METROGEL-VAGINAL
+ CURATEK

0.75%
0.75%

N20208 001
AUG 17, 1992
N20208 001
AUG 17, 1992

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MONISTAT DUAL-PAK
* JOHNSON RW

2%, 200MG

N18888 002
OCT 17, 1988

TABLET; ORAL
METROMIDOL
LABS AF

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

250MG
500MG

N74523 001
OCT 24, 1996
N74523 002
OCT 24, 1996

2.5MG
5MG

N19815 001
SEP 06, 1996
N19815 002
SEP 06, 1996

METRONIDAZOLE
HALSEY

250MG
500MG
250MG

N70021 001
APR 02, 1985
N70593 001
FEB 27, 1986
N70021 001
APR 02, 1985
N70593 001
FEB 27, 1986
N18517 001
N18517 002
MAY 05, 1982
N18517 001
N18517 002
MAY 05, 1982

ZENITH GOLDLINE

250MG
500MG
250MG
500MG

N50451 002
AUG 10, 1982
N50451 002
AUG 10, 1982

ZENITH LABS

250MG
500MG

METRAPONE

CAPSULE; ORAL
METOPIRON
+ CIBA

250MG

N12911 002
AUG 09, 1996

SOLUTION; TOPICAL
ROGAINE
* UPJOHN

2%

N19501 001
AUG 17, 1988

MIRTAZAPINE

TABLET; ORAL
REMERON
ORGANON

15MG
30MG

+

N20415 001
JUN 14, 1996
N20415 002
JUN 14, 1996

N74229 001
AUG 30, 1996
N74229 002
AUG 30, 1996
N74255 001
JAN 24, 1996

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
KADIAN
+ FAULDING SVCS

20MG
50MG
100MG

N20616 001
JUL 03, 1996
N20616 002
JUL 03, 1996
N20616 003
JUL 03, 1996

ZENITH LABS

N74255 002
JAN 24, 1996
N74255 003
JAN 24, 1996
N74255 001
JAN 24, 1996
N74255 002
JAN 24, 1996
N74255 003
JAN 24, 1996

INJECTABLE; INJECTION

MORPHINE SULFATE

MALLINCKRODT

AP

1MG/ML
2MG/ML

N20631 001
JUL 03, 1996
N20631 002
JUL 03, 1996

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL
+ ABBOTT

1.5MG/ML

N20200 001
MAR 12, 1993

NALBUPHINE HYDROCHLORIDE
ABBOTT

1.5MG/ML

N20200 001
MAR 12, 1993

MOXALACTAM DISODIUM

INJECTABLE; INJECTION

MOXAM

+ ELLI

> DLT >
> DLT >
> DLT >
> DLT >
> DLT >
> DLT >
> DLT >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

EQ 250MG BASE/VIAL
EQ 500MG BASE/VIAL
EQ 1GM BASE/VIAL
EQ 2GM BASE/VIAL
EQ 10GM BASE/VIAL
EQ 250MG BASE/VIAL
EQ 500MG BASE/VIAL
EQ 1GM BASE/VIAL
EQ 2GM BASE/VIAL
EQ 10GM BASE/VIAL

N50550 001
N50550 002
N50550 003
N50550 004
N50550 008
N50550 001
N50550 002
N50550 003
N50550 004
N50550 008

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL
SMITH AND NEPHEW

0.4MG/ML

N71682 001
NOV 17, 1987
N71682 001
NOV 17, 1987

NAPROXEN

TABLET; ORAL
NAPROXEN
BIOCRAFT

250MG

N74216 001
APR 11, 1996

NAPROXEN

TABLET; ORAL
NAPROXEN
BIOCRAFT

AB 375MG N74216 002
AB 500MG APR 11, 1996
AB 250MG N74216 003
AB 375MG APR 11, 1996
AB 500MG N74182 001
AB 375MG JUN 27, 1996
AB 500MG N74182 002
AB 375MG JUN 27, 1996
AB 500MG N74182 003
AB 500MG JUN 27, 1996

SIDMAK LABS NJ

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM
AL HIKWA

AB EQ 500MG BASE N74480 001
AB EQ 250MG BASE MAY 14, 1996
AB EQ 500MG BASE N74242 001
AB EQ 500MG BASE JUN 20, 1996
AB EQ 500MG BASE N74242 002
AB EQ 500MG BASE JUN 20, 1996
AB EQ 500MG BASE N74480 001
AB EQ 500MG BASE MAY 14, 1996

SIDMAK LABS NJ

WEST WARD PHARM

TABLET, EXTENDED RELEASE; ORAL
NAPRELAN
+ ELAN PHARM
EQ 375MG BASE
EQ 500MG BASE
EQ 750MG BASE

NEOMYCIN SULFATE

INJECTABLE; INJECTION
MYCIFRADIN
+ UPJOHN
NEOMYCIN SULFATE
PFIZER
SQUIBB

AP EQ 350MG BASE/VIAL N60477 001
AP EQ 350MG BASE/VIAL N61084 001
AP EQ 350MG BASE/VIAL N60366 001

POWDER; FOR RX COMPOUNDING
NEO-RX
PHARMA TEK
100%

N61579 001

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING
NEO-RX

PHARMA TEK
NEOMYCIN SULFATE
ELKINS SINN
PADDOCK
100%
100%
100%

N61579 001
N61698 001
N62385 001
JUN 01, 1982

NEVIRAPINE

TABLET; ORAL
VIRAMUNE
+ BOEHRINGER INGELHEIM

200MG

N20636 001
JUN 21, 1996

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL
CARDENE
SYNTEX

AB 20MG
AB 30MG

N19488 001
DEC 21, 1988
N19488 002
DEC 21, 1988

NICARDIPINE HCL
CHELSEA LABS

AB 20MG
AB 30MG
AB 20MG
AB 30MG
AB 20MG
AB 30MG
AB 20MG
AB 30MG
AB 20MG
AB 30MG

N20353 001
JAN 05, 1996
N20353 002
JAN 05, 1996
N20353 003
JAN 05, 1996

LEMMON

MYLAN

N74670 001
OCT 28, 1996
N74670 002
OCT 28, 1996
N74540 001
OCT 28, 1996
N74540 002
OCT 28, 1996
N74642 001
JUL 18, 1996
N74642 002
JUL 18, 1996

NICLOSAMIDE

TABLET, CHEWABLE; ORAL
NICLOCIDE
* BAYER

500MG

N18669 001
MAY 14, 1982

NICLOSAMIDE

TABLET, CHEWABLE, ORAL
NICLOXIDE
® BAYER

500MG

N18669 001
MAY 14, 1982

NILUTAMIDE

TABLET, ORAL
NILANDRON
+ ROUSSEL UCLAF

50MG

N20169 001
SEP 19, 1996

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

HABITROL

BC * CIBA

7MG/24HR

N20076 001

BC *

14MG/24HR

N20076 002

BC *

21MG/24HR

N20076 003

+ *

7MG/24HR

N20076 001

+ *

14MG/24HR

N20076 002

+ *

21MG/24HR

N20076 003

+ *

7MG/24HR

N20076 001

+ *

14MG/24HR

N20076 002

+ *

21MG/24HR

N20076 003

+ *

7MG/24HR

N20076 001

NICODERM

* HOECHST MARION ROSS

7MG/24HR

N20165 001

BC *

14MG/24HR

N20165 002

BC *

21MG/24HR

N20165 003

BC *

7MG/24HR

N20165 001

SPRAY, METERED; NASAL

NICOTROL

+ PHARMACIA AND UPJOHN 0.5MG/INH

N20385 001

MAR 22, 1996

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICORETTE

* SMITHKLINE BEECHAM

EQ 2MG BASE

N18612 001

JAN 13, 1984

NICORETTE DS

* SMITHKLINE BEECHAM

EQ 4MG BASE

N20066 001

JUN 08, 1992

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN

+ DURA

25MG/5ML

N09175 001

+ PROCTER AND GAMBLE

25MG/5ML

N09175 001

NITROFURAZONE

OINTMENT; TOPICAL

NITROFURAZONE

AMBIX

AT

0.2%

N86077 001

®

0.2%

N86077 001

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRAN

3M

AB1

0.1MG/HR

N89771 001

AB1

0.2MG/HR

N89772 001

AB1

0.4MG/HR

N89773 001

AB1

0.6MG/HR

N89774 001

AB1

0.1MG/HR

N20145 001

AB1

0.2MG/HR

N20145 002

AB1

0.4MG/HR

N20145 004

AB1

0.6MG/HR

N20145 005

AB1

0.1MG/HR

N20145 001

AB1

0.2MG/HR

N20145 002

AB1

0.4MG/HR

N20145 004

AB1

0.6MG/HR

N20145 005

AB1

0.1MG/HR

N20145 001

AB1

0.2MG/HR

N20145 002

AB1

0.4MG/HR

N20145 004

AB1

0.6MG/HR

N20145 005

AB1

0.1MG/HR

N20145 001

AB1

0.2MG/HR

N20145 002

AB1

0.4MG/HR

N20145 004

AB1

0.6MG/HR

N20145 005

AB1

0.1MG/HR

N20145 001

AB1

0.2MG/HR

N20145 002

AB1

0.4MG/HR

N20145 004

AB1

0.6MG/HR

N20145 005

AB1

0.1MG/HR

N20145 001

AB1

0.2MG/HR

N20145 002

AB1

0.4MG/HR

N20145 004

AB1

0.6MG/HR

N20145 005

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

NITRO-DUR
AB1 + KEY PHARMS

0.4MG/HR

N20145 004
APR 04, 1995

0.6MG/HR

N20145 005
APR 04, 1995

0.8MG/HR

N20145 006
APR 04, 1995

NITROGLYCERIN
MYLAN

0.2MG/HR

N74609 001
AUG 30, 1996

0.4MG/HR

N74607 001
AUG 30, 1996

0.6MG/HR

N74559 001
AUG 30, 1996

TRANSDERM-NITRO
CIBA

0.2MG/HR

N20144 002
FEB 27, 1996

0.4MG/HR

N20144 003
FEB 27, 1996

0.6MG/HR

N20144 004
FEB 27, 1996

0.2MG/HR

N20144 002
FEB 27, 1996

0.4MG/HR

N20144 003
FEB 27, 1996

0.6MG/HR

N20144 004
FEB 27, 1996

0.1MG/HR

N20144 001
FEB 27, 1996

0.1MG/HR

N20144 001
FEB 27, 1996

0.8MG/HR

N20144 005
FEB 27, 1996

0.8MG/HR

N20144 005
FEB 27, 1996

NORETHINDRONE

TABLET; ORAL

NOR-Q.D.

SEARLE

NOR-QD

+ SEARLE

0.35MG

N17060 001

0.35MG

N17060 001

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HCL
BIOCRAFT

EQ 10MG BASE

N73667 001
APR 11, 1996

EQ 25MG BASE

N73667 002
APR 11, 1996

EQ 50MG BASE

N73667 003
APR 11, 1996

EQ 75MG BASE

N73667 004
APR 11, 1996

NYSTATIN

POWDER; TOPICAL

MYCOSTATIN
+ WESTWOOD SQUIBB

100,000 UNITS/GM

N60578 001

NYSTOP

100,000 UNITS/GM

N64118 001

PADDOCK

100,000 UNITS/GM

AUG 16, 1996

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYCOLOG-II
+ APOTHECON

100,000 UNITS/GM;0.1%

N60576 002
MAY 01, 1985

100,000 UNITS/GM;0.1%

N62606 001
MAY 15, 1985

100,000 UNITS/GM;0.1%

N62606 001
MAY 15, 1985

100,000 UNITS/GM;0.1%

N60576 002
MAY 01, 1985

OLANZAPINE

TABLET; ORAL

ZYPREXA

@ LILLY

2.5MG

N20592 001
SEP 30, 1996

5MG

N20592 002
SEP 30, 1996

7.5MG

N20592 003
SEP 30, 1996

OLANZAPINE

TABLET; ORAL
ZYPREXA
+ LILLY

10MG

N20592 004
SEP 30, 1996

N18211 001
N74520 001
MAR 29, 1996

5MG/5ML
5MG/5ML

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ZOFAN PRESERVATIVE FREE
+ GLAXO WELLCOME

N20007 003
DEC 10, 1993

5MG

N74625 001
JUL 31, 1996

OXAZEPAM

TABLET; ORAL
OXAZEPAM

AB PARKE DAVIS

15MG

e

15MG

N71508 001
FEB 02, 1987
N71508 001
FEB 02, 1987

EQ 10MG BASE

N20031 001

EQ 30MG BASE

N20031 003

EQ 40MG BASE

N20031 005

OXTRIPHYLLINE

SOLUTION; ORAL
CHOLEDYL
PARKE DAVIS

100MG/5ML

100MG/5ML

N09268 012
NOV 27, 1984
N09268 012
NOV 27, 1984

EQ 10MG BASE

N20031 001

EQ 30MG BASE

N20031 003

EQ 40MG BASE

N20031 005

SYRUP; ORAL
CHOLEDYL
PARKE DAVIS

50MG/5ML
50MG/5ML

N09268 011
N09268 011

CREAM; TOPICAL

DENAVIR
+ SMITHKLINE BEECHAM

1g

N20629 001
SEP 24, 1996

TABLET, DELAYED RELEASE; ORAL
CHOLEDYL

* PARKE DAVIS

100MG

200MG

100MG

200MG

N09268 003
N09268 007
N09268 003
N09268 007

POWDER FOR RECONSTITUTION; ORAL

AA PENICILLIN
+ BIOCRRAFT

400,000 UNITS/5ML
400,000 UNITS/5ML

N60307 004
N60307 004

AA PFIZERPEN G
+ PFIZER

400,000 UNITS/5ML

N60587 001

PENICILLIN G POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

PFIZERPEN G

@ PFIZER

400,000 UNITS/5ML

N60587 001

TABLET; ORAL

PENICILLIN G POTASSIUM

MYLAN

800,000 UNITS

N60781 004

AB

AB

PFIZERPEN G

PFIZER

200,000 UNITS

N60075 003

AB

AB

250,000 UNITS

N60075 004

AB

AB

400,000 UNITS

N60075 005

AB

AB

800,000 UNITS

N60075 006

AB

50,000 UNITS

N60075 001

AB

100,000 UNITS

N60075 002

AB

50,000 UNITS

N60075 001

AB

100,000 UNITS

N60075 002

AB

200,000 UNITS

N60075 003

AB

250,000 UNITS

N60075 004

AB

400,000 UNITS

N60075 005

AB

800,000 UNITS

N60075 006

AB

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

PFIZERPEN VK

PFIZER

EQ 125MG BASE/5ML

N61815 001

AA

AA

EQ 250MG BASE/5ML

N61815 002

AA

EQ 125MG BASE/5ML

N61815 001

AA

EQ 250MG BASE/5ML

N61815 002

AA

TABLET; ORAL

PFIZERPEN VK

PFIZER

EQ 250MG BASE

N61836 001

AB

AB

EQ 500MG BASE

N61836 002

AB

EQ 250MG BASE

N61836 001

AB

EQ 500MG BASE

N61836 002

AB

PENTAMIDINE ISETHIONATE

POWDER FOR RECONSTITUTION; INHALATION

NEBUPENT

FUJISAWA

600MG/VIAL

N19887 002

MAR 22, 1996

PENTOBARBITAL SODIUM

CAPSULE; ORAL

SODIUM PENTOBARBITAL

HAUSEY

100MG

N84677 001

100MG

N84677 001

@

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

+ BAKER NORTON

100MG

N20193 001

SEP 26, 1996

PERFLUBRON

LIQUID; ORAL

IMAGENT

+ ALLIANCE PHARM

100%

N20091 001

AUG 13, 1993

N20091 001

AUG 13, 1993

100%

N20091 001

AUG 13, 1993

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

AMARIC

2MG

N20184 001

DEC 30, 1993

N20184 002

4MG

DEC 30, 1993

N20184 003

8MG

DEC 30, 1993

*

RHONE POULENC RORER

2MG

N20184 001

DEC 30, 1993

N20184 002

4MG

DEC 30, 1993

N20184 003

8MG

DEC 30, 1993

+

PHENSUXIMIDE

CAPSULE; ORAL

MILONTIN

+ PARKE DAVIS

500MG

N08855 004

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDEAB BIOCRRAFT 10MEQ N73532 001 EQ 0.23% PHOSPHATE; 10% N74511 001
APR 26, 1996 JUL 30, 1996

INJECTABLE; INJECTION

POTASSIUM CHLORIDEAP FUJISAWA 2MEQ/ML N87787 001
APR 20, 1982

@

2MEQ/ML N87787 001
APR 20, 1982

TABLET, EXTENDED RELEASE; ORAL

K-DUR 10

BC + KEY PHARMS 10MEQ N19439 002
JUN 13, 1986BC * SCHERING 10MEQ N19439 002
JUN 13, 1986

K-DUR 20

+ KEY PHARMS 20MEQ N19439 001
JUN 13, 1986* SCHERING 20MEQ N19439 001
JUN 13, 1986PREDNISOLONE

SYRUP; ORAL

PRELONE

MURQ

5MG/5ML N89654 001
JAN 17, 198915MG/5ML N89081 001
FEB 04, 1986+ 5MG/5ML N89654 001
JAN 17, 1989+ 15MG/5ML N89081 001
FEB 04, 1986PREDNISOLONE ACETATE

SUSPENSION; OPHTHALMIC

PRED FORTE

BX * ALLERGAN 1% N17011 001
JAN 31, 1996

SUSPENSION/DROPS; OPHTHALMIC

PRED FORTE

AB + ALLERGAN 1% N17011 001
JAN 31, 1996PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDEAT + AKORN EQ 0.23% PHOSPHATE; 10% N74511 001
JUL 30, 1996PREDNISONE

TABLET; ORAL

PREDNISONE

INTERPHARM

5MG N89597 001
OCT 05, 198710MG N89598 001
OCT 05, 198720MG N89599 001
OCT 05, 19875MG N89597 001
OCT 05, 198710MG N89598 001
OCT 05, 198720MG N89599 001
OCT 05, 19875MG N88865 001
OCT 25, 198410MG N88866 001
OCT 25, 198420MG N88867 001
OCT 25, 19845MG N88865 001
OCT 25, 198410MG N88866 001
OCT 25, 198420MG N88867 001
OCT 25, 1984PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PROCANBID

+ PARKE DAVIS 500MG N20545 001
JAN 31, 1996+ 1GM N20545 002
JAN 31, 1996

PROCHLORPERAZINE MALEATE

TABLET; ORAL

AB	COMPazine	EQ 5MG BASE	N10571 001	AA	PRO-BANTHINE	15MG	N88732 002
AB	SMITHKLINE BEECHAM	EQ 10MG BASE	N10571 002	BP	* ROBERTS LABS	7.5MG	N88732 003
AB		EQ 25MG BASE	N10571 003	BP	+	15MG	N88732 002
AB	PROCHLORPERAZINE MALEATE			AA	PROPANTHELINE BROMIDE	15MG	N88377 001
AB	COPLEY PHARM	EQ 5MG BASE	N40120 001	BP	PAR PHARM	15MG	DEC 08, 1983
AB			JUL 11, 1996				
AB		EQ 10MG BASE	N40120 002			15MG	N88377 001
AB			JUL 11, 1996				DEC 08, 1983
AB	INVAMED	EQ 5MG BASE	N40101 001	AA	ROXANE	7.5MG	N88927 001
AB			JUL 19, 1996	AA		15MG	N88927 002
AB		EQ 10MG BASE	N40101 002	BP		7.5MG	N88927 001
AB			JUL 19, 1996	BP		15MG	N88927 002
AB		EQ 25MG BASE	N40101 003				
AB			JUL 19, 1996				
AB	MYLAN	EQ 5MG BASE	N40185 002				
AB			OCT 28, 1996				
AB		EQ 10MG BASE	N40185 001				
			OCT 28, 1996				

> ADD >
> ADD >
> ADD >
> ADD >

PROMAZINE HYDROCHLORIDE

TABLET; ORAL

	SPARINE	50MG	N10348 002
*	WYETH AYERST	100MG	N10348 003
+		50MG	N10348 002
@		100MG	N10348 003

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

AA	PROMETHAZINE	6.25MG/5ML	N89013 001
	CENCI		SEP 20, 1985
@		6.25MG/5ML	N89013 001
			SEP 20, 1985

PROPANTHELINE BROMIDE

TABLET; ORAL

AA	PRO-BANTHINE	7.5MG	N88732 003
	* ROBERTS LABS		

PROPANTHELINE BROMIDE

TABLET; ORAL

AA	PRO-BANTHINE	15MG	N88732 002
BP	* ROBERTS LABS	7.5MG	N88732 003
BP	+	15MG	N88732 002
AA	PROPANTHELINE BROMIDE	15MG	N88377 001
BP	PAR PHARM	15MG	DEC 08, 1983
BP		15MG	N88377 001
BP			DEC 08, 1983
AA	ROXANE	7.5MG	N88927 001
AA		15MG	N88927 002
BP		7.5MG	N88927 001
BP		15MG	N88927 002

PROPOFOL

INJECTABLE; INJECTION

	DIPRIVAN	10MG/ML	N19627 001
*	ZENECA		OCT 02, 1989
@		10MG/ML	N19627 001
+		10MG/ML	OCT 02, 1989
			N19627 002
			JUN 11, 1996

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

AA	PROPHENE 65	65MG	N83538 002
	HALSEY	65MG	N83538 002
@			

PROPYLTHIOURACIL

TABLET; ORAL

BD	PROPYLTHIOURACIL	50MG	N80015 001
@	HALSEY	50MG	N80015 001

PROTIRELIN

INJECTABLE; INJECTION

THYFINONE

AP * ABBOTT

0.5MG/ML

0.5MG/ML

N17638 001

N17638 001

THYREL TRH

AP FERRING LABS

0.5MG/ML

0.5MG/ML

N18087 001

N18087 001

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NOVAFED

* DOW PHARM

+ HOECHST MARION RSSL

120MG

120MG

N17603 001

N17603 001

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

ACTAHIST

CENCI

30MG/5ML; 1.25MG/5ML

30MG/5ML; 1.25MG/5ML

N88344 001

FEB 09, 1984

N88344 001

FEB 09, 1984

TRILITRON

NEWTRON PHARMS

30MG/5ML; 1.25MG/5ML

30MG/5ML; 1.25MG/5ML

N88474 001

FEB 12, 1985

N88474 001

FEB 12, 1985

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HCL

DELL LABS

100MG/ML

50MG/ML

100MG/ML

N83772 001

N83771 001

N83771 001

N83772 001

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

HALSEY

324MG

N89476 001

APR 10, 1987

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

@ HALSEY

324MG

N89476 001

APR 10, 1987

QUINIDINE SULFATE

CAPSULE; ORAL

CIN-QUIN

SOLVAY

200MG

300MG

200MG

300MG

N85296 001

N85297 001

N85296 001

N85297 001

+ QUINIDINE SULFATE

@ LILLY

200MG

200MG

N85103 001

N85103 001

TABLET; ORAL

QUINIDINE SULFATE

1ST TX

BAR

200MG

200MG

N85068 001

N84177 001

N84177 001

N83583 001

N83583 001

200MG

200MG

@ HALSEY

@ ICN

200MG

200MG

N83393 001

N83393 001

200MG

200MG

@ LILLY

@ ROXANE

200MG

200MG

N85038 001

N83640 001

200MG

300MG

N83640 001

N85632 001

300MG

300MG

N85632 001

N85068 001

@ SCHERER

QUINORA

* KEY PHARMS

@ SCHERING

300MG

300MG

N85222 001

N85222 001

RAMIPRIL

CAPSULE; ORAL

ALTACE

HOECHST MARION RSSL

1.25MG

N19901 001

JAN 28, 1991

N19901 002

JAN 28, 1991

2.5MG

RAMIPRIL

CAPSULE; ORAL

ALTACE

HOECHST MARION RSSL

5MG

+

10MG

HOECHST ROUSSEL

1.25MG

2.5MG

5MG

10MG

*

N19901 003
JAN 28, 1991

N19901 004
JAN 28, 1991

N19901 001
JAN 28, 1991

N19901 002
JAN 28, 1991

N19901 003
JAN 28, 1991

N19901 004
JAN 28, 1991

N19901 005
JAN 28, 1991

N19901 006
JAN 28, 1991

N19901 007
JAN 28, 1991

SOLUTION; ORAL

RISPERDAL

+ JANSSEN

1MG/ML

N20588 001
JUN 10, 1996

RITONAVIR

CAPSULE; ORAL

NORVIR

+ ABBOTT

100MG

N20680 001
MAR 01, 1996

SOLUTION; ORAL

NORVIR

ABBOTT

80MG/ML

N20659 001
MAR 01, 1996

RANITIDINE BISMUTH CITRATE

TABLET; ORAL

TRITEC

+ GLAXO WELLCOME

400MG

N20559 001
AUG 08, 1996

ROPIVACAINE HYDROCHLORIDE MONOHYDRATE

INJECTABLE; INJECTION

NAROPIN

ASTRA

2MG/ML

N20533 001
SEP 24, 1996

5MG/ML

N20533 003
SEP 24, 1996

7.5MG/ML

N20533 004
SEP 24, 1996

10MG/ML

N20533 005
SEP 24, 1996

+

N09108 002
JUL 12, 1996

N09108 004
JUL 12, 1996

N09108 002
JUL 12, 1996

N09108 004
JUL 12, 1996

50MG

100MG

50MG

100MG

TABLET; ORAL

RAUVAL

PAL PAK

+

VALE

*

> ADD >

> ADD >

> DLT >

> DLT >

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ULTIVA

GLAXO WELLCOME

EQ 1MG BASE/VIAL

EQ 2MG BASE/VIAL

EQ 5MG BASE/VIAL

+

5MG

N20647 001
MAY 15, 1996

TABLET; ORAL

ELDEPRYL

* SOMERSET

5MG

N19334 001
JUN 05, 1989

5MG

N19334 001
JUN 05, 1989

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
SELEGILINE HCL
ENDO LABS

5MG

N74565 001
AUG 02, 1996

5MG

N74641 001
AUG 02, 1996

5MG

N74537 001
AUG 02, 1996

POWDER; ORAL
BUPHENYL
+ UCYCLYD

3GM/TEASPOONFUL

N20573 001
APR 30, 1996

TABLET; ORAL
BUPHENYL
+ UCYCLYD

500MG

N20572 001
MAY 13, 1996

SERTRALINE HYDROCHLORIDE

TABLET; ORAL
ZOLOFT
PFIZER

EQ 25MG BASE

N19839 005
MAR 06, 1996

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
SAIZEN

BX

5MG/VIAL

N19764 002
OCT 08, 1996

BX

6MG/VIAL

N19764 001
OCT 08, 1996

BX

5MG/VIAL

N20604 002
AUG 23, 1996

BX

6MG/VIAL

N20604 001
AUG 23, 1996

DLT

6MG/VIAL

N20604 001
AUG 23, 1996

DLT

6MG/VIAL

N20604 001
AUG 23, 1996

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

MCGAW

N18186 001
N18186 001

SOYBEAN OIL

INJECTABLE; INJECTION

INTRALIPID 20%

AP PHARMACIA AND UPJOHN 20%

N20248 001
AUG 07, 1996

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NIBRIDE

* ROCHE

50MG/VIAL

N17546 001
N17546 001

50MG/VIAL

N18581 001
JUL 28, 1982

SODIUM NITROPRUSSIDE

ELKINS SINN

50MG/VIAL

N18581 001
JUL 28, 1982

50MG/VIAL

N18581 001
JUL 28, 1982

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL

RENORMAX

SANDOZ

3MG

N20240 001
DEC 29, 1994

6MG

N20240 002
DEC 29, 1994

12MG

N20240 003
DEC 29, 1994

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL

RENORMAX

* SANDOZ

@ SCHERING

@

@

@

24MG

3MG

6MG

12MG

24MG

N20240 004

DEC 29, 1994

N20240 001

DEC 29, 1994

N20240 002

DEC 29, 1994

N20240 003

DEC 29, 1994

N20240 004

DEC 29, 1994

SPIRONOLACTONE

TABLET; ORAL

ALDACTONE

* SEARLE

AB

> DLT >

> DLT >

> ADD >

> DLT >

> DLT >

> ADD >

> ADD >

25MG

25MG

100MG

100MG

N12151 009

DEC 30, 1983

N12151 009

DEC 30, 1983

N12151 010

DEC 30, 1983

N12151 010

DEC 30, 1983

SUCRALFATE

TABLET; ORAL

CARAFATE

+ BLUE RIDGE

SUCRALFATE

BIOCRAFT

AB

AB

1GM

1GM

N18333 001

N70848 001

MAR 29, 1996

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFATRIM-DS

SUPERPHARM

@

800MG/160MG

800MG/160MG

N70066 001

JUN 24, 1985

N70066 001

JUN 24, 1985

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFATRIM-SS

SUPERPHARM

AB

@

400MG; 80MG

400MG; 80MG

N70065 002

JUN 24, 1985

N70065 002

JUN 24, 1985

SULFISOXAZOLE

TABLET; ORAL

GANTRISIN

* ROCHE

AB

@

500MG

500MG

N06525 001

N06525 001

SULFISOXAZOLE

ZENITH LABS

AB

AB

500MG

500MG

N80142 001

N80142 001

TAMOXIFEN CITRATE

TABLET; ORAL

NOLVADEX

@ ZENECA

@

EQ 20MG BASE

EQ 20MG BASE

N17970 002

MAR 21, 1994

N17970 002

MAR 21, 1994

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVUE

MEDI PHYSICS

N/A

N20372 001

FEB 09, 1996

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL

HYTRIN

@ ABBOTT

@

EQ 1MG BASE

EQ 2MG BASE

N19057 001

AUG 07, 1987

N19057 002

AUG 07, 1987

N19057 003

AUG 07, 1987

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL
HYTRIN
@ ABBOTT

EQ 10MG BASE
EQ 1MG BASE
EQ 2MG BASE
EQ 5MG BASE
EQ 10MG BASE

N19057 004
AUG 07, 1987
N19057 001
AUG 07, 1987
N19057 002
AUG 07, 1987
N19057 003
AUG 07, 1987
N19057 004
AUG 07, 1987

+

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEOVENT
@ SCHERING

BC 125MG
BC 250MG
@ 125MG
@ 250MG

N87010 001
JAN 31, 1985
N87910 001
JAN 31, 1985
N87010 001
JAN 31, 1985
N87910 001
JAN 31, 1985

ELIXIR; ORAL

ELIXOMIN
@ CENCI

AA 80MG/15ML
@ 80MG/15ML

N88303 001
JAN 25, 1984
N88303 001
JAN 25, 1984

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL
LAMISIL
+ SANDOZ

EQ 250MG BASE

N20539 001
MAY 10, 1996

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL
@ SUPERPHARM

AB 250MG
AB 500MG
@ 250MG
@ 500MG

N62540 001
MAR 21, 1985
N62540 002
MAR 21, 1985
N62540 001
MAR 21, 1985
N62540 002
MAR 21, 1985

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201
@ MED. PHYSICS
2mCi/ML
1mCi/ML

N18110 001
FEB 01, 1982
N18110 002
FEB 27, 1996

SUSPENSION; ORAL

ELIXICON
* FOREST LABS

100MG/5ML

N85502 001

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER
MCGAW

AP 40MG/100ML
@ 40MG/100ML

N19083 001
NOV 07, 1984
N19083 001
NOV 07, 1984

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER
MCGAW

AP 80MG/100ML
@ 80MG/100ML

N19083 002
NOV 07, 1984
N19083 002
NOV 07, 1984

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER
MCGAW

AP 160MG/100ML
@ 160MG/100ML

N19083 003
NOV 07, 1984
N19083 003
NOV 07, 1984

THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER
MCGAW

AP 200MG/100ML
@ 200MG/100ML

N19836 004
AUG 14, 1992
N19826 004
AUG 14, 1992

THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
MCGAW

AP 400MG/100ML
@ 400MG/100ML

N19836 005
AUG 14, 1992
N19826 005
AUG 14, 1992

THEOPHYLLINE

SUSPENSION; ORAL
ELIXICON
@ FOREST LABS

100MG/5ML

TABLET, EXTENDED RELEASE; ORAL

BC * UNI-DUR
BC * KEY PHARMS

400MG

BC *
BC + SCHERING

600MG

400MG

BC +

600MG

UNIPHYL

600MG

PURDUE FREDERICK

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HCL

@ DELL LABS

100MG/ML

100MG/ML

100MG/ML

AP * SANOFI WINTHROP

AP

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

MELLARIL

SANDOZ

AA +

AA +

AA +

AA +

THIORIDAZINE HCL

HI TECH PHARMA

AA

AA

30MG/ML

30MG/ML

100MG/ML

100MG/ML

30MG/ML

100MG/ML

TABLET; ORAL

THIORIDAZINE HCL

SUPERPHARM

10MG

AB

N85502 001

N89822 001

JAN 04, 1995

N89823 001

JAN 04, 1995

N89822 001

JAN 04, 1995

N89823 001

JAN 04, 1995

N40086 001

APR 15, 1996

N83775 001

N83775 001

N40079 001

MAY 03, 1996

N11808 012

N11808 012

N11808 018

N11808 018

N40125 001

AUG 16, 1996

N40126 001

AUG 16, 1996

N89103 001

JUL 02, 1985

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HCL

SUPERPHARM

25MG

50MG

10MG

25MG

50MG

N89104 001

JUL 02, 1985

N89105 001

JUL 02, 1985

N89103 001

JUL 02, 1985

N89104 001

JUL 02, 1985

N89105 001

JUL 02, 1985

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

AKTOB

AKORN

0.3%

N64096 001

JAN 31, 1996

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

BARR

100MG

250MG

500MG

100MG

250MG

500MG

100MG

250MG

500MG

100MG

250MG

500MG

100MG

250MG

500MG

100MG

250MG

500MG

100MG

N70162 001

JAN 14, 1986

N70163 001

JAN 14, 1986

N70164 001

JAN 14, 1986

N70162 001

JAN 14, 1986

N70163 001

JAN 14, 1986

N70164 001

JAN 14, 1986

N18894 001

NOV 02, 1984

N18894 002

NOV 02, 1984

N18894 003

NOV 02, 1984

N18894 001

NOV 02, 1984

TOLAZAMIDE

TABLET; ORAL

AB TOLAZAMIDE
ZENITH LABS

250MG

500MG

N18894 002
NOV 02, 1984
N18894 003
NOV 02, 1984

TRANDOLAPRILTABLET; ORAL
MAVIK

KNOLL PHARM

2MG

4MG

N20528 002
APR 26, 1996
N20528 003
APR 26, 1996

TOLBUTAMIDE

TABLET; ORAL

ORINASE

AB @ PHARMACIA AND UPJOHN 500MG
* UPJOHN 500MG

AB TOLBUTAMIDE
BARR 500MG

AB @ EON LABS 500MG

AB 500MG

AB + SUPERPHARM 500MG

AB 500MG

@ 500MG

N10670 001
N10670 001
N87121 001
N87121 001
N12678 001
N12678 001
N88893 001
NOV 19, 1984
N88893 001
NOV 19, 1984

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
TARKA

+ KNOLL PHARM

1MG; 240MG

2MG; 180MG

2MG; 240MG

4MG; 240MG

N20591 003
OCT 22, 1996
N20591 001
OCT 22, 1996
N20591 004
OCT 22, 1996
N20591 002
OCT 22, 1996

TRANEXAMIC ACIDTOLMETIN SODIUM

TABLET; ORAL

AB TOLMETIN SODIUM
BAKER NORTON

EQ 600MG BASE

N74399 001
MAR 28, 1996

TABLET, ORAL
CYKLOKAPRON
* PHARMACIA

500MG

@ PHARMACIA AND UPJOHN 500MG

N19280 001
DEC 30, 1986
N19280 001
DEC 30, 1986

TOPOTECAN HYDROCHLORIDEINJECTABLE; INJECTION
HYCAMTIN

+ SMITHKLINE BEECHAM

EQ 4MG BASE/VIAL

N20671 001
MAY 28, 1996

CREAM; TOPICAL
RENOVA
JOHNSON RW

0.05%

N19963 001
DEC 29, 1995

TRANDOLAPRIL

TABLET; ORAL

MAVIK

KNOLL PHARM

1MG

N20528 001
APR 26, 1996

CREAM; TOPICAL

KENALOG-H

APOTHECON

0.1%

0.1%

N86240 001
N86240 001

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

ARISTOCORT A

LEDERLE

+ KENALOG

* APOTHECON

@

0.5%

0.5%

0.5%

0.5%

SPRAY, METERED; NASAL

NASACORT AQ

+ RHONE POULENC RORER

0.055MG/INH

N80745 003

N80745 003

N83944 001

N83944 001

N20468 001

MAY 20, 1996

> ADD >

> DLT >

AB

AB

TABLET; ORAL

TRIPLE SULFOID

PAL PAK

VALIE

167MG; 167MG; 167MG

167MG; 167MG; 167MG

N80094 001

N80094 001

UREA, C-13

POWDER FOR RECONSTITUTION; ORAL

MERETEK UBT KIT (W/ PRANACTIN)

+ MERETEK

125MG/VIAL

N20586 001

SEP 17, 1996

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HCL

INVAMED

EQ 1MG BASE

EQ 2MG BASE

EQ 5MG BASE

EQ 10MG BASE

N40153 001

OCT 25, 1996

N40153 002

OCT 25, 1996

N40153 003

OCT 25, 1996

N40153 004

OCT 25, 1996

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

INJECTABLE; INJECTION

METRODIN

+ SERONO

75 IU/AMP

150 IU/AMP

N19415 002

SEP 18, 1986

N19415 003

SEP 18, 1986

INJECTABLE; INTRAMUSCULAR

METRODIN

+ SERONO

75 IU/AMP

150 IU/AMP

N19415 002

SEP 18, 1986

N19415 003

SEP 18, 1986

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL

TRIPLE SULFA

ALPHARMA

3.7%; 2.86%; 3.42%

3.7%; 2.86%; 3.42%

N87864 001

SEP 01, 1982

N87864 001

SEP 01, 1982

> ADD >

> ADD >

> DLT >

> DLT >

INJECTABLE; SUBCUTANEOUS

FERTINEX

+ SERONO

75 IU/AMP

150 IU/AMP

N19415 005

AUG 23, 1996

N19415 004

AUG 23, 1996

TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIPROLIDINE HCL

HALSEY

1.25MG/5ML

1.25MG/5ML

N88735 001

JAN 17, 1985

N88735 001

JAN 17, 1985

CAPSULE, EXTENDED RELEASE; ORAL

VERELAN

+ ELAN PHARM

360MG

N19614 004

MAY 10, 1996

@

TABLET; ORAL

VERAPAMIL HCL

SIDMAK LABS NJ

40MG

N72751 001

FEB 23, 1996

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL		
BC	COVERA-HS SEARLE	180MG N20552 001 FEB 26, 1996
BC		N20552 002 FEB 26, 1996
<u>VERAPAMIL HCL</u>		
AB	MYLAN	240MG N74587 001 MAR 23, 1996
AB	SIDMAK LABS NJ	N72922 001 MAR 01, 1996

VIDARABINE

INJECTABLE; INJECTION		
	VIRA-A	
	+ PARKE DAVIS	N58523 001 N50523 001
	@	
	EQ 187.4MG BASE/ML	
	EQ 187.4MG BASE/ML	

ZAFIRLUKAST

TABLET; ORAL		
	ACCOLATE	
	+ ZENECA	20MG N20547 001 SEP 26, 1996

ZIDOVUDINE

TABLET; ORAL		
	RETROVIR	
	+ GLAXO WELLCOME	300MG N20518 002 OCT 04, 1996

ASPIRIN

TABLET, EXTENDED RELEASE; ORAL
8-HOUR BAYER
+ BAYER 650MG
* STERLING 650MG
MEASURIN
+ BAYER 650MG
* STERLING 650MG

N16030 001
N16030 001
N16030 002
N16030 002

BENTOQUATAM

LOTION; TOPICAL
IVY BLOCK
+ ENVIRODERM 5%

N20532 001
AUG 26, 1996

BROMPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL
DIMETAPP
* ROBINS AH 8MG
* 12MG

@ WHITEHALL ROBINS 8MG

DIMETAPP
+ WHITEHALL ROBINS 12MG

N10799 010
JUN 10, 1983
N10799 011
JUN 10, 1983
N10799 010
JUN 10, 1983
N10799 011
JUN 10, 1983

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR; ORAL
DIMETAPP
* ROBINS AH 2MG/5ML; 12.5MG/5ML
+ WHITEHALL ROBINS 2MG/5ML; 12.5MG/5ML

N13087 003
MAR 29, 1984
N13087 003
MAR 29, 1984

TABLET, EXTENDED RELEASE; ORAL
DIMETAPP
* ROBINS AH 12MG; 75MG
+ WHITEHALL ROBINS 12MG; 75MG

N12436 003
MAY 14, 1985
N12436 003
MAY 14, 1985

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
EFIDAC 24 PSEUDOEPHEDRINE HCL/BROMPHENIRAMINE MALEATE
+ ALZA 16MG; 240MG

N19672 001
MAR 29, 1996

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CODIMAL-L. A. 12
CENT PHARMS 12MG; 120MG

+ 12MG; 120MG

PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE
+ CENT PHARMS 8MG; 120MG

N18935 001
APR 15, 1985
N18935 001
APR 15, 1985
N19428 001
AUG 02, 1988

PSEUDOEPHEDRINE HCL/CHLORPHENIRAMINE MALEATE
* GRAHAM 8MG; 120MG

+ 12MG; 120MG

@ 8MG; 120MG

@ 12MG; 120MG

PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE
CENT PHARMS 8MG; 120MG

N18844 001
MAR 20, 1985
N18843 001
MAR 18, 1985
N18844 001
MAR 20, 1985
N18843 001
MAR 18, 1985
N19428 001
AUG 02, 1988

CHLORPHENIRAMINE POLISTIREX; PHENYLPROPANOLAMINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL
CORSYM
@ FISOXS EQ 4MG MALEATE/5ML;
EQ 37.5MG HCL/5ML

@ MEDEVA PHARMS EQ 4MG MALEATE/5ML;
EQ 37.5MG HCL/5ML

N18050 001
JAN 04, 1984
N18050 001
JAN 04, 1984

OTC DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 10 / JAN'96 - OCT'96

CIMETIDINE

TABLET; ORAL

TAGAMET HB

* SMITHKLINE BEECHAM

100MG

N20238 001

JUN 19, 1995

N20238 001

JUN 19, 1995

N20238 002

AUG 21, 1996

+

200MG

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TAVIST-D

SANDOZ

1.34MG; 75MG

N20640 001

AUG 09, 1996

CLOTRIMAZOLECREAM, SUPPOSITORY; TOPICAL, VAGINAL
GYNE-LOTIMIN 3 COMBINATION PACK
+ SCHERING PLOUGH

1%, 200MG

N20526 002

JUL 29, 1996

SUPPOSITORY; VAGINAL

GYNE-LOTIMIN

+ SCHERING PLOUGH

100MG

N17717 002

NOV 30, 1990

GYNE-LOTIMIN 3

+ SCHERING PLOUGH

200MG

N20525 001

JUL 29, 1996

MYCELEX-7

BAYER

100MG

N18182 002

DEC 26, 1991

TABLET; VAGINAL

GYNE-LOTIMIN

+ SCHERING PLOUGH

100MG

N17717 002

NOV 30, 1990

MYCELEX-7

BAYER

100MG

N18182 002

DEC 26, 1991

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DELSYM

* Fisons

+ MEDEVA PHARMS

EQ 30MG HBR/5ML

EQ 30MG HBR/5ML

N18658 001

N18658 001

DOXYLAMINE SUCCINATE

TABLET; ORAL

DOXYLAMINE SUCCINATE

PERRIGO

25MG

N40167 001

SEP 18, 1996

IBUPROFEN

CAPSULE; ORAL

MIDOL

@ BAYER

200MG

N70626 001

SEP 02, 1987

@

200MG

N71002 001

SEP 02, 1987

@ WINTHROP

200MG

N70626 001

SEP 02, 1987

@

200MG

N71002 001

SEP 02, 1987

PROVEL

* SANDOZ

200MG

N20402 001

APR 20, 1995

@

200MG

N20402 001

APR 20, 1995

SUSPENSION; ORAL

CHILDREN'S ADVIL

WHITEHALL ROBINS

100MG/5ML

N20589 001

JUN 27, 1996

SUSPENSION/DROPS; ORAL

CHILDREN'S MOTRIN

+ MCNEIL CONS PRODS

40MG/ML

N20603 001

JUN 10, 1996

TABLET; ORAL

IBUPROFEN

HALSEY

200MG

N71027 001

SEP 29, 1987

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)
ALPHARMA

2%

N74588 001
APR 05, 1996

BAUSCH AND LOMB

2%

N74643 001
APR 09, 1996

COBLEY PHARM

2%

N74500 001
MAY 23, 1996

LEMMON

2%

N74589 001
APR 05, 1996

SIGHT PHARMS

2%

N74743 002
OCT 18, 1996

MINOXIDIL (FOR WOMEN)
SIGHT PHARMS

2%

N74743 001
OCT 18, 1996

ROGAINE (FOR MEN)
+ PHARMACIA AND UPJOHN 2%

2%

N19501 002
FEB 09, 1996

ROGAINE (FOR WOMEN)

2%

N19501 003
FEB 09, 1996

+ PHARMACIA AND UPJOHN 2%

2%

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

NICOTINE

FILM, EXTENDED RELEASE; TRANSFERMAL
NICOTROL
+ MCNEIL CONS PRODS 15MG/16HR

N20536 001
JUL 03, 1996

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL
NICORETTE

+ SMITHKLINE BEECHAM EQ 2MG BASE

N18612 002
FEB 09, 1996

+

EQ 4MG BASE

N20066 002
FEB 09, 1996

NIZATIDINE

TABLET; ORAL
AXID AR

+ WHITEHALL ROBINS 75MG

N20555 001
MAY 09, 1996

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC
OCUHIST
AKORN

0.025%; 0.3%

N20485 001
JAN 31, 1996

OPCON-A

+ BAUSCH AND LOMB

0.027%; 0.315%

N20065 001
JUN 08, 1994

0.02675%; 0.315%

N20065 001
JUN 08, 1994

TABLET, EXTENDED RELEASE; ORAL
EFIDAC 24 PSEUDOEPHEDRINE HCL
+ ALZA 240MG

N20021 002
DEC 15, 1992

+ CIBA 240MG

N20021 002
DEC 15, 1992

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL
PSEUDO-12

+ FISON'S

EQ 60MG HCL/5ML

N19401 001
JUN 19, 1987

+ MEDEVA PHARMS

EQ 60MG HCL/5ML

N19401 001
JUN 19, 1987

NICOTINE

FILM, EXTENDED RELEASE; TRANSFERMAL
NICODERM CQ

+ HOECHST MARION RSSL 7MG/24HR

N20165 006
AUG 02, 1996

14MG/24HR

N20165 005
AUG 02, 1996

21MG/24HR

N20165 004
AUG 02, 1996

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 10/ OCT '96

NO OCTOBER 1996 APPROVALS

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS
[January 1, 1996 thru October 31, 1996]

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
2'- deoxycytidine TN=	As a host-protective agent in the treatment of acute myelogenous leukemia.	Grant, Steven M.D. Massey Cancer Center, VCU P.O. Box 980230 Richmond, VA 23298 DD=09/09/96 MA= / /
9-nitro-20-(S)-camptothecin (9-NC) TN=	Treatment of pancreatic cancer.	Stehlin Foundation for Cancer Cancer Research 1315 Calhoun, Suite 1818 Houston, TX 77002 DD=09/16/96 MA= / /
Amphotericin B lipid complex TN= Abelcet	Treatment of invasive candidiasis.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=06/27/96 MA= / /
Amphotericin B lipid complex TN= Abelcet	Treatment of invasive zygomycosis.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=05/06/96 MA= / /
Amphotericin B lipid complex TN= Abelcet	Treatment of invasive coccidioidomycosis.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=05/06/96 MA= / /
Amphotericin B lipid complex TN= Abelcet	Treatment of invasive protothecosis.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=08/21/96 MA= / /
Amphotericin B lipid complex TN= Abelcet	Treatment of invasive sporotrichosis.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=09/23/96 MA= / /
Antihemophilic factor (human) TN= Alphanate	Treatment of von Willebrand's disease.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles, CA 90032 DD=01/05/96 MA= / /
Arcitumomab TN= 99m Tc-labeled CBA-Scan	Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma.	Immunomedics, Inc. 300 American Road Morris Plains, NJ 07950 DD=05/10/96 MA= / /
Clostridial collagenase TN=	Treatment of advanced (involucional or residual stage) Dupuytren's disease.	Hurst, L. M.D. & Badalamente, M. Ph.D. State University of New York at Stony Brook School of Medicine Health Sciences Center T18-020 Stony Brook, NY 11794 DD=05/23/96 MA= / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

66

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
Collagenase (lyophilized) for injection TN= Plaquase	Treatment of Peyronie's disease.	Advance Biofactures Corporation 35 Wilbur Street Lynbrook, NY 11563 DD=03/12/96 MA= / /
C1-esterase inhibitor (human) TN=	Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles, CA 90032 DD=08/21/96 MA= / /
DAB389IL-2 TN=	Treatment of cutaneous T-cell lymphoma.	Seragen, Inc. 97 South Street Hopkinton, MA 01748 DD=08/21/96 MA= / /
Dihydrotestosterone TN=Androgel-DHT	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Unimed Pharmaceuticals, Inc. 2150 East Lake Cook Road, Suite 210 Buffalo Grove, IL 60089 DD=02/05/96 MA= / /
DMP 777 TN=	Therapeutic management of patients with lung disease attributable to cystic fibrosis.	Dupont Merck Pharmaceutical Company Dupont Merck Plaza, Maple Run 2110 Wilmington, DE 19805 DD=06/04/96 MA= / /
Etiocholanedione TN=	Treatment of Prader-Willi syndrome.	SuperGen, Inc. 3158 Des Plains Avenue Suite 10 Des Plains, IL 60018 DD=05/07/96 MA= / /
Gusperimus TN=Spanidin	Treatment of acute renal graft rejection episodes.	Bristol-Myers Squibb Company 5 Research Parkway P.O. Box 5100 Wallingford, CT 06492 DD=06/27/96 MA= / /
Human acid alpha-glucosidase TN=	Treatment of glycogen storage disease type II.	Pharming B.V. Niels Bohrweg 11-13 2333 CA Leiden The Netherlands DD=09/10/96 MA= / /
Ibuprofen i.v. solution TN=Salprofen	Prevention of patent ductus arteriosus.	Farmacon, Inc. 90 Grove Street, Suite 109 Ridgefield, CT 06877 DD=10/29/96 MA= / /
Ibuprofen i.v. solution TN=	Treatment of patent ductus arteriosus.	Farmacon, Inc. 90 Grove Street, Suite 109 Ridgefield, CT 06877 DD=10/29/96 MA= / /
Indoxuridine TN=	Treatment of nonparenchymatous sarcomas.	NeoPharm, Inc. 225 East Deerpath, Suite 250 Lake Forest, IL 60045 DD=04/08/96 MA= / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
Interferon beta-1a TN=Rebif	Treatment of patients with secondary progressive multiple sclerosis.	Serono Laboratories, Inc. 100 Longwater Circle Norwell, MA 02061 DD=03/11/96 MA= / /
Interferon gamma-1b TN=Actimmune	Treatment of severe congenital osteopetrosis.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco, CA 94080 DD=09/30/96 MA= / /
KL4-Surfactant TN=	Treatment of meconium aspiration syndrome in newborn infants.	Cochrane, Charles, M.D. The Scripps Research Institute 10666 Torrey Pines Road LaJolla, CA 92037 DD=07/30/96 MA= / /
L-2-oxothiazolidine 4-carboxylic acid TN=Procysteine	Treatment of amyotrophic lateral sclerosis.	Transcend Therapeutics, Inc. 640 Memorial Drive, 3rd Floor West Cambridge, MA 02139 DD=07/30/96 MA= / /
Leflunomide TN=	Prevention of acute and chronic rejection in patients who have received solid organ transplants.	James W. Williams, M.D. 655 Superior Oak Park, IL 60302 DD=10/18/96 MA= / /
Lipid/DNA human cystic fibrosis gene TN=	Treatment of cystic fibrosis.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=04/08/96 MA= / /
Liposomal prostaglandin E1 injection TN=	Treatment of acute respiratory distress syndrome.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=04/25/96 MA= / /
Methionine/L-methionine TN=	Treatment of AIDS myelopathy.	DiRocco, Alessandro M.D. The Mount Sinai Medical Center One Gustave L. Levy Place, Box 1139 New York, NY 10029 DD=08/21/96 MA= / /
Methylnaltrexone TN=	Treatment of chronic opioid-induced constipation unresponsive to conventional therapy.	The University of Chicago 5841 South Maryland Avenue MC 4028 Chicago, IL 60637 DD=06/17/96 MA= / /
Mitoxantrone TN=Novantrone	Treatment of hormone refractory prostate cancer.	Immunex Corporation 51 University Street Seattle, WA 98101 DD=08/21/96 MA= / /
Nitazoxanide TN=	Treatment of cryptosporidiosis in HIV-positive and AIDS patients.	Unimed Pharmaceuticals, Inc. 2150 East Lake Cook Road, Suite 210 Buffalo Grove, IL 60089 DD=01/05/96 MA= / /
Prostaglandin E1 in lipid emulsion TN=	Treatment of ischemic ulceration of the lower limbs due to peripheral arterial disease.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles, CA 90032 DD=09/10/96 MA= / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
Rifapentine TN=	Prophylactic treatment of Mycobacterium avium complex in patients with acquired immunodeficiency syndrome and a CD4+ count less than or equal to 75/mm ³ .	Marion Merrell Dow Inc. P.O. Box 9627 (Park A) Kansas City, MO 64137 DD=03/12/96 MA= / /
Riluzole TN=Rilutek	Treatment of Huntington's disease.	Rhone-Poulenc Rorer Pharmaceuticals, Inc. 500 Arcola Road Collegeville, PA 19426 DD=10/15/96 MA= / /
R-VIII SQ TN= REFACTO	For long-term and/or hospital treatment of hemophilia A or for treatment of patients with hemophilia A in connection with surgical procedures.	Pharmacia & Upjohn 7000 Portage Road Kalamazoo, MI 49001 DD=02/08/96 MA= / /
Somatropin for injection TN=Serostim	Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.	Serono Laboratories, Inc. 100 Longwater Circle Norwell, MA 02061 DD=03/26/96 MA= / /
SU101 TN=	Treatment of ovarian cancer.	Sugen, Inc. 515 Galveston Drive Redwood City, CA 94063 DD=03/12/96 MA= / /
Testosterone TN=Androgel	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Unimed Pharmaceuticals, Inc. 2150 East Lake Cook Road, Suite 21 Buffalo Grove, IL 60089 DD=02/05/96 MA= / /
Thalidomide TN=Synovir	Treatment of HIV-associated wasting syndrome.	Celgene Corporation P.O. Box 4914 7 Powder Horn Drive Warren, NJ 07059 DD=03/11/96 MA= / /
Uridine 5'triphosphate TN=	To facilitate the removal of lung secretions in the treatment of patients with primary ciliary dyskinesia.	Inspire Pharmaceuticals, Inc. 4222 Emperor Boulevard, Suite 470 Durham, NC 27703 DD=06/26/96 MA= / /
Valine, isoleucine and leucine TN=VIL	Treatment of hyperphenylalaninemia.	Leas Research Products 4 Brookview Lane Troy, NY 12180 DD=01/05/96 MA= / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
ORPHAN DRUG PRODUCT APPROVALS FOR 1996		
Albendazole TN= Albenza	Treatment of hydatid disease (cystic echinococcosis due to <i>E. granulosus</i> larvae or alveolar echinococcosis due to <i>E. multilocularis</i> larvae).	SmithKline Beecham Pharmaceuticals One Franklin Plaza P.O. Box 7929 Philadelphia, PA 19101 DD=01/17/96 MA=06/11/96
Albendazole TN= Albenza	Treatment of neurocysticercosis due to <i>Taenia solium</i> as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis.	SmithKline Beecham Pharmaceuticals One Franklin Plaza P.O. Box 7929 Philadelphia, PA 19101 DD=01/18/96 MA=06/11/96
Allopurinol sodium TN= Zyloprim for Injection	Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.	Glaxo Wellcome Inc. Five Moore Drive P.O. Box 13398 Research Triangle Park, NC 27709 DD=10/16/92 MA=05/17/96
Betaine TN=Cystadane	Treatment of homocystinuria.	Orphan Medical 13911 Ridgedale Drive, Suite 475 Minnetonka, MN 55305 DD=05/16/94 MA=10/25/96
Bleomycin sulfate TN=Blenoxane	Treatment of malignant pleural effusion.	Bristol-Myers Squibb P.O. Box 4000 Princeton, NJ 08543 DD=09/17/93 MA=02/20/96
Buffered intrathecal electrolyte/dextrose injection TN=Elliotts B Solution	For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment of meningeal leukemia and lymphocytic lymphoma.	Orphan Medical 13911 Ridgedale Drive Minnetonka, MN 55305 DD=08/24/94 MA=09/27/96
Clonidine TN=Duraclon	For continuous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=01/24/89 MA=10/02/96
Corticotropin ovine trifluate TN=Acthrel	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.	Ferring Laboratories, Inc. 400 Rella Boulevard, Suite 201 Suffern, NY 10901 DD=11/24/89 MA=05/23/96
Daunorubicin citrate liposome injection TN=DaunoXome	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.	NeXstar Pharmaceuticals, Inc. 650 Cliffside Drive San Dimas, CA 91773 DD=05/14/93 MA=04/08/96

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

70

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
---	-----------------------	--

ORPHAN DRUG PRODUCT APPROVALS FOR 1996

Fosphenytoin TN=	For the acute treatment of patients with status epilepticus of the grand mal type.	Warner-Lambert Company 2800 Plymouth Road Ann Arbor, MI 48106 DD=06/04/91 MA=08/05/96
Ganciclovir intravitreal implant TN=Vitrasert Implant	Treatment of cytomegalovirus retinitis.	Chiron Vision 500 Iolab Drive Claremont, CA 91711 DD=06/07/95 MA=03/04/96
Interferon beta-la TN=Avonex	Treatment of multiple sclerosis.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=12/16/91 MA=05/17/96
Midodrine HCl TN=Amatine	Treatment of idiopathic orthostatic hypotension, i.e., Shy-Drager Syndrome, Bradbury-Eggleston Syndrome.	Roberts Pharmaceutical Corp. Meridian Center III 6 Industrial Way West Eastontown, NJ 07724 DD=06/21/85 MA=09/06/96
Ofloxacin TN=Ocuflox Ophthalmic Solution	Treatment of bacterial corneal ulcers.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine, CA 92713 DD=04/18/91 MA=05/22/96
Pentosan polysulfate sodium TN=Elmiron	Treatment of interstitial cystitis.	Baker Norton Pharmaceuticals 4400 Biscayne Boulevard Miami, FL 33137 DD=08/07/85 MA=09/26/96
Polifeprosan 20 with carmustine TN=Gliadel	Treatment of malignant glioma.	Guilford Pharmaceuticals, Inc. 6611 Tributary Street Baltimore, MD 21224 DD=12/13/89 MA=09/23/96
Respiratory syncytial virus immune globulin (human) TN=Respigam	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.	MedImmune, Inc. 35 West Watkins Mill Road Gaithersburg, MD 20878 DD=09/27/90 MA=01/18/96

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

71

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
---	-----------------------	--

ORPHAN DRUG PRODUCT APPROVALS FOR 1996

Sodium phenylbutyrate
TN=Buphenyl

Treatment of urea cycle disorders carbamylphosphate
synthetase deficiency, ornithine transcarbamylase
deficiency, and arginiosuccinic acid synthetase deficiency.

Ucyclyd Pharma
10819 Gilroy Road, Suite 100
Hunt Valley, MD 21031
DD=11/22/93 MA=04/30/96

Somatropin for injection
TN=Serostim

Treatment of AIDS-associated catabolism/weight loss.

Serono Laboratories, Inc.
100 Longwater Circle
Norwell, MA 02061
DD=11/15/91 MA=08/23/96

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO OCTOBER 1996 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
-------------------------	------	--------------

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 7500 STANDISH PLACE, ROCKVILLE, MD 20855. COPIES OF THESE GUIDANCES MAY ALSO BE OBTAINED FROM THE DIVISION OF COMMUNICATION MANAGEMENT, CENTER FOR DRUG EVALUATION AND RESEARCH, FDA, 5600 FISHERS LANE (HFD-210) ROCKVILLE, MD 20857 OR BY CALLING (301) 827-4573, FAX: (301) 827-4577.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 16TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

CLOZAPINE *IN VITRO* AND *IN VIVO* (TABLET)

NOV 15, 1995

APR 19, 1996

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
---------------------------------	------------------------------	---------------	------------	------------------------	--------

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 1-23, PARK BUILDING, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 16TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ACETAMINOPHEN; BUTALBITAL; CAFFEINE SOLUTION; ORAL	325MG/15ML 50MG/15ML 40MG/15ML	96 P-0208/ CP1	MIKART	NEW DOSAGE FORM	APPROVED OCT 10, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE CAPSULE; ORAL	325MG 50MG 40MG 7.5MG	95 P-0279/ CP2	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE CAPSULE; ORAL	325MG 50MG 40MG 10MG	95 P-0279/ CP1	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE CAPSULE; ORAL	500MG 50MG 40MG 7.5MG	95 P-0279/ CP4	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE CAPSULE; ORAL	500MG 50MG 40MG 10MG	95 P-0279/ CP3	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE TABLET; ORAL	325MG 50MG 40MG 7.5MG	95 P-0279/ CP2	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE TABLET; ORAL	325MG 50MG 40MG 10MG	95 P-0279/ CP1	MIKART	NEW COMBIANTION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08. 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE TABLET; ORAL	500MG 50MG 40MG 7.5MG	95 P-0279/ CP4	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE TABLET; ORAL	500MG 50MG 40MG 10MG	95 P-0279/ CP3	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; HYDROCODONE BITARTRATE CAPSULE; ORAL	325MG 5MG	95 P-0278/ CP1	MIKART	NEW STRENGTH	APPROVED MAY 28, 1996
ACYCLOVIR SODIUM INJECTABLE; INJECTION	EQ 5MG BASE/ML (100ML/CONTAINER) (200ML/CONTAINER)	95 P-0268/ CP1	WILMER, CUTLER, & PICKERING	NEW DOSAGE FORM NEW STRENGTH	APPROVED FEB 27, 1996
ACYCLOVIR SODIUM INJECTABLE; INJECTION	EQ 250MG/VIAL	96 P-0284/ CP1	ABBOTT	NEW STRENGTH	APPROVED OCT 10, 1996
ASPIRIN; BUTALBITAL CAPSULE; ORAL	650MG 50MG	96 P-0021/ CP1	SAVAGE	NEW DOSAGE FORM	APPROVED APR 19, 1996
ATRACURIUM BESYLATE INJECTABLE; INJECTION	0.5MG/ML 1MG/ML (100ML CONTAINER)	95 P-0372/ CP1	ABBOTT	NEW STRENGTH	APPROVED MAR 08, 1996
CARBIDOPA; LEVODOPA POWDER FOR RECONSTITUTION; ORAL	25MG/PACKET 100MG/PACKET	95 P-0100/ CP1	ATHENA	NEW DOSAGE FORM	APPROVED MAY 28, 1996
CARBIDOPA; LEVODOPA POWDER FOR RECONSTITUTION; ORAL	25MG/PACKET 250MG/PACKET	95 P-0100/ CP1	ATHENA	NEW DOSAGE FORM	APPROVED MAY 28, 1996
CHOLESTYRAMINE TABLET, CHEWABLE; ORAL ORAL	EQ 2GM RESIN	95 P-0277/ CP1	MAYRAND	NEW DOSAGE FORM NEW STRENGTH	APPROVED FEB 27, 1996
CYTARABINE INJECTABLE; INJECTION	100MG/ML (1ML/VIAL) (5ML/VIAL)	92 P-0183/ CP1	FAULDING	NEW DOSAGE FORM NEW STRENGTH	APPROVED JUL 26, 1996
CYTARABINE INJECTABLE; INJECTION	100MG/ML (10ML/VIAL) (20ML/VIAL)	92 P-0184/ CP1	FAULDING	NEW DOSAGE FORM	APPROVED JUL 26, 1996
DILTIAZEM HYDROCHLORIDE INJECTABLE, INJECTION	5MG/ML (25ML/SYRINGE) (50ML/SYRINGE)	95 P-0196/ CP1	INTL MEDICATION	NEW STRENGTH	APPROVED FEB 27, 1996
EPINEPHRINE INJECTABLE; SUBCUTANEOUS	0.3MG/DELIVERY	95 P-0190/ CP1	SENETCK PLC	NEW ROUTE OF ADMINISTRATION	APPROVED FEB 15, 1996
ETOPOSIDE CAPSULE; ORAL	25MG	95 P-0142/ CP1	GUIDELINES	NEW STRENGTH	APPROVED SEP 12, 1996

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
HYDROCORTISONE BUTYRATE LOTION; TOPICAL	0.1%	95 P-0223/ CP1	MCKENNA & CUNEO	NEW DOSAGE FORM	APPROVED FEB 21, 1996
LACTULOSE CRYSTALS, FOR RECONSTITUTION; ORAL	20GM/PACKET	95 P-0287/ CP1	BENNETT	NEW DOSAGE FORM NEW STRENGTH	APPROVED APR 19, 1996
MEPERIDINE HYDROCHLORIDE INJECTABLE; INJECTION	10MG/ML (60ML/SYRINGE)	95 P-0348/ CP1	MALLINCKRODT	NEW STRENGTH	APPROVED MAR 08, 1996
METRONIDAZOLE LOTION; TOPICAL	0.75%	95 P-0328/ CP1	RNB PHARM	NEW DOSAGE FORM	APPROVED FEB 23, 1996
NIFEDIPINE CAPSULE, EXTENDED RELEASE; ORAL	30MG 60MG 90MG	95-P-0326/ CP1	KV	NEW DOSAGE FORM	APPROVED FEB 23, 1996
PACLITAXEL INJECTABLE; INJECTION	6MG/ML (16.7ML/VIAL) (33.3ML/VIAL) (50ML/VIAL)	95 P-0360/ CP1	ABBOTT	NEW STRENGTH	APPROVED APR 29, 1996
PENTOXIFYLLINE SUSPENSION, EXTENDED RELEASE; ORAL	400MG/PACKET	96 P-0079/ CP1	KV PHARM	NEW DOSAGE FORM	APPROVED AUG 13, 1996
POTASSIUM CHLORIDE SUSPENSION, EXTENDED RELEASE; ORAL	10MEQ	96 P-0054/ CP1	KV PHARM	NEW DOSAGE FORM	APPROVED AUG 19, 1996
POTASSIUM CHLORIDE CAPSULE, EXTENDED RELEASE; ORAL	20MEQ	96 P-0018/ CP1	KV PHARM	NEW DOSAGE FORM	APPROVED AUG 19, 1996

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
HYDROCODONE BITRATRATE; PHENYLEPHRINE HYDROCHLORIDE SOLUTION; ORAL	2.5MG/5ML 5MG/5ML	95 P-0336/ CP1	BOCK PHARMA	NEW COMBINATION	DENIED AUG 19, 1996
HYDROCODONE BITRATRATE; PHENYLEPHRINE HYDROCHLORIDE SOLUTION; ORAL	5MG/5ML 10MG/5ML	95 P-0336/ CP2	BOCK PHARMA	NEW COMBINATION	DENIED AUG 19, 1996

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 16TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES
NEW DOSING SCHEDULE

- D-29 INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF THE CNS IN ADULTS
D-30 5000 IU DOSE FOR PHOPHYLAXIS AGAINST DEEP VEIN THROMBOSIS
D-31 CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32 REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS

NEW INDICATION

- I-141 TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
I-142 LOCALIZE MYOCARDIAL ISCHEMIA (REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
I-143 EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-144 ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
I-145 0.1MMOL/KG AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
I-146 CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
I-147 PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
I-148 TREATMENT OF ACUTE PNEUMOCYSTIC CARINII PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE ($AaDO_2$) IS LESS THAN OR EQUAL TO 55 TORR
I-149 TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
I-150 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
I-151 PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
I-152 SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
I-153 MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN]
I-154 PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
I-155 TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
I-156 ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
I-157 TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
I-158 TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
I-159 FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES
I-160 TREATMENT OF BACTERIAL CORNEAL ULCERS
I-161 TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY
I-162 FOR USE IN PATIENTS 6-11 YEARS OF AGE
I-163 TREATMENT OF PHOTOPHOBIA
I-164 CHRONIC BACTERIAL PROSTATITIS
I-165 MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE

PATENT USE CODE

- U-121 METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS
U-122 A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS
U-123 METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS
U-124 TREATMENT OF ACNE
U-125 TREATING NEUROGENERATIVE DISEASES

U-126
U-127
U-128
U-129
U-130
U-131
U-132
U-133
U-134
U-135
U-136
U-137
U-138
U-139
U-140
U-141
U-142
U-143
U-144
U-145
U-146
U-147
U-148
U-149

U-150
U-151
U-152
U-153

EXCLUSIVITY TERMS

PATENT USE CODE

U-126	TREATMENT OF GASTRITIS
U-127	METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE
U-128	METHODS FOR TREATMENT OF TUMORS
U-129	METHOD TO DESTROY OR IMPAIR TARGET CELLS
U-130	MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS
U-131	PHOTODAMAGED SKIN
U-132	INHIBITING HIV PROTEASE
U-133	MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET
U-134	TREATMENT OF ACNE VULGARIS
U-135	ANTITUMOR AGENT
U-136	PROCESS FOR WASTE NITROGEN REMOVAL
U-137	METHOD OF TREATING BACTERIAL VAGINOSIS
U-138	TREATMENT OF ALLERGIC RHINITIS
U-139	TREATMENT OF ALLERGIC REACTIONS
U-140	USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION
U-141	TREATMENT OF ULCERATIVE COLITIS
U-142	METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE
U-143	BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING
U-144	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS
U-145	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS
U-146	METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS
U-147	DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF $^{13}\text{CO}_2$
U-148	DEVICE FOR COLLECTING A BREATH SAMPLE
U-149	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES
U-150	METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE
U-151	RELIEF OF SYMPTOMS OF THE COMMON COLD
U-152	METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER
U-153	TREATMENT OF INITIAL EPISODE GENITAL HERPES

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
18731 002	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
		4182763	MAY 22, 2000	U-13		
18731 003	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
		4182763	MAY 22, 2000	U-13		
18731 004	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
		4182763	MAY 22, 2000	U-13		
>ADD>					NCE	OCT 18, 2001
20524 001	BUTENAFINE HYDROCHLORIDE; MENTAX	4078071	MAR 07, 1997			
19215 001	BUTOCONAZOLE NITRATE; FEMSTAT	4078071	MAR 07, 1997			
19359 001	BUTOCONAZOLE NITRATE; FEMSTAT	4078071	MAR 07, 1997			
20421 001	BUTOCONAZOLE NITRATE; FEMSTAT 3	4866048	DEC 29, 2007	U-88		DEC 21, 1998
20273 001	CALCIPOTRIENE; DOVONEX	4866048	SEP 12, 2006			DEC 29, 1998
20554 001	CALCIPOTRIENE; DOVONEX	4308264	JAN 28, 2001			JUL 22, 1999
18874 001	CALCITRIOL; CALCIJEX	4308264	JAN 28, 2001			
18874 002	CALCITRIOL; CALCIJEX					
20577 001	CALCIUM CHLORIDE; ELLIOTT'S B SOLUTION				ODE	SEP 27, 2003
18343 004	CAPTOPRIL; CAPOTEN				I-95	SEP 23, 1996
					I-101	JAN 28, 1997
					I-95	SEP 23, 1996
					I-101	JAN 28, 1997
18343 007	CAPTOPRIL; CAPOTEN					
20234 001	CARBAMAZEPINE; TEGRETOL-XR	5284662	FEB 08, 2011			
		RE34990	JUL 29, 2007			
20234 002	CARBAMAZEPINE; TEGRETOL-XR	5284662	FEB 08, 2011			
		RE34990	JUL 29, 2007			
20234 003	CARBAMAZEPINE; TEGRETOL-XR	5284662	FEB 08, 2011			
		RE34990	JUL 29, 2007			
19880 001	CARBOPLATIN; PARAPLATIN	4140707	AUG 24, 1998			
19880 002	CARBOPLATIN; PARAPLATIN	4140707	AUG 24, 1998			
19880 003	CARBOPLATIN; PARAPLATIN	4140707	AUG 24, 1998			
20637 001	CARMUSTINE; GLIADEL	4140707	AUG 24, 1998			
19835 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC				NP	AUG 23, 1999
19835 002	CETIRIZINE HYDROCHLORIDE; ZYRTEC				ODE	AUG 23, 2003
20346 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC					
20638 001	CIDOFOVIR; VISTIDE					
20238 002	CIMETIDINE; TAGAMET HB	4525358	JUN 25, 2002			
		4525358	JUN 25, 2002			
19537 001	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	5142051	AUG 25, 2009			
19537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO					
>ADD>					NDF	DEC 27, 1999
>ADD>					NCE	DEC 08, 2000
					NCE	JUN 26, 2001
					NS	JUN 19, 1998
					I-137	NOV 15, 1998
					I-157	APR 08, 1999
					I-164	SEP 11, 1999
					I-157	APR 08, 1999
					I-164	SEP 11, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4962115	OCT 09, 2007	U-79	I-157	APR 08, 1999
19537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	5453510	SEP 26, 2012	U-127	I-164	SEP 11, 1999
20398 001	CISAPRIDE MONOHYDRATE; PROPULSID	4179507	DEC 18, 1996	U-127	I-157	APR 08, 1999
20551 001	CISATRACURIUM BESYLATE; NIMBEX	5453510	SEP 26, 2012	U-127	I-164	SEP 11, 1999
20551 002	CISATRACURIUM BESYLATE; NIMBEX PRESERVATIVE FREE	4179507	DEC 18, 1996	U-127	NCE	JUL 29, 1998
20551 003	CISATRACURIUM BESYLATE; NIMBEX PRESERVATIVE FREE	5453510	SEP 26, 2012	U-127		
18057 001	CISPLATIN; PLATINOL	4179507	DEC 18, 1996	U-127		
18057 002	CISPLATIN; PLATINOL	5562925	MAY 08, 2012			
18057 003	CISPLATIN; PLATINOL-AQ	5562925	MAY 08, 2012			
18057 004	CISPLATIN; PLATINOL-AQ	5562925	MAY 08, 2012			
17661 003	CLEMASTINE FUMARATE; TAVIST-1	5562925	MAY 08, 2012			
18298 002	CLEMASTINE FUMARATE; TAVIST-D					
20340 001	CLOBETASOL PROPIONATE; TEMOVATE E					
20525 001	CLOTRIMAZOLE; GYNE-LOTIRIMIN 3					
20526 002	CLOTRIMAZOLE; GYNE-LOTIRIMIN 3 COMBINATION PACK					
20162 001	CORTICORELIN OVINE TRIFLUATE; ACTHREL					
20479 001	CROMOLYN SODIUM; GASTROCROM					
20287 001	DALTEPARIN SODIUM; FRAGMIN	4515805	MAY 07, 2002	U-130	I-151	OCT 31, 1999
20287 003	DALTEPARIN SODIUM; FRAGMIN	4421762	DEC 20, 2000	U-130	I-151	OCT 31, 1999
		4303651	JAN 04, 2005		D-32	MAY 03, 1999
					NP	JUL 29, 1999
					NP	JUL 29, 1999
					NCE	MAY 23, 2001
50704 002	DAUNORUBICIN CITRATE; DAUNOXOME	4515805	MAY 07, 2002	U-130		
20118 001	DESFLURANE; SUPRANE	4421762	DEC 20, 2000	U-130	NCE	DEC 22, 1999
19955 001	DESMOPRESSIN ACETATE; DDAVP	4303651	JAN 04, 2005		D-30	MAR 18, 1999
19955 002	DESMOPRESSIN ACETATE; DDAVP				NCE	DEC 22, 1999
20071 001	DESOGESTREL; DESOGEN				D-30	MAR 18, 1999
20071 002	DESOGESTREL; DESOGEN				ODE	APR 08, 2003
20301 001	DESOGESTREL; ORTHO-CEPT				NCE	SEP 18, 1997
20301 002	DESOGESTREL; ORTHO-CEPT					
20344 001	DEXFENFLURAMINE HYDROCHLORIDE; REDUX	4762856	FEB 02, 2007	U-67		
20037 001	DICLOFENAC SODIUM; VOLTAREN	5047398	SEP 10, 2008			
20254 001	DICLOFENAC SODIUM; VOLTAREN-XR	5047398	SEP 10, 2008			
20092 001	DILTIAZEM HYDROCHLORIDE; DILACOR XR	3927046	NOV 19, 1995			
20092 002	DILTIAZEM HYDROCHLORIDE; DILACOR XR	3927046	NOV 19, 1995			
20092 003	DILTIAZEM HYDROCHLORIDE; DILACOR XR	3927046	NOV 19, 1995			
20401 001	DILTIAZEM HYDROCHLORIDE; TIAZAC	3927046	NOV 19, 1995			
		4309445	JUN 16, 2000	U-133		
		4960799	OCT 02, 2007			
					I-163	JUL 23, 1999
					NDF	MAR 08, 1999
		5422123	JUN 06, 2012			
		5422123	JUN 06, 2012			
		5422123	JUN 06, 2012			
		5529791	JUN 25, 2013			

>ADD>

>ADD>

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20401 002	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013			
20401 003	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013			
20401 004	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013			
20401 005	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013	NS		SEP 11, 1998
20506 001	DILTIAZEM MALATE; TIAMATE	4968507	JUL 25, 2006	NE		OCT 04, 1999
>ADD>		4880631	SEP 24, 2007			
>ADD>		4968507	JUL 25, 2006	NE		OCT 04, 1999
>ADD>		4880631	SEP 24, 2007			
>ADD>		4968507	JUL 25, 2006	NE		OCT 04, 1999
20506 002	DILTIAZEM MALATE; TIAMATE	4880631	SEP 24, 2007			
20506 003	DILTIAZEM MALATE; TIAMATE	4968507	JUL 25, 2006			
>ADD>		4880631	SEP 24, 2007	NE		OCT 04, 1999
20507 001	DILTIAZEM MALATE; TECZEM	4983598	JAN 08, 2008			
>ADD>		4968507	JUL 25, 2006			
>ADD>		4880631	SEP 24, 2007			
>ADD>		4472380	SEP 18, 2001	NC		OCT 04, 1999
>ADD>		4374829	FEB 22, 2000	NE		OCT 04, 1999
18723 001	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008	U-3		
18723 002	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008		I-41	MAR 18, 1999
18723 003	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008		I-41	MAR 18, 1999
20449 001	DOCETAXEL; TAXOTERE	5403858	JUL 03, 2012		I-41	MAR 18, 1999
20164 001	ENOXAPARIN SODIUM; LOVENOX	4814470	JUL 14, 2007		NCE	MAY 14, 2001
20472 001	ESTRADIOL; ESTRING	5389618	FEB 14, 2012			
20538 001	ESTRADIOL; ESTRADIOL	4692435	DEC 24, 2004	U-123		
		4486420	DEC 04, 2001	U-122		
		5300291	APR 05, 2011		NDF	APR 26, 1999
		4994278	MAR 04, 2008		NS	OCT 28, 1997
		4994267	MAR 04, 2008			
		4814168	MAR 04, 2008			
20538 002	ESTRADIOL; ESTRADIOL	5300291	APR 05, 2011			
		4994278	MAR 04, 2008			
		4994267	MAR 04, 2008			
		4814168	MAR 04, 2008			
20538 003	ESTRADIOL; ESTRADIOL	5300291	APR 05, 2011		NS	OCT 28, 1997
		4994278	MAR 04, 2008			
		4994267	MAR 04, 2008			
		4814168	MAR 04, 2008			
20538 004	ESTRADIOL; ESTRADIOL	5300291	APR 05, 2011			
		4994278	MAR 04, 2008			
		4994267	MAR 04, 2008			
		4814168	MAR 04, 2008			
20130 001	ETHINYL ESTRADIOL; ESTROSTEP 21	4814168	MAR 04, 2008			
20130 002	ETHINYL ESTRADIOL; ESTROSTEP FE	4962098	OCT 09, 2007	U-112		
>ADD>		4962098	OCT 09, 2007	U-112		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
18922 002	ETODOLAC; LODINE	4966768	OCT 30, 2007		I-24	JUN 28, 1999
18922 003	ETODOLAC; LODINE	4966768	OCT 30, 2007		I-24	JUN 28, 1999
18922 004	ETODOLAC; LODINE	5041424	AUG 20, 2008		I-24	JUN 28, 1999
20584 001	ETODOLAC; LODINE XL	4904768	FEB 27, 2007	U-135		
20584 002	ETODOLAC; LODINE XL	4671953	MAY 01, 2005	U-87	NE	MAY 17, 1999
20457 001	ETOPOSIDE PHOSPHATE; ETOPOPHOS	4671953	MAY 01, 2005	U-87	NDF	OCT 04, 1996
20195 001	FENTANYL CITRATE; FENTANYL	4671953	MAY 01, 2005	U-87	NDF	OCT 04, 1996
20195 002	FENTANYL CITRATE; FENTANYL	4671953	MAY 01, 2005	U-87	NDF	OCT 04, 1996
20195 003	FENTANYL CITRATE; FENTANYL	4671953	MAY 01, 2005	U-87	NDF	OCT 04, 1996
20195 007	FENTANYL CITRATE; FENTANYL	4671953	MAY 01, 2005	U-87	NDF	OCT 04, 1996
20416 001	FERUMOXIDES; FERIDEX I.V.	5248492	SEP 28, 2010		NCE	AUG 30, 2001
		5219554	JUN 15, 2010			
		5102652	FEB 06, 2009			
		5055288	OCT 08, 2008			
		4951675	AUG 28, 2007	U-143		
		4827945	MAY 09, 2006	U-144		
		4770183	SEP 13, 2005	U-145		
20625 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	5375693	AUG 03, 2012	U-138	NCE	JUL 25, 2001
		4254129	APR 10, 1999	U-139		
		4760071	JUN 19, 2006			
20180 001	FINASTERIDE; PROSCAR	4760071	JUL 26, 2005			
20480 001	FINASTERIDE; PROSCAR	4335121	NOV 14, 2003		NP	MAR 27, 1999
20548 001	FLUTICASON PROPIONATE; FLOVENT	4335121	MAR 15, 2002		NP	MAR 27, 1999
20548 002	FLUTICASON PROPIONATE; FLOVENT	4335121	NOV 14, 2003		NP	MAR 27, 1999
20548 003	FLUTICASON PROPIONATE; FLOVENT	4335121	MAR 15, 2002		NP	MAR 27, 1999
20548 004	FLUTICASON PROPIONATE; FLOVENT	4335121	NOV 14, 2003		NP	MAR 27, 1999
20548 005	FLUTICASON PROPIONATE; FLOVENT	4335121	MAR 15, 2002		NP	MAR 27, 1999
20261 001	FLUVASTATIN SODIUM; LESCOL	4335121	MAR 15, 2002		NP	MAR 27, 1999
20261 002	FLUVASTATIN SODIUM; LESCOL	4335121	MAR 15, 2002		NP	MAR 27, 1999
20450 001	FOSPHENYTOIN SODIUM; CEREBYX	4925860	AUG 05, 2007		D-31	MAR 20, 1999
20235 001	GABAPENTIN; NEURONTIN	4260769	APR 07, 1998		D-31	MAR 20, 1999
		5084479	JAN 02, 2010		ODE	AUG 05, 2003
		4894476	MAY 02, 2008	U-125	NCE	AUG 05, 2001
20235 002	GABAPENTIN; NEURONTIN	4087544	JAN 17, 2001	U-86		DEC 30, 1998
		5084479	JAN 02, 2010	U-125		
20235 003	GABAPENTIN; NEURONTIN	4894476	MAY 02, 2008			
		4087544	JAN 17, 2001	U-86	NCE	DEC 30, 1998
		5084479	JAN 02, 2010	U-125		
		4894476	MAY 02, 2008			
		4087544	JAN 17, 2001	U-86	NCE	DEC 30, 1998
		5084479	JAN 02, 2010	U-125		
		4894476	MAY 02, 2008			
		4087544	JAN 17, 2001	U-86	NCE	DEC 30, 1998

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20123 001	GADODIAMIDE; OMNISCAN	4687659	MAY 04, 2007		D-29	FEB 05, 1999
					I-145	FEB 05, 1999
19596 001	GADOPENTETATE DIMEGLUMINE; MAGNEVIST	4647447	MAR 03, 2004		I-144	FEB 05, 1999
20569 001	GANCICLOVIR; VITRASERT	5378475	JAN 03, 2012		I-146	FEB 28, 1999
					NP	MAR 04, 1999
20509 001	GEMCITABINE HYDROCHLORIDE; GEMZAR	5464826	NOV 07, 2012	U-146	ODE	MAR 04, 2003
20509 002	GEMCITABINE HYDROCHLORIDE; GEMZAR	4808614	FEB 28, 2006	U-146	NCE	MAY 15, 2001
20329 001	GLIPIZIDE; GLUCOTROL XL	4808614	FEB 28, 2006	U-146	NCE	MAY 15, 2001
20329 002	GLIPIZIDE; GLUCOTROL XL	5545413	JUL 02, 2008	U-150		
19726 001	GOSERELIN ACETATE; ZOLADEX	5082668	SEP 16, 2003	U-150		
20578 001	GOSERELIN ACETATE; ZOLADEX	5545413	JUL 02, 2008			
		5082668	SEP 16, 2003			
		5366734	NOV 22, 2011			
		4767628	AUG 30, 2005			
		5366734	NOV 22, 2011		I-88	FEB 02, 1996
		4767628	AUG 30, 2005			
20239 001	GRANISETRON HYDROCHLORIDE; KYTRIL	4100274	APR 22, 1999	U-89	NP	JAN 11, 1999
20305 001	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 29, 2007	U-105		
19836 001	HISTRELIN ACETATE; SUPPRELIN	4886808	DEC 29, 2007			
19836 002	HISTRELIN ACETATE; SUPPRELIN	4244946	JAN 13, 2000		NCE	DEC 24, 1996
19836 003	HISTRELIN ACETATE; SUPPRELIN	4244946	JAN 13, 2000		NCE	DEC 24, 1996
20589 001	IBUPROFEN; CHILDREN'S ADVIL	4244946	JAN 13, 2000		NCE	DEC 24, 1996
20602 001	IBUPROFEN; JUNIOR STRENGTH MOTRIN	4788220	JUL 08, 2007		NP	JUN 16, 1998
20603 001	IBUPROFEN; CHILDREN'S MOTRIN				NP	JUN 16, 1998
20685 001	INDINAVIR SULFATE; CRIXIVAN	5374659	DEC 20, 2011		NP	JUN 16, 1998
20685 003	INDINAVIR SULFATE; CRIXIVAN	5413999	MAY 07, 2013	U-132	NCE	MAR 13, 2001
20563 001	INSULIN LISPRO; HUMALOG	5413999	MAY 07, 2013	U-132	NCE	MAR 13, 2001
		5514646	MAY 07, 2013	U-111	NCE	JUN 14, 2001
		5474978	JUN 16, 2014			
20351 001	IODIXANOL; VISIPAQUE 270	5349085	SEP 20, 2011		NCE	MAR 22, 2001
		4396597	JUL 03, 1999			
		4278654	JUL 03, 1999			
20351 002	IODIXANOL; VISIPAQUE 320	5349085	SEP 20, 2011		NCE	MAR 22, 2001
		4396597	JUL 03, 1999			
		4278654	JUL 03, 1999			
18735 001	IOPAMIDOL; ISOVUE-M 200	4001323	JAN 04, 1996			
18735 002	IOPAMIDOL; ISOVUE-300	4001323	JAN 04, 1996			
18735 003	IOPAMIDOL; ISOVUE-370	4001323	JAN 04, 1996			
18735 004	IOPAMIDOL; ISOVUE-M 300	4001323	JAN 04, 1996			
18735 007	IOPAMIDOL; ISOVUE-250	4001323	JAN 04, 1996			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20327 001	IOPAMIDOL; ISOVUE-200	4001323	JAN 04, 1996			
20327 002	IOPAMIDOL; ISOVUE-250	4001323	JAN 04, 1996			
20327 003	IOPAMIDOL; ISOVUE-300	4001323	JAN 04, 1996			
20327 004	IOPAMIDOL; ISOVUE-370	4001323	JAN 04, 1996			
20220 001	IOPROMIDE; ULTRAVIST 370	4364921	MAR 06, 2005	U-113	NCE	MAY 10, 2000
20220 002	IOPROMIDE; ULTRAVIST 300	4364921	DEC 21, 1999	U-113	NCE	MAY 10, 2000
20220 003	IOPROMIDE; ULTRAVIST 300	4364921	MAR 06, 2005	U-113	NCE	MAY 10, 2000
20220 004	IOPROMIDE; ULTRAVIST 240	4364921	MAR 06, 2005	U-113	NCE	MAY 10, 2000
20220 005	IOPROMIDE; ULTRAVIST 150	4364921	DEC 21, 1999	U-113	NCE	MAY 10, 2000
20220 006	IOPROMIDE; ULTRAVIST 150	4364921	MAR 06, 2005	U-113	NCE	MAY 10, 2000
20220 007	IOPROMIDE; ULTRAVIST 150	4364921	DEC 21, 1999	U-113	NCE	MAY 10, 2000
20571 001	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR	4604463	JUL 05, 2004			
20083 001	ITRACONAZOLE; SPORANOX	4089969	MAY 16, 1997	U-55	I-155	SEP 28, 1998
19645 001	KETOROLAC TROMETHAMINE; TORADOL	4089969	MAY 16, 1997	U-55	NR	DEC 07, 1997
19698 001	KETOROLAC TROMETHAMINE; TORADOL	4089969	MAY 16, 1997	U-55	NR	DEC 07, 1997
19698 002	KETOROLAC TROMETHAMINE; TORADOL	4089969	MAY 16, 1997	U-55	NR	DEC 07, 1997
19700 001	KETOROLAC TROMETHAMINE; ACULAR	4089969	MAY 16, 1997	U-75		
20564 001	LAMIVUDINE; EPIVIR	5047407	FEB 08, 2009			
20596 001	LAMIVUDINE; EPIVIR	5047407	FEB 08, 2009			
20241 001	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
20241 002	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
20241 003	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
20241 004	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
20241 005	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
20241 006	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
20406 001	LANSOPRAZOLE; PREVACID	4689333	JUL 29, 2005	U-126	I-116	APR 08, 1999
20406 002	LANSOPRAZOLE; PREVACID	4689333	JUL 29, 2005	U-126	I-116	APR 08, 1999
20597 001	LATANOPROST; XALATAN	4689333	JUL 29, 2005	U-126	NCE	JUN 05, 2001
20517 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5480656	JAN 02, 2013			
20219 001	LEVOCABASTINE HYDROCHLORIDE; LIVOSTIN	4369184	DEC 07, 2004			
20575 001	LIDOCAINE; LIDOCAINE	5446070	FEB 27, 2011			
20575 002	LIDOCAINE; LIDOCAINE	5332576	JUL 26, 2011			
20575 003	LIDOCAINE; LIDOCAINE	5234957	FEB 27, 2011			
20575 004	LIDOCAINE; LIDOCAINE	5446070	FEB 27, 2011			
20575 005	LIDOCAINE; LIDOCAINE	5332576	JUL 26, 2011			
20575 006	LIDOCAINE; LIDOCAINE	5234957	FEB 27, 2011			
19558 001	LISINAPRIL; PRINIVIL					
19558 002	LISINAPRIL; PRINIVIL					
19558 003	LISINAPRIL; PRINIVIL					
19558 004	LISINAPRIL; PRINIVIL					
19558 005	LISINAPRIL; PRINIVIL					
19558 006	LISINAPRIL; PRINIVIL					

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19777 001	LISINAPRIL; ZESTRIL				I-141	NOV 24, 1998
19777 002	LISINAPRIL; ZESTRIL				I-141	NOV 24, 1998
19777 003	LISINAPRIL; ZESTRIL				I-141	NOV 24, 1998
19777 004	LISINAPRIL; ZESTRIL				I-141	NOV 24, 1998
19777 005	LISINAPRIL; ZESTRIL				I-141	NOV 24, 1998
19658 001	LORATADINE; CLARITIN	4659716	APR 21, 2004	U-142	I-136	SEP 20, 1998
19670 001	LORATADINE; CLARITIN-D	4659716	APR 21, 2004	U-142	NC	NOV 14, 1997
20470 001	LORATADINE; CLARITIN-D 24 HOUR	5314697	OCT 23, 2012			
		4659716	APR 21, 2004	U-142	NP	AUG 23, 1999
20641 001	LORATADINE; CLARITIN	4282233	JUL 19, 2002	U-77	NCE	APR 12, 1998
19940 001	MASOPROCOL; ACTINEX	4282233	JUN 19, 2002	U-77	NDF	OCT 10, 1999
19651 001	MESALAMINE; ASACOL	5541171	JUL 30, 2013	U-141		
		5541170	JUL 30, 2013	U-141		
		5536743	JUL 16, 2013	U-137		
20208 001	METRONIDAZOLE; METROGEL-VAGINAL				NP	APR 16, 1999
20670 002	MICONAZOLE NITRATE; MONISTAT-3 COMBINATION PACK				NCE	SEP 06, 2001
19815 001	MIDODRINE HYDROCHLORIDE; PROAMATINE				NCE	SEP 06, 2001
19815 002	MIDODRINE HYDROCHLORIDE; PROAMATINE				NCE	JUN 14, 2001
20415 001	MIRTAZAPINE; REMERON				NCE	JUN 14, 2001
20415 002	MIRTAZAPINE; REMERON					
20312 001	MOEXIPRIL HYDROCHLORIDE; UNIVASC	4344949	OCT 03, 2000			
20312 002	MOEXIPRIL HYDROCHLORIDE; UNIVASC	4344949	OCT 03, 2000			
20616 001	MORPHINE SULFATE; KADIAN	5378474	MAR 23, 2010			
20616 002	MORPHINE SULFATE; KADIAN	5378474	MAR 23, 2010		NDF	JUL 03, 1999
20616 003	MORPHINE SULFATE; KADIAN	5378474	MAR 23, 2010		NDF	JUL 03, 1999
		5202128	APR 13, 2010		NDF	JUL 03, 1999
		5378474	MAR 23, 2010		NDF	JUL 03, 1999
		5202128	APR 13, 2010		NDF	JUL 03, 1999
		4234571	JUN 11, 2011		NDF	JAN 05, 1999
19886 001	NAFARELIN ACETATE; SYNAREL				NDF	JAN 05, 1999
20353 001	NAPROXEN SODIUM; NAPRELAN				NDF	JAN 05, 1999
20353 002	NAPROXEN SODIUM; NAPRELAN				NDF	JAN 05, 1999
20353 003	NAPROXEN SODIUM; NAPRELAN				NDF	JAN 05, 1999
20152 001	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	U-12	NCE	DEC 22, 1999
20152 002	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	U-12	NCE	DEC 22, 1999
20152 003	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	U-12	NCE	DEC 22, 1999
20152 004	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	U-12	NCE	DEC 22, 1999
20152 005	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	U-12	NCE	DEC 22, 1999
20152 006	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	U-12	NCE	DEC 22, 1999
20636 001	NEVIRAPINE; VIRAMUNE	5366972	NOV 22, 2011		NCE	JUN 21, 2001
19488 001	NICARDIPINE HYDROCHLORIDE; CARDENE	3985758	OCT 12, 1995			
19488 002	NICARDIPINE HYDROCHLORIDE; CARDENE	3985758	OCT 12, 1995			
19734 001	NICARDIPINE HYDROCHLORIDE; CARDENE	3985758	OCT 12, 1995			

>ADD>

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20184 001	PERINDOPRIL ERBUMINE; ACEON	4508729	AUG 21, 2006			
20184 002	PERINDOPRIL ERBUMINE; ACEON	4508729	AUG 21, 2006			
20184 003	PERINDOPRIL ERBUMINE; ACEON	4508729	AUG 21, 2006			
20451 001	PORFIMER SODIUM; PHOTOFRIN	5438071	AUG 01, 2012	U-129	ODE	DEC 27, 2002
		5145863	JUN 12, 2007			
		5028621	MAR 10, 2004			
		4932934	JUN 12, 2007	U-128	NCE	DEC 27, 2000
		4866168	MAR 10, 2004			
		4649151	MAR 10, 2004			
19898 005	PRAVASTATIN SODIUM; PRAVACHOL	5180589	JUL 09, 2008			
		5030447	JUL 09, 2008			
		4346227	OCT 20, 2005	I-159		JUL 02, 1999
		5180589	JUL 09, 2008	I-152		MAR 22, 1999
19898 006	PRAVASTATIN SODIUM; PRAVACHOL	5180589	JUL 09, 2008			
		5030447	JUL 09, 2008			
		4346227	OCT 20, 2005	I-159		JUL 02, 1999
19898 007	PRAVASTATIN SODIUM; PRAVACHOL	5180589	JUL 09, 2008			
		5030447	JUL 09, 2008			
		4346227	OCT 20, 2005	I-152		MAR 22, 1999
20279 001	PREDNICARBATE; DERMATOP			I-154		MAY 03, 1999
20545 001	PROCAINAMIDE HYDROCHLORIDE; PROCANBID			NP		JAN 31, 1999
20545 002	PROCAINAMIDE HYDROCHLORIDE; PROCANBID			NP		JAN 31, 1999
19627 001	PROPOFOL; DIPRIVAN	4056635	NOV 01, 1996	I-90		MAR 08, 1996
19885 001	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949	OCT 03, 2002			
19885 002	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949	OCT 03, 2002			
19885 003	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949	OCT 03, 2002			
19885 004	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949	OCT 03, 2002			
20559 001	RANITIDINE BISMUTH CITRATE; TRITEC	5008256	JUL 17, 2009	NE		AUG 08, 1999
19593 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	MAY 11, 2004			
		4521431	JUN 04, 2002	U-121		
		4128658	JUL 25, 1997	U-121		
19593 002	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	MAY 11, 2004			
		4521431	JUN 04, 2002	U-121		
		4128658	JUL 25, 1997	U-121		
20520 001	RANITIDINE HYDROCHLORIDE; ZANTAC 75	4128658	JUL 25, 1997			
		4880636	MAY 13, 2008			
		4521431	JUN 04, 2002	U-121		
		4128658	JUL 25, 1997	U-121		
20630 001	REMIFENTANIL HYDROCHLORIDE; ULTIVA	5019583	FEB 15, 2009	NCE		JUL 12, 2001
20630 002	REMIFENTANIL HYDROCHLORIDE; ULTIVA	5019583	FEB 15, 2009	NCE		JUL 12, 2001
20630 003	REMIFENTANIL HYDROCHLORIDE; ULTIVA	5019583	FEB 15, 2009	NCE		JUL 12, 2001
20272 001	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007			
20272 002	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90		
20272 003	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90		

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20272 004	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90		
20272 005	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90		
20588 001	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90	NCE	DEC 29, 1998
20659 001	RITONAVIR; NORVIR	5541206	JUL 30, 2013	U-140		
		5484801	JAN 28, 2014		NCE	MAR 01, 2001
20680 001	RITONAVIR; NORVIR	5541206	JUL 30, 2013	U-140	NCE	MAR 01, 2001
20533 001	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE; NAROPIN	4870086	SEP 26, 2006		NCE	SEP 24, 2001
		4695576	SEP 22, 2004			
20533 003	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE; NAROPIN	4870086	SEP 26, 2006		NCE	SEP 24, 2001
		4695576	SEP 22, 2004			
20533 004	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE; NAROPIN	4870086	SEP 26, 2006		NCE	SEP 24, 2001
		4695576	SEP 22, 2004			
20533 005	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE; NAROPIN	4870086	SEP 26, 2006		NCE	SEP 24, 2001
		4695576	SEP 22, 2004			
20628 001	SAGUINAVIR MESYLATE; INVIRASE	5196438	NOV 19, 2010			
19839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	4962128	NOV 02, 2009	U-152		
		4536518	DEC 31, 2005	U-152	I-102	OCT 25, 1999
19839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT	4962128	NOV 02, 2009	U-152		
		4536518	DEC 31, 2005	U-152	I-102	OCT 25, 1999
19839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT	4962128	NOV 02, 2009	U-152		
		4536518	DEC 31, 2005	U-152	I-102	OCT 25, 1999
19839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT	4962128	NOV 02, 2009	U-152		
		4536518	DEC 31, 2005	U-152	I-102	OCT 25, 1999
19839 005	SERTRALINE HYDROCHLORIDE; ZOLOFT	4962128	NOV 02, 2009	U-152		
		4536518	DEC 31, 2005	U-152	I-102	OCT 25, 1999
20572 001	SODIUM PHENYLBUTYRATE; BUPHENYL	4536518	DEC 31, 2005	U-152		
20573 001	SODIUM PHENYLBUTYRATE; BUPHENYL	4457942	AUG 20, 2002	U-136	NCE	APR 30, 2001
		4457942	AUG 20, 2002	U-136	NCE	APR 30, 2001
19640 001	SOMATROPIN, BIOSYNTHETIC; HUMATROPE				ODE	APR 30, 2003
19640 004	SOMATROPIN, BIOSYNTHETIC; HUMATROPE				I-161	AUG 01, 1999
20280 004	SOMATROPIN, BIOSYNTHETIC; GENOTROPIN				NS	AUG 24, 1998
20280 006	SOMATROPIN, BIOSYNTHETIC; GENOTROPIN				NS	AUG 24, 1998
20604 001	SOMATROPIN, BIOSYNTHETIC; SEROSTIM				ODE	AUG 23, 2003
					NP	AUG 23, 1999
20604 002	SOMATROPIN, BIOSYNTHETIC; SEROSTIM				ODE	AUG 23, 2003
					NP	AUG 23, 1999
20240 001	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2003	U-3	NCE	DEC 29, 1999
20240 002	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2003	U-3	NCE	DEC 29, 1999
20240 003	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2003	U-3	NCE	DEC 29, 1999
20240 004	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2003	U-3	NCE	DEC 29, 1999
20412 001	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		
20412 002	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20412 003	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		
20412 004	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		
20412 005	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		
07073 002	SULFASALAZINE; AZULFIDINE EN-TABS	5279811	NOV 23, 2008	U-101	I-165	OCT 17, 1999
20256 001	TECHNETIUM TC-99M BICISATE KIT; NEUROLITE				NCE	NOV 23, 1999
19785 001	TECHNETIUM TC-99M SESTAMIBI KIT; CARDIOLITE				I-142	DEC 14, 1998
20372 001	TECHNETIUM TC-99M TETROFOSMIN KIT; MYOVIEW				NCE	FEB 09, 2001
19057 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	5045302	APR 10, 2007	U-3		
19057 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013	U-3		
19057 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013	U-3		
19057 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013	U-3		
20347 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013			
20347 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013			
20347 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013			
20347 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013			
20539 001	TERBINAFINE HYDROCHLORIDE; LAMISIL	4755534	JUL 05, 2005	U-73	NDF	MAY 10, 1999
					NCE	DEC 30, 1999
20489 001	TESTOSTERONE; ANDRODERM	5164190	NOV 17, 2008			
		5152997	OCT 06, 2009			
		4983395	JAN 08, 2009			
		4863970	SEP 05, 2006			
		4855294	AUG 08, 2006			
		4849224	JUL 18, 2006			
		5004758	APR 02, 2008		NS	SEP 29, 1998
		RE30633	APR 19, 1999		NCE	MAY 28, 2001
20671 001	TOPOTECAN HYDROCHLORIDE; HYCAMTIN	RE30633	APR 19, 1999			
20136 001	TORSEMIDE; DEMADAX	RE30633	APR 19, 1999			
20136 002	TORSEMIDE; DEMADAX	RE30633	APR 19, 1999			
20136 003	TORSEMIDE; DEMADAX	RE30633	APR 19, 1999			
20136 004	TORSEMIDE; DEMADAX	RE30633	APR 19, 1999			
20137 002	TORSEMIDE; DEMADAX	RE30633	APR 19, 1999			
20528 001	TRANDOLAPRIL; MAVIK	4933361	JUN 12, 2007		NCE	APR 26, 2001
20528 002	TRANDOLAPRIL; MAVIK	4933361	JUN 12, 2007		NCE	APR 26, 2001
20528 003	TRANDOLAPRIL; MAVIK	4933361	JUN 12, 2007		NCE	APR 26, 2001
20591 001	TRANDOLAPRIL; TARKA	4933361	JUN 12, 2007		NCE	APR 26, 2001
					NC	OCT 22, 1999
20591 002	TRANDOLAPRIL; TARKA	4933361	JUN 12, 2007		NCE	APR 26, 2001
					NC	OCT 22, 1999
20591 003	TRANDOLAPRIL; TARKA	4933361	JUN 12, 2007		NCE	APR 26, 2001
					NC	OCT 22, 1999
20591 004	TRANDOLAPRIL; TARKA	4933361	JUN 12, 2007		NCE	APR 26, 2001
					NC	OCT 22, 1999

>ADD>

 >ADD>
 >ADD>
 >ADD>
 >ADD>
 >ADD>
 >ADD>
 >ADD>

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19963 001	TRETINOLIN; RENOVA	4877805	OCT 31, 2006	U-131		
		4603146	JUL 29, 2003	U-131	NP	DEC 29, 1998
		4423041	DEC 27, 2000			
		4767612	JAN 23, 2007	U-85	I-162	MAY 20, 1999
					NDF	MAY 20, 1999
19798 001	TRIAMCINOLONE ACETONIDE; NASACORT	5140993	AUG 24, 2009	U-148		
20468 001	TRIAMCINOLONE ACETONIDE; NASACORT AQ	4830010	MAY 15, 2006	U-147	NCE	SEP 17, 2001
20586 001	UREA, C-13; MERETEK UBT KIT (W/ PRANACTIN)				NR	AUG 23, 1999
					NR	AUG 23, 1999
19415 002	UROFOLLITROPIN; METRODIN				I-147	MAR 29, 1999
19415 003	UROFOLLITROPIN; METRODIN				I-143	DEC 15, 1998
19594 002	URSODIOL; ACTIGALL				I-143	DEC 15, 1998
20487 001	VALACYCLOVIR HYDROCHLORIDE; VALTREX	4957924	AUG 05, 2008		I-153	OCT 04, 1999
20487 002	VALACYCLOVIR HYDROCHLORIDE; VALTREX	4957924	AUG 05, 2008		I-153	OCT 04, 1999
20550 001	VALACYCLOVIR; VALTREX				NCE	DEC 28, 1998
20550 002	VALACYCLOVIR; VALTREX				NCE	DEC 28, 1998
20151 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		NCE	DEC 28, 1998
20151 002	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		NCE	DEC 28, 1998
20151 003	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		NCE	DEC 28, 1998
20151 004	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		NCE	DEC 28, 1998
20151 005	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		NCE	DEC 28, 1998
20151 006	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	5252338	JUN 27, 2011		NP	FEB 26, 1999
20552 001	VERAPAMIL HYDROCHLORIDE; COVERA-HS	5190765	AUG 14, 2007			
		5160744	JUN 27, 2011			
20552 002	VERAPAMIL HYDROCHLORIDE; COVERA-HS	4753802	MAR 19, 2006		NP	FEB 26, 1999
		5252338	JUN 27, 2011			
		5190765	AUG 14, 2007			
		5160744	JUN 27, 2011			
20388 001	VINORELBINE TARTRATE; NAVELBINE	4753802	MAR 19, 2006		NCE	DEC 23, 1999
20547 001	ZAFIRLUKAST; ACCOLATE	4307100	JUL 07, 2002			
		5482963	JAN 09, 2013			
		5319097	DEC 11, 2011			
		5294636	DEC 11, 2011			
		4859692	AUG 22, 2006		NCE	SEP 26, 2001

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

Order Processing Code
* 7971

***Charge your order.
It's easy!***



— subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for \$77.00 per year.

The total cost of my order is \$_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents☐ GPO Deposit Account☐ VISA or MasterCard

Company or personal name

Additional address/attention line

Street address

City, State, ZIP Code

()
Daytime phone including area code

Purchase Order No. (optional)

(Credit card expiration date)

Thank you for your order!

(Authorizing Signature)

(10/95)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To FAX your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.

RM301.45 .A66 1996 Oct Suppl

Approved drug products with
therapeutic equivalence

C:355661 M:174736 O:12937927

Library Use Only

ST. LOUIS COLLEGE OF PHARMACY



3 2201 90036 5707